Form 10-Q

Large accelerated filer x

Accelerated filer ¨

Non-accelerated filer ¨

Smaller reporting Company ¨

(Do not check if a smaller reporting company)

0001193125-12-195656.txt : 20120430 0001193125-12-195656.hdr.sgml : 20120430 20120430152552 ACCESSION NUMBER: 0001193125-12-195656 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120430 DATE AS OF CHANGE: 20120430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LILLY ELI & CO CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 12794601 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1112 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1112 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 10-Q 1 d340670d10q.htm FORM 10-Q Form 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

Quarterly Report Under Section 13 or 15(d) of the

Securities Exchange Act of 1934

FOR THE QUARTER ENDED MARCH 31, 2012

COMMISSION FILE NUMBER 001-6351

ELI LILLY AND COMPANY

(Exact name of Registrant as specified in its charter)


INDIANA		35-0470950
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

LILLY CORPORATE CENTER, INDIANAPOLIS, INDIANA 46285

(Address of principal executive offices)

Registrant’s telephone number, including area code (317) 276-2000

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of a “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No ¨

The number of shares of common stock outstanding as of April 20, 2012:


Class		Number of Shares Outstanding
Common		1,160,415,307

PART I. Financial Information

Item 1. Financial Statements

Consolidated Condensed Statements of Operations

(Unaudited)

ELI LILLY AND COMPANY AND SUBSIDIARIES


	Three Months Ended March 31,
	2012		2011

	(Dollars in millions, except per-share data)
Revenue	$	5,602.0	$	5,839.2
Cost of sales		1,197.9		1,180.1
Research and development		1,151.5		1,124.0
Marketing, selling, and administrative		1,847.5		1,785.7
Acquired in-process research and development (Note 4)		—		388.0
Asset impairments, restructuring, and other special charges (Note 5)		23.8		76.3
Other – net, expense (Note 13)		46.0		11.2

		4,266.7		4,565.3

Income before income taxes		1,335.3		1,273.9
Income taxes (Note 10)		324.2		218.0

Net income	$	1,011.1	$	1,055.9


Earnings per share – basic and diluted (Note 9)	$	.91	$	.95


Dividends paid per share	$	.49	$	.49

See Notes to Consolidated Condensed Financial Statements.

Consolidated Condensed Statements of Comprehensive Income

(Unaudited)

ELI LILLY AND COMPANY AND SUBSIDIARIES


	Three Months Ended March 31,
	2012		2011

	(Dollars in millions)

Net income	$	1,011.1	$	1,055.9

Other comprehensive income, net of tax		309.4		481.3


Comprehensive income	$	1,320.5	$	1,537.2

See Notes to Consolidated Condensed Financial Statements.

Consolidated Condensed Balance Sheets

ELI LILLY AND COMPANY AND SUBSIDIARIES


	March 31, 2012			December 31, 2011

	(Dollars in millions)
	(Unaudited)
Assets
Current Assets
Cash and cash equivalents (Note 6)	$	4,122.2		$	5,922.5
Short-term investments (Note 6)		802.4			974.6
Accounts receivable, net of allowances of $108.4 (2012) and $110.1 (2011)		3,402.1			3,597.7
Other receivables		529.2			640.2
Inventories		2,424.2			2,299.8
Prepaid taxes		324.0			158.5
Prepaid expenses and other		998.5			654.9

Total current assets		12,602.6			14,248.2

Other Assets
Investments (Note 6)		4,521.1			4,029.8
Goodwill and other intangibles – net (Note 3)		5,266.7			5,128.1
Sundry		2,093.2			2,493.4

Total other assets		11,881.0			11,651.3

Property and Equipment
Land, buildings, equipment, and construction-in-progress		14,765.7			14,594.0
Less accumulated depreciation		(7,011.1	)		(6,833.7)

Property and equipment, net		7,754.6			7,760.3

Total assets	$	32,238.2		$	33,659.8


Liabilities and Shareholders’ Equity
Current Liabilities
Short-term borrowings and current maturities of long-term debt	$	10.6		$	1,522.3
Accounts payable		1,246.3			1,125.2
Employee compensation		533.8			804.7
Sales rebates and discounts		1,619.8			1,771.3
Dividends payable		—			542.3
Income taxes payable		388.8			261.6
Other current liabilities		2,754.4			2,903.5

Total current liabilities		6,553.7			8,930.9

Other Liabilities
Long-term debt		5,403.2			5,464.7
Accrued retirement benefits (Note 11)		2,766.5			3,068.5
Long-term income taxes payable (Note 10)		1,158.3			1,086.3
Other noncurrent liabilities		1,533.9			1,573.8

Total other liabilities		10,861.9			11,193.3

Shareholders’ Equity (Notes 7 and 8)
Common stock		725.8			724.1
Additional paid-in capital		4,858.2			4,886.8
Retained earnings		15,906.7			14,897.8
Employee benefit trust		(3,013.1	)		(3,013.1)
Accumulated other comprehensive loss		(3,549.2	)		(3,858.6)
Noncontrolling interests		(11.5	)		(6.1)
Cost of common stock in treasury		(94.3	)		(95.3)

Total shareholders’ equity		14,822.6			13,535.6

Total liabilities and shareholders’ equity	$	32,238.2		$	33,659.8

See Notes to Consolidated Condensed Financial Statements.

Consolidated Condensed Statements of Cash Flows

(Unaudited)

ELI LILLY AND COMPANY AND SUBSIDIARIES


	Three Months Ended March 31,
	2012			2011

	(Dollars in millions)
Cash Flows from Operating Activities
Net income	$	1,011.1		$	1,055.9
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization		385.9			340.9
Change in deferred income taxes		132.1			92.5
Stock-based compensation expense		28.2			37.9
Acquired in-process research and development, net of tax		—			252.2
Other changes in operating assets and liabilities		(698.7	)		(595.6)
Other operating activities, net		(6.1	)		(7.7)


Net Cash Provided by Operating Activities		852.5			1,176.1

Cash Flows from Investing Activities
Net purchases of property and equipment		(130.7	)		(101.4)
Net change in short-term investments		457.6			539.0
Proceeds from sales and maturities of noncurrent investments		1,423.2			211.9
Purchases of noncurrent investments		(2,156.1	)		(238.3)
Purchase of product rights		—			(29.6)
Purchase of in-process research and development		—			(388.0)
Cash paid for acquisitions, net of cash acquired		(195.4	)		—
Other investing activities, net		(50.9	)		(34.3)


Net Cash Used for Investing Activities		(652.3	)		(40.7)

Cash Flows from Financing Activities
Dividends paid		(544.6	)		(543.2)
Net change in short-term borrowings		(12.4	)		(116.2)
Repayment of long-term debt		(1,500.0	)		(54.6)
Other financing activities, net		—			0.2


Net Cash Used in Financing Activities		(2,057.0	)		(713.8)

Effect of exchange rate changes on cash and cash equivalents		56.5			91.6


Net (decrease) increase in cash and cash equivalents		(1,800.3	)		513.2

Cash and cash equivalents at January 1		5,922.5			5,993.2


Cash and Cash Equivalents at March 31	$	4,122.2		$	6,506.4

See Notes to Consolidated Condensed Financial Statements

Segment Information

We operate in one significant business segment—human pharmaceutical products. Operations of the animal health business segment are not material and share many of the same economic and operating characteristics as human pharmaceutical products. Therefore, they are included with pharmaceutical products for purposes of segment reporting. Our business segments are distinguished by the ultimate end user of the product: humans or animals. Performance is evaluated based on profit or loss from operations before income taxes. Income before income taxes for the animal health business for the first quarters of 2012 and 2011 was $127.0 million and $65.3 million, respectively.

Revenue by Category

Worldwide revenue by category was as follows:


	Three Months Ended March 31,
	2012		2011

	(Dollars in millions)
Revenue — to unaffiliated customers:
Pharmaceutical products
Neuroscience	$	1,903.7	$	2,405.1
Endocrinology		1,690.9		1,589.0
Oncology		803.9		839.9
Cardiovascular		638.4		581.8
Other pharmaceuticals		74.4		53.6

Total pharmaceutical products		5,111.3		5,469.4
Animal health		490.7		369.8

Total revenue	$	5,602.0	$	5,839.2

Notes to Consolidated Condensed Financial Statements

Note 1: Basis of Presentation

We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2011. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing.

Note 2: Implementation of New Financial Accounting Pronouncements

There are no new accounting pronouncements that have had or will have a material impact on our consolidated condensed financial statements.

Note 3: Acquisitions

Acquisitions of Businesses

On February 17, 2012, we acquired all of the outstanding stock of ChemGen Corporation, a privately-held bioscience company specializing in the development and commercialization of innovative feed enzyme products that improve the efficiency of poultry, egg, and meat production, for total purchase consideration of approximately $205 million. We have not yet finalized our acquisition accounting but we anticipate the majority of the value of the assets recorded will be marketed product intangibles. This transaction was not material to our consolidated condensed financial statements.

On July 7, 2011, we acquired the animal health business of Janssen Pharmaceutica NV, a Johnson & Johnson company, for total purchase consideration of $307.8 million in cash. We obtained a portfolio of more than 50 marketed animal health products. In connection with this acquisition, we preliminarily recorded $234.4 million of marketed product assets and $29.6 million of acquired in-process research and development (IPR&D) assets, with $43.8 million of other net assets. The final determination may result in asset and liability fair values that differ from the preliminary estimates, but it is not expected that these differences will be material to our financial results.

Note 4: Collaborations

We often enter into collaborative arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These collaborations often require milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the third party. Revenues related to products sold by us pursuant to these arrangements are included in net product sales, while other sources of revenue (e.g., royalties and profit share payments) are included in collaboration and other revenue. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments made to or reimbursements received from our collaboration partners. Each collaboration is unique in nature, and our more significant arrangements are discussed below. The following table summarizes the composition of our total revenue recognized from all transactions, including collaboration activity:


	Three Months Ended March 31,
	2012		2011

	(Dollars in millions)
Net product sales	$	5,413.8	$	5,689.9
Collaboration and other revenue		188.2		149.3

Total revenue	$	5,602.0	$	5,839.2

Erbitux^®

We have several collaborations with respect to Erbitux. The most significant collaborations are in the U.S., Japan, and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). The agreements are expected to expire in 2018, upon which all of the rights with respect to Erbitux in the U.S. and Canada return to us and certain rights with respect to Erbitux outside the U.S. and Canada (excluding Japan) remain with Merck KGaA (Merck). The following table summarizes the revenue recognized with respect to Erbitux:


	Three Months Ended March 31,
	2012		2011

	(Dollars in millions)
Net product sales	$	34.0	$	27.1
Collaboration and other revenue		79.3		76.9

Total revenue	$	113.3	$	104.0

Bristol-Myers Squibb Company

Pursuant to a commercial agreement with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), relating to Erbitux, we are co-developing Erbitux in the U.S. and Canada with BMS, exclusively, and in Japan with BMS and Merck. The companies have jointly agreed to expand the investment in the ongoing clinical development plan for Erbitux to further explore its use in additional tumor types. Under this arrangement, Erbitux research and development and other costs are shared by both companies according to a predetermined ratio.

Responsibilities associated with clinical and other ongoing studies are apportioned between the parties under the agreement. Collaborative reimbursements received by us for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated condensed statement of operations. We receive a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in the U.S. and Canada, which is recorded in collaboration and other revenue. Royalty expense paid to third parties, net of any reimbursements received, is recorded as a reduction of collaboration and other revenue.

We are responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the territory, and BMS will purchase all of its requirements of API for commercial use from us, subject to certain stipulations per the agreement. Sales of Erbitux to BMS for commercial use are reported in net product sales.

Merck KGaA

A development and license agreement with Merck with respect to Erbitux granted Merck exclusive rights to market Erbitux outside of the U.S. and Canada, and co-exclusive rights with BMS and us in Japan. Merck also has rights to manufacture Erbitux for supply in its territory. We receive a royalty on the sales of Erbitux outside of the U.S. and Canada, which is included in collaboration and other revenue as earned. Collaborative reimbursements received for research and for development; and marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated condensed statement of operations. Royalty expense paid to third parties, net of any royalty reimbursements received, is recorded as a reduction of collaboration and other revenue.

Necitumumab

The commercial agreement with BMS described above includes the co-development and co-commercialization of necitumumab, which is currently in Phase III clinical testing for squamous non-small cell lung cancer. We and BMS share the cost of developing and potentially commercializing necitumumab in the U.S., Canada, and Japan. We maintain exclusive rights to necitumumab in all other markets. We will fund 45 percent of the development costs for studies that will be used only in the U.S., and 72.5 percent for global studies. We will be responsible for the manufacturing of API, and BMS will be responsible for manufacturing the finished product. We could receive a payment of $250.0 million upon approval in the U.S. In the U.S. and Canada, BMS will record sales and we will receive 45 percent of the profits for necitumumab, while we will provide 50 percent of the selling effort. In Japan, we and BMS will share costs and profits evenly.

Exenatide

In November 2011, we agreed with Amylin Pharmaceuticals, Inc. (Amylin) to terminate our collaborative arrangement for the joint development, marketing, and selling of Byetta^® (exenatide injection) and other forms of exenatide such as Bydureon™ (exenatide extended-release for injectable suspension). Under the terms of the termination agreement,

Amylin made a one-time, upfront payment to us of $250.0 million. Amylin also agreed to make future revenue-sharing payments to us in an amount equal to 15 percent of their global net sales of exenatide products until Amylin has made aggregate payments to us of $1.20 billion plus interest, which will accrue at 9.5 percent. Amylin issued a secured note in the amount of $1.20 billion to us under which any revenue-sharing payments made to us will reduce amounts outstanding under the note. In general, Amylin’s obligation for the revenue-sharing payments and the secured note will terminate if all exenatide products are withdrawn from the market due to safety or efficacy issues and are not sold for a period of four years. Amylin will also pay a $150.0 million milestone to us contingent upon FDA approval of a once-monthly suspension version of exenatide that is currently in Phase II clinical trials.

Commercial operations were transferred to Amylin in the U.S. at the end of November 2011, although we continue to provide certain transition services. Outside the U.S., we will transfer responsibility for commercialization of exenatide to Amylin on a market-by-market basis over a period beginning no earlier than the second half of 2012 and that will not extend beyond December 31, 2013.

Payments received from Amylin are allocated 65 percent to the U.S., which is treated as a contract termination, and 35 percent to the business outside the U.S., which will be treated as the disposition of a business. The allocation was based upon relative fair values. Revenue-sharing payments will be recognized as income as Amylin records sales. The income allocated to the U.S. is recognized as collaboration and other revenue and the income allocated to the business outside the U.S. will be recognized as proceeds from the disposition of a business in other–net, expense in our consolidated condensed income statement beginning at the time control of the business transfers to Amylin. The amounts we may receive pursuant to the revenue-sharing arrangement represent contingent consideration and, therefore, do not qualify for recognition as income until the contingency is resolved and the amount becomes fixed or determinable. As a consequence, the note has not been recognized in our consolidated condensed balance sheet.

Prior to termination of the collaboration, we and Amylin were co-promoting Byetta in the U.S. Amylin was responsible for manufacturing and primarily utilized third-party contract manufacturers to supply Byetta. We supplied Byetta pen delivery devices for Amylin and will continue to do so for a period that will not extend beyond December 31, 2013, unless we and Amylin agree otherwise. We are responsible for certain development costs related to certain clinical trials outside the U.S. that we were conducting as of the date of the termination agreement as well as commercialization costs outside the U.S. until the commercial operations are transferred to Amylin.

Under the terms of our prior arrangement, we reported as collaboration and other revenue our 50 percent share of gross margin on Amylin’s net product sales in the U.S. We reported as net product sales 100 percent of sales outside the U.S. and our sales of Byetta pen delivery devices to Amylin. We paid Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs were recorded in cost of sales. This arrangement for the commercial operations outside the U.S. will continue until those operations transfer to Amylin. Prior to its termination, under the 50/50 profit-sharing arrangement for the U.S., in addition to recording as revenue our 50 percent share of exenatide’s gross margin, we also recorded approximately 50 percent of U.S. related research and development costs and marketing and selling costs in the respective line items on the consolidated condensed statements of operations.

The following table summarizes the revenue recognized with respect to exenatide:


	Three Months Ended March 31,
	2012		2011

	(Dollars in millions)
Net product sales	$	48.5	$	40.8
Collaboration and other revenue		51.3		61.0

Total revenue	$	99.8	$	101.8

In accordance with the prior arrangement and pursuant to Amylin’s request, in the second quarter of 2011 we loaned Amylin $165.0 million. Interest on this loan is to be received quarterly and all outstanding principal and interest is due five years from the date of the advance.

Cymbalta^®

We were in a collaborative arrangement with Boehringer Ingelheim (Boehringer) to jointly develop, market, and promote Cymbalta (duloxetine), outside the U.S. and Japan. Pursuant to the terms of the agreement, we generally shared equally in development, marketing, and selling expenses, and paid Boehringer a commission on sales in the co-promotion territories. We manufactured the product for all territories. Reimbursements or payments for the cost sharing of marketing, selling, and administrative expenses were recorded in the respective expense line items in the consolidated condensed statements of operations. The commission paid to Boehringer was recorded in marketing, selling, and

administrative expenses. In March 2010, the parties agreed to terminate this agreement, and we reacquired the exclusive rights to develop and market duloxetine for all indications in countries outside the U.S. and Japan. In connection with the termination, we paid Boehringer approximately $400 million and will also pay to Boehringer a percentage of our sales of duloxetine in these countries through 2012 as consideration for the rights acquired. We record these costs as intangible assets, which will be amortized to marketing, selling, and administrative expenses using the straight-line method over the life of the original agreement, which is through 2015.

Effient^®

We are in a collaborative arrangement with Daiichi Sankyo Company, Limited (D-S) to develop, market, and promote Effient. We and D-S have agreed to co-promote in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. D-S has exclusive marketing rights in Japan. The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories. We record product sales in our exclusive and co-promotion territories. In our exclusive territories, we pay D-S a royalty specific to these territories. Profit share payments made to D-S are recorded as marketing, selling, and administrative expenses. All royalties paid to D-S and the third-party manufacturer are recorded in cost of sales. Worldwide Effient sales were $115.8 million and $56.3 million in the quarters ended March 31, 2012 and 2011, respectively.

Diabetes Collaboration

In January 2011, we and Boehringer entered into a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Included are Boehringer’s two oral diabetes agents, linagliptin and empagliflozin (BI 10773). Subsequently in 2011, linagliptin was approved and launched in the U.S. (tradename Tradjenta™), Japan (tradename Trazenta^®), Europe (tradename Trajenta^®), and other countries. Empagliflozin is currently in Phase III clinical testing. Also included in the agreement is our new insulin glargine product and our novel basal insulin analog, both of which began Phase III clinical testing in the second half of 2011; and an option granted to Boehringer to co-develop and co-commercialize our anti-TGF-beta monoclonal antibody, which is currently in Phase II clinical testing. Under the terms of the agreement, we made an initial one-time payment to Boehringer of $388.0 million and recorded an acquired IPR&D charge, which was included as expense in the first quarter of 2011 and is deductible for tax purposes.

In connection with the approval of linagliptin in the U.S., Japan, and Europe, in 2011 we paid $478.7 million in success-based regulatory milestones, all of which were capitalized as intangible assets and are being amortized to cost of sales. We may pay up to €300.0 million in additional success-based regulatory milestones for empagliflozin. We will be eligible to receive up to a total of $650.0 million in success-based regulatory milestones on our two insulin products. Should Boehringer elect to opt in to the Phase III development and potential commercialization of the anti-TGF-beta monoclonal antibody, we would be eligible for up to $525.0 million in opt-in and success-based regulatory milestone payments. The companies share ongoing development costs equally. The companies also share in the commercialization costs and gross margin for any product resulting from the collaboration that receives regulatory approval. We record our portion of the gross margin as collaboration and other revenue, and we record our portion of the commercialization costs as marketing, selling, and administrative expense. Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration. Revenue related to this collaboration has not been significant to date.

Solanezumab

We have an agreement with an affiliate of TPG-Axon Capital (TPG) whereby both we and TPG were obligated to fund the Phase III development of solanezumab. Under the agreement, TPG’s obligation to fund solanezumab costs was not material and ended in the first half of 2011. In exchange for their funding, TPG may receive success-based sales milestones totaling approximately $70.0 million and mid-single digit royalties that are contingent upon the successful development of solanezumab. The royalties relating to solanezumab would be paid for approximately eight years after launch of a product.

Summary of Collaboration-Related Commission and Profit Share Payments

The aggregate amount of commission and profit share payments included in marketing, selling, and administrative expense pursuant to the collaborations described above was $72.0 million and $45.4 million for the first quarter ended March 31, 2012 and 2011, respectively.

Note 5: Asset Impairments, Restructuring, and Other Special Charges

We recognized asset impairments, restructuring, and other special charges of $23.8 million in the first quarter of 2012, primarily consisting of a change in our estimates of returned product related to the withdrawal of Xigris^® from the market during the fourth quarter of 2011.

We recognized severance costs of $76.3 million in the first quarter of 2011 as a result of the 2009 initiative to reorganize global operations, streamline various functions of the business, and reduce total employees, as well as other previously announced strategic actions to reduce our cost structure.

Note 6: Financial Instruments

Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we limit the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.

Accounting Policy for Risk-Management Instruments

Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate the instruments individually as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.

For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized currently in earnings during the period of change.

We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are entered into with the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other — net, expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At March 31, 2012, we had outstanding foreign currency forward commitments to purchase 365.2 million U.S. dollars and sell 275.5 million euro, commitments to buy 871.5 million euro and sell 1.15 billion U.S. dollars, and commitments to purchase 380.2 million British pounds and sell 456.8 million euro, which will all settle within 35 days.

In the normal course of business, our operations are exposed to fluctuations in interest rates. These fluctuations can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.

Interest rate swaps or collars that convert our fixed-rate debt or investments to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating rate debt or investments to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. At March 31, 2012, approximately 100 percent of our total debt is at a fixed rate. We have converted approximately 60 percent of our fixed-rate debt to floating rates through the use of interest rate swaps.

We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.

The Effect of Risk-Management Instruments on the Consolidated Condensed Statement of Operations

The following effects of risk-management instruments were recognized in other—net, expense:


	Three Months Ended March 31,
	2012			2011

	(Dollars in millions)
Fair value hedges
Effect from hedged fixed-rate debt	$	(65.9	)	$	(53.3)
Effect from interest rate contracts		65.9			53.3

Cash flow hedges
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss		2.2			2.2

Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments		(32.8	)		30.0

The effective portion of net losses on equity contracts in designated cash flow hedging relationships recorded in other comprehensive income was $10.0 million for the first quarter of 2011.

We expect to reclassify $9.0 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on floating rate debt from accumulated other comprehensive loss to earnings during the next 12 months.

During the first quarters of 2012 and 2011, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.

Fair Value of Financial Instruments

The following tables summarize certain fair value information at March 31, 2012 and December 31, 2011 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:


					Fair Value Measurements Using
Description	Carrying Amount		Amortized Cost		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Fair Value
	(Dollars in millions)
March 31, 2012
Cash and cash equivalents	$	4,122.2	$	4,122.2	$	4,006.4	$	115.8	$		$	4,122.2


Short-term investments
U.S. government and agencies	$	46.2	$	46.2	$	46.2	$				$	46.2
Corporate debt securities		735.8		735.1				735.8				735.8
Other securities		20.4		20.4				20.4				20.4

Short-term investments	$	802.4	$	801.7


Noncurrent investments
U.S. government and agencies	$	978.4	$	976.1	$	978.4	$		$		$	978.4
Corporate debt securities		2,373.7		2,362.7				2,373.7				2,373.7
Mortgage-backed		476.2		506.8				476.2				476.2
Asset-backed		306.6		313.9				306.6				306.6
Other securities		11.1		11.1				10.1		1.0		11.1
Marketable equity		201.6		109.3		201.6						201.6
Equity method and other investments⁽¹⁾		173.5		173.5

Noncurrent investments	$	4,521.1	$	4,453.4


December 31, 2011
Cash and cash equivalents	$	5,922.5	$	5,922.5	$	5,264.6	$	657.9	$		$	5,922.5

Short-term investments
U.S. government and agencies	$	362.3	$	362.3	$	362.3	$		$		$	362.3
Corporate debt securities		600.7		601.1				600.7				600.7
Other securities		11.6		11.6				11.6				11.6

Short-term investments	$	974.6	$	975.0


Noncurrent investments
U.S. government and agencies	$	908.8	$	901.3	$	908.8	$		$		$	908.8
Corporate debt securities		2,081.3		2,093.3				2,081.3				2,081.3
Mortgage-backed		443.8		479.1				443.8				443.8
Asset-backed		245.0		253.2				245.0				245.0
Other securities		10.0		11.9				8.7		1.3		10.0
Marketable equity		180.8		107.5		180.8						180.8
Equity methods and other investments⁽¹⁾		160.1		160.1

Noncurrent investments	$	4,029.8	$	4,006.4

⁽¹⁾ — Fair value not applicable


				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Fair Value
	(Dollars in millions)
Long-term debt, including current portion

March 31, 2012	$	(5,413.8	)	$	$	(5,845.2	)	$	$	(5,845.2	)
December 31, 2011	$	(6,981.5	)	$	$	(7,451.5	)	$	$	(7,451.5	)


				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Fair Value
	(Dollars in millions)
March 31, 2012
Risk-management instruments
Interest rate contracts designated as hedging instruments
Sundry	$	472.0		$	$	472.0		$	$	472.0
Foreign exchange contracts not designated as hedging instruments
Other receivables		12.1				12.1				12.1
Other current liabilities		(5.3	)			(5.3	)			(5.3	)

December 31, 2011
Risk-management instruments
Interest rate contracts designated as hedging instruments
Other receivables	$	6.1		$	$	6.1		$	$	6.1
Sundry		531.7				531.7				531.7
Foreign exchange contracts not designated as hedging instruments
Other receivables		16.2				16.2				16.2
Other current liabilities		(25.9	)			(25.9	)			(25.9	)

The fair value of the contingent consideration liability related to prior acquisitions, a Level 3 measurement in the fair value hierarchy, was $121.6 million as of March 31, 2012 and December 31, 2011, respectively.

We determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair value of equity method investments and other investments is not readily available.

Approximately $4.19 billion of our investments in debt securities, measured at fair value, will mature within five years.

A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:


	March 31, 2012		December 31, 2011

		(Dollars in millions)
Unrealized gross gains	$	124.8		$ 103.0
Unrealized gross losses		56.4		80.0
Fair value of securities in an unrealized gain position		3,159.0		2,498.9
Fair value of securities in an unrealized loss position		1,877.5		2,164.4

Other-than-temporary impairment losses on fixed income securities of $3.7 million were recognized in the statement of operations for the first quarter of 2012 compared with $0.5 million for the same period in 2011. The amount of credit losses represents the difference between the present value of cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing the credit loss were the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.

The securities in an unrealized loss position include fixed-rate debt securities of varying maturities. The value of fixed income securities is sensitive to changes in the yield curve and other market conditions. Approximately 90 percent of the securities in a loss position are investment-grade debt securities. At this time, there is no indication of default on interest or principal payments for debt securities other than those for which an other-than-temporary impairment charge has been recorded. We do not intend to sell and it is not more likely than not we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and we have concluded that no additional other-than-temporary loss is required to be charged to earnings as of March 31, 2012.

Activity related to our available-for-sale investment portfolio was as follows:


	Three Months Ended March 31,
	2012		2011

	(Dollars in millions)
Proceeds from sales	$	2,383.4	$	260.9
Realized gross gains on sales		13.7		39.4
Realized gross losses on sales		2.7		3.5

Realized gains and losses on sales of available-for-sale securities are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.

Note 7: Stock-Based Compensation

Our stock-based compensation expense consists primarily of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognized pretax stock-based compensation cost of $30.9 million and $37.9 million in the first quarter of 2012 and 2011, respectively.

PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain earnings per share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. As of March 31, 2012, the total remaining unrecognized compensation cost related to nonvested PAs amounted to $42.6 million, which will be amortized over the weighted-average remaining requisite service period of approximately 17 months.

SVAs are granted to officers and management and are payable in shares of common stock at the end of a three-year period. The number of shares actually issued varies depending on our stock price at the end of the three-year vesting period compared to pre-established target prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. As of March 31, 2012, the total remaining unrecognized compensation cost related to nonvested SVAs amounted to $84.5 million, which will be amortized over the weighted-average remaining requisite service period of approximately 26 months.

RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. As of March 31, 2012, the total remaining unrecognized compensation cost related to nonvested RSUs amounted to $91.3 million, which will be amortized over the weighted-average remaining requisite service period of 27 months.

Note 8: Shareholders’ Equity

As of March 31, 2012, we have purchased $2.58 billion of our previously announced $3.00 billion share repurchase program. We did not acquire any shares pursuant to this program during the first three months of 2012, and we have no current plans to repurchase shares under this program for the remainder of 2012.

Note 9: Earnings Per Share

Unless otherwise noted in the footnotes, all per-share amounts are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of all potentially dilutive common shares (primarily contingently issuable shares and unexercised stock options).

Note 10: Income Taxes

We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in major taxing jurisdictions for years before 2007.

The U.S. examination of certain matters related to tax years 2008-2009 that were not settled as part of previous examinations remains in progress. Because this examination is still in its early stages, the resolution of all issues in this audit period will likely extend beyond the next 12 months.

Note 11: Retirement Benefits

Net pension and retiree health benefit expense included the following components:


	Defined Benefit Pension Plans						Retiree Health Benefit Plans
	Three Months Ended March 31,						Three Months Ended March 31,
	2012			2011			2012			2011

		(Dollars in millions)
Components of net periodic benefit cost
Service cost	$	63.0		$	58.9		$	16.4		$	14.8
Interest cost		113.0			111.8			28.5			29.5
Expected return on plan assets		(171.1	)		(171.6	)		(31.8	)		(32.0	)
Amortization of prior service cost		.9			2.2			(8.8	)		(10.8	)
Recognized actuarial loss		70.9			49.5			23.7			22.2

Net periodic benefit cost	$	76.7		$	50.8		$	28.0		$	23.7

On a global basis, we have contributed approximately $30 million required to satisfy minimum funding requirements to our defined benefit pension plans in 2012. In addition, we have contributed $300 million of discretionary funding to our global post-retirement benefit plans in 2012. During the remainder of 2012, we expect to make contributions to our defined benefit pension plans of approximately $40 million to satisfy minimum funding requirements. We do not anticipate making any additional discretionary contributions in 2012.

Note 12: Contingencies

We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as specifically noted below with respect to the Alimta^® Hatch-Waxman Act patent challenges, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.

Patent Litigation

We are engaged in U.S. patent litigation matters involving Alimta brought pursuant to procedures set out in the Hatch-Waxman Act (the Drug Price Competition and Patent Term Restoration Act of 1984). Teva Parenteral Medicines, Inc. (Teva); APP Pharmaceuticals, LLC (APP); and Barr Laboratories, Inc. (Barr) each submitted ANDAs seeking approval to market generic versions of Alimta prior to the expiration of the relevant U.S. patents and data-based pediatric exclusivity period (compound patent licensed from the Trustees of Princeton University and expiring in 2017, concomitant nutritional supplement use patent expiring in 2022) and alleging the patents are invalid. We, along with Princeton, filed lawsuits in the U.S. District Court for the District of Delaware against Teva, APP, and Barr seeking rulings that the compound patent is valid and infringed. In July 2011, the district court entered judgment in our favor, upholding that patent’s validity. The generic manufacturers have appealed this decision. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP, Pliva Hrvatska D.O.O., and Barr seeking rulings that our concomitant nutritional supplement use patent is valid and infringed. No trial date has yet been set. In January 2012 and April 2012, we filed similar lawsuits against Accord Healthcare Inc. and Apotex Inc., respectively.

We believe the Hatch-Waxman challenges to the Alimta patents are without merit and expect to prevail in this litigation. However, it is not possible to determine the outcome of this litigation, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues in the relevant market.

Zyprexa^® Litigation

We are a defendant in approximately 20 Zyprexa product liability lawsuits in the U.S. covering approximately 80 plaintiffs. The lawsuits allege a variety of injuries from the use of Zyprexa, with the majority alleging that the product caused or contributed to diabetes or high blood-glucose levels. The claims seek substantial compensatory and punitive damages and typically accuse us of inadequately testing for and warning about side effects of Zyprexa. Many of the claims also allege that we improperly promoted the drug. Approximately 15 of the lawsuits, covering about 15 plaintiffs, are part of a Multi-District Litigation (MDL) proceeding before The Honorable Jack Weinstein in the Federal District Court for the Eastern District of New York (EDNY) (MDL No. 1596). We are prepared to continue our vigorous defense of Zyprexa in all these lawsuits and claims.

Byetta Litigation

We have been named as a defendant in approximately 115 lawsuits involving approximately 490 plaintiffs, primarily seeking to recover damages for pancreatitis experienced by patients prescribed Byetta. We are aware of approximately 520 additional claimants who have not yet filed suit. Approximately 100 of these lawsuits are filed in California and coordinated in a Los Angeles Superior Court. We believe these claims are without merit and are prepared to defend against them vigorously.

Diethylstilbestrol Litigation

In approximately 100 U.S. lawsuits against us involving approximately 115 claimants, plaintiffs seek to recover damages on behalf of children or grandchildren of women who were prescribed diethylstilbestrol (DES) during pregnancy in the 1950s and 1960s. Approximately 85 of these claimants allege that they were indirectly exposed in utero to the medicine and later developed breast cancer as a consequence. In December 2009, a lawsuit was filed in U.S. District Court in Washington, D.C. against Lilly and other manufacturers (Michele Fecho, et al. v. Eli Lilly and Company, et al.) seeking to assert product liability claims on behalf of a putative class of men and women allegedly exposed to the medicine who claim to have later developed breast cancer; this case was dismissed in April 2012. Certain parties in this case participated in court-ordered mediation on April 20, 2012 which did not result in a decision. Five cases involving similar allegations are scheduled for trial in January 2013. We believe these claims are without merit and are prepared to defend against them vigorously.

Product Liability Insurance

Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. In the past several years, we have been unable to obtain product liability insurance due to a very restrictive insurance market. Therefore, for substantially all of our currently marketed products, we have been and expect that we will continue to be completely self-insured for future product liability losses. The DES claims are covered by insurance, subject to deductibles and coverage limits. There is no assurance that we will be able to fully collect from our insurance carriers in the future.

Note 13: Other - Net, Expense

Other - net, expense comprised the following:


	Three Months Ended March 31,
	2012			2011

	(Dollars in millions)
Interest expense	$	45.3		$	45.8
Interest income		(26.1	)		(15.5)
Other		26.8			(19.1)

Other-net, expense	$	46.0		$	11.2

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Operating Results

Executive Overview

Financial Results

Worldwide total revenue was $5.60 billion, a decrease of 4 percent compared with the first quarter of 2011. The decrease was primarily driven by the loss of patent exclusivity for Zyprexa, partially offset by growth in Cymbalta, Forteo^®, Effient, diabetes care, and our animal health portfolio. The decrease in revenues, lower gross margin, and an increase in the effective tax rate, were partially offset by the acquired in-process research and development (IPR&D) charge in the first quarter 2011described below. As a result, net income decreased 4 percent to $1.01 billion, and earnings per share decreased 4 percent to $0.91 per share, in the first quarter of 2012 as compared to $1.06 billion, or $0.95 per share, in the first quarter of 2011.

2012

Asset Impairments and Restructuring and Other Special Charges (Note 5)

•

We recognized asset impairments, restructuring, and other special charges of $23.8 million (pretax), or $.01 per share, primarily related to changes in returns reserve estimates for the withdrawal of Xigris in the fourth quarter of 2011.

2011

Collaborations (Note 4)

•

We incurred acquired IPR&D charges associated with the diabetes collaboration with Boehringer Ingelheim of $388.0 million (pretax), which decreased earnings per share by $.23.

Asset Impairments and Restructuring and Other Special Charges (Note 5)

•

We recognized asset impairments, restructuring, and other special charges of $76.3 million (pretax), or $.06 per share, related to severance costs from previously announced strategic actions.

Late-Stage Pipeline

Our long-term success depends to a great extent on our ability to continue to discover and develop innovative pharmaceutical products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies. We currently have approximately 65 potential new drugs in human testing or under regulatory review, and a larger number of projects in preclinical research.

There are many difficulties and uncertainties inherent in pharmaceutical research and development (R&D) and the introduction of new products. A high rate of failure is inherent in new drug discovery and development. The process to bring a drug from the discovery phase to regulatory approval can take 12 to 15 years or longer and cost more than $1 billion. Failure can occur at any point in the process, including late in the process after substantial investment. As a result, most research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain necessary regulatory approvals, limited scope of approved uses, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Delays and uncertainties in the U.S. Food and Drug Administration (FDA) approval process and the approval processes in other countries can result in delays in product launches and lost market opportunity. Consequently, it is very difficult to predict which products will ultimately be approved and the sales growth of those products.

We manage R&D spending across our portfolio of molecules, and a delay in, or termination of, any one project will not necessarily cause a significant change in our total R&D spending. Due to the risks and uncertainties involved in the R&D process, we cannot reliably estimate the nature, timing, completion dates, and costs of the efforts necessary to complete the development of our R&D projects, nor can we reliably estimate the future potential revenue that will be generated from a successful R&D project. Each project represents only a portion of the overall pipeline, and none is individually material to our consolidated R&D expense. While we do accumulate certain R&D costs on a project level for internal reporting purposes, we must make significant cost estimations and allocations, some of which rely on data that are neither reproducible nor validated through accepted control mechanisms. Therefore, we do not have sufficiently reliable data to report on total R&D costs by project, by preclinical versus clinical spend, or by therapeutic category.

The following new molecular entities (NMEs) are currently in Phase III clinical trial testing for potential use in the diseases described. The quarter in which the NME initially entered Phase III for any indication is shown in parentheses:

Dulaglutide* (Q3 2008) – a glucagon-like peptide 1 analog for the treatment of type 2 diabetes

Edivoxetine (Q4 2010) – a norepinepherine reuptake inhibitor for the treatment of major depression

Empagliflozin-BI10773 (Q3 2010) – a sodium glucose co-transporter (SGLT-2) inhibitor for the treatment of type 2 diabetes (in collaboration with Boehringer Ingelheim)

Enzastaurin (Q1 2006) – a small molecule for the treatment of diffuse large B-cell lymphoma

Ixekizumab* (Q4 2011) – a monoclonal antibody for the treatment of psoriasis

Necitumumab* (Q4 2009) – a fully human monoclonal antibody for the treatment of squamous non-small cell lung cancer (NSCLC) (in collaboration with Bristol Myers Squibb)

New insulin glargine product (Q3 2011) – a new insulin glargine product for the treatment of type 1 and type 2 diabetes (in collaboration with Boehringer Ingelheim)

Novel basal insulin analog* (Q4 2011) – a novel basal insulin for the treatment of type 1 and type 2 diabetes (in collaboration with Boehringer Ingelheim)

Pomaglumetad Methionil (Q1 2011) – a metabotropic glutamate 2/3 (mGlu 2/3) receptor agonist for the treatment of schizophrenia

Ramucirumab* (Q4 2009) – a monoclonal antibody for the treatment of metastatic breast, gastric, liver, NSCLC, and colorectal cancers

Solanezumab* (Q2 2009) – an amyloid beta (Aß) antibody for the treatment of Alzheimer’s disease

Tabalumab* (Q4 2010) – an anti-BAFF monoclonal antibody for the treatment of lupus and rheumatoid arthritis

Biologic molecule subject to the U.S. Biologics Price Competition and Innovation Act

The following NME has been submitted for regulatory review for potential use in the disease described. The quarter the NME initially was submitted for any indication is shown in parentheses:

Liprotamase (Q1 2010) – a non-porcine pancreatic enzyme replacement therapy for the treatment of exocrine pancreatic insufficiency.

The following are late-stage pipeline updates since January 1, 2012:

Florbetapir – On April 6, 2012, the FDA approved Amyvid™ (florbetapir), a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes of cognitive decline. Beginning in June, a limited number of radiopharmacies will be distributing Amyvid.

Linagliptin – In January 2012, the FDA approved Jentadueto™, a combination of linagliptin and metformin for the treatment of adults with type 2 diabetes (in collaboration with Boehringer Ingelheim).

Solanezumab – In January 2012, an independent Data Monitoring Committee (DMC) recommended that we continue the two ongoing Phase III randomized pivotal trials for solanezumab without modifications, based on pre-planned interim safety and futility analyses. The DMC also recommended that we make a protocol modification to EXPEDITION-XT, the open-label extension study of the two Phase III trials, making the protocol for the open-label extension more consistent with the current protocol for the pivotal studies. We expect to report the results of the two Phase III pivotal trials in the second half of 2012.

Legal, Regulatory, and Other Matters

The enactment of the “Patient Protection and Affordable Care Act” (PPACA) and “The Health Care and Education Reconciliation Act of 2010” in March 2010 brought significant changes to U.S. health care. These changes began to affect our financial results in the first quarter of 2010 and will continue to have significant impact on our results in the future. The U.S. Supreme Court has agreed to decide the constitutionality of the PPACA, including the Medicaid expansion and the individual mandate for health insurance scheduled to take effect in 2014. Oral arguments took place in March 2012 and a decision is expected in June 2012. We are unable to predict the impact to our consolidated results of operations, liquidity, and financial position should the Supreme Court rule that all or part of the PPACA is unconstitutional.

The continuing prominence of U.S. budget deficits as both a policy and political issue increases the risk that taxes, fees, rebates, or other measures that would further reduce pharmaceutical companies’ revenue or increase expenses may be enacted. Certain other federal and state health care proposals continue to be debated, and could place downward pressure on pharmaceutical industry sales or prices. We also expect pricing pressures at state levels could become more severe. These federal and state proposals, or state price pressures, could have a material adverse effect on our consolidated results of operations.

The Obama administration has proposed changes to the manner in which the U.S. would tax the international income of U.S.-based companies. There also have been tax proposals under discussion or introduced in the U.S. Congress that could change the manner in which, and the rate at which, income of U.S. companies would be taxed. While it is uncertain how the U.S. Congress may address U.S. tax policy matters in the future, reform of U.S. taxation, including taxation of international income, will continue to be a topic of discussion for Congress and the Obama administration. A significant change to the U.S. tax system, including changes to the taxation of international income, could have a material adverse effect on our consolidated results of operations.

International operations also are generally subject to extensive price and market regulations, and several European countries have recently required either price decreases or rebate increases in response to economic pressures. There are proposals for cost-containment measures pending in a number of additional countries, including proposals that would directly or indirectly impose additional price controls, limit access to or reimbursement for our products, or reduce the value of our intellectual property protection. Such proposals are expected to increase in both frequency and impact, given the pressures on national and regional health care budgets as a result of austerity measures being pursued in a number of countries.

Revenue

Revenue decreased 4 percent, to $5.60 billion, compared with the first quarter of 2011. This 4 percent revenue decline was comprised of a decrease of 7 percent due to lower volume, partially offset by an increase of 4 percent in prices. Foreign exchange rates had a negligible impact (numbers do not add due to rounding). The decrease in volume was driven by the loss of patent exclusivity for Zyprexa in most major markets, partially offset by volume gains for other products. Total revenue in the U.S. remained relatively flat at $3.08 billion due to the loss of patent exclusivity for Zyprexa, offset by higher prices and, to a lesser extent, increased volume in other products. Revenue outside the U.S. decreased $245.9 million, or 9 percent, for the first quarter of 2012 driven by the loss of patent exclusivity for Zyprexa, partially offset by increased volume in other products including Cymbalta, Forteo, Humalog^®, Effient, and the animal health portfolio.

The following table summarizes our revenue activity for the three months ended March 31, 2012 and 2011:


	Three Months Ended March 31, 2012						Three Months Ended March 31, 2011 Total		Percent Change from 2011
Product	U.S.¹		Outside U.S.		Total²		Three Months Ended March 31, 2011 Total		Percent Change from 2011
	(Dollars in millions)
Cymbalta	$	857.6	$	257.3	$	1,114.9	$	908.8		23	%
Alimta		256.6		350.2		606.8		579.9		5	%
Humalog		348.4		241.9		590.3		525.4		12	%
Zyprexa		202.8		359.9		562.7		1,281.9		(56	)%
Animal health products		269.6		221.1		490.7		369.8		33	%
Cialis^®		178.8		283.0		461.8		434.4		6	%
Humulin^®		155.1		152.6		307.7		289.8		6	%
Forteo		121.9		149.4		271.3		216.1		26	%
Evista^®		171.7		84.5		256.2		266.1		(4	)%
Strattera^®		104.8		54.1		158.9		138.7		15	%
Effient		89.8		26.0		115.8		56.3		NM
Other pharmaceutical products		166.7		310.0		476.7		622.7		(23	)%

Total net product sales		2,923.8		2,490.0		5,413.8		5,689.9		(5	)%
Collaboration and other revenue³		161.1		27.1		188.2		149.3		26	%

Total revenue	$	3,084.9	$	2,517.1	$	5,602.0	$	5,839.2		(4	)%

NM – Not Meaningful

¹	U.S. revenue includes revenue in Puerto Rico.

²	Numbers may not add due to rounding.

³	Collaboration and other revenue consists primarily of Erbitux royalties and revenue associated with exenatide in the U.S.

Product Highlights

U.S. sales of Cymbalta, a product for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the U.S. for the treatment of chronic musculoskeletal pain and the management of fibromyalgia, increased 24 percent during the first three months of 2012. The increase was due to higher prices and increased demand. Sales outside the U.S. increased 18 percent during the first three months of 2012 compared with the same period in 2011, driven by increased demand.

U.S. sales of Alimta, a treatment for various cancers, increased 10 percent during the first three months of 2012 due to increased demand and, to a lesser extent, higher prices. Sales outside the U.S. increased 1 percent for the same period due to increased demand, partially offset by lower prices in Japan.

U.S. sales of Humalog, our injectable human insulin analog for the treatment of diabetes, increased 15 percent for the first quarter of 2012 due to higher prices. Sales outside the U.S. increased 9 percent for the first three months of 2012, driven by increased demand.

U.S. sales of Zyprexa, a treatment for schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance, decreased 66 percent in the first three months of 2012. Sales outside the U.S. decreased 47 percent. The decreases in both the U.S. and outside the U.S. were due to the loss of patent exclusivity in the U.S. and most major international markets outside of Japan. We expect further erosion of Zyprexa sales throughout 2012.

U.S. sales of Cialis, a treatment for erectile dysfunction, increased 13 percent for the first quarter of 2012, driven by increased demand. Sales outside the U.S. increased 2 percent, driven by increased demand and higher prices, partially offset by the unfavorable impact of foreign exchange rates.

U.S. sales of Humulin, an injectable human insulin for the treatment of diabetes, increased 20 percent during the first three months of 2012, driven primarily by higher prices. Sales outside the U.S. decreased 5 percent during the first three months of 2012, driven by the unfavorable impact of foreign exchange rates, lower prices, and decreased volume.

U.S. sales of Forteo, an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in postmenopausal women and men, increased 9 percent during the first quarter of 2012, driven by higher prices, largely offset by decreased demand. Sales outside the U.S. increased 43 percent the first quarter of 2012, due primarily to increased demand in Japan.

U.S. sales of Evista, a product for the prevention and treatment of osteoporosis in postmenopausal women and for reduction of risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer, decreased 1 percent during the first three months of 2012, driven by decreased demand, largely offset by higher prices. Sales outside the U.S. decreased 8 percent for the first quarter of 2012, driven by decreased volume in Japan.

U.S. sales of Strattera, a treatment for attention-deficit hyperactivity disorder in children, adolescents, and in the U.S. in adults, increased 21 percent during the first three months of 2012, due to higher prices. Sales outside the U.S. increased 4 percent for the first three months of 2012, driven primarily by increased demand, partially offset by lower prices.

U.S. sales of Effient, a product for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), including patients undergoing angioplasty, atherectomy, or stent placement, increased 114 percent during the first three months of 2012 due to increased demand and higher prices. Sales outside the U.S. increased 82 percent due to increased demand.

We report as revenue for Erbitux, a product approved to treat various cancers, the net royalties received from our collaboration partners and our product sales. Our revenues increased 9 percent, to $113.3 million, during the first quarter of 2012.

Animal health product sales in the U.S. increased 33 percent during the first quarter of 2012 due primarily to increased demand and the favorable impact from customer buying patterns. Sales outside the U.S. increased 32 percent during the first quarter of 2012, driven primarily by the impact of the acquisition of the Janssen animal health assets in Europe.

Gross Margin, Costs, and Expenses

For the first quarter of 2012, gross margin as a percent of total revenue decreased by 1.2 percentage points, to 78.6 percent. The decrease was primarily due to lower sales of Zyprexa following its patent expiration in most major markets, partially offset by the impact of foreign exchange rates on international inventories sold.

Marketing, selling, and administrative expenses increased 3 percent, to $1.85 billion, for the first quarter of 2012, driven by the diabetes collaboration with Boehringer Ingelheim (BI) and increased expense for newer pharmaceutical and animal health products, partially offset by lower administrative expenses. Research and development expenses were $1.15 billion for the first quarter of 2012. Compared with the same period of 2011, research and development expenses increased 2 percent, driven by expenses related to the diabetes collaboration with BI and other late-stage clinical trial costs.

No acquired IPR&D charges were incurred in the first three months of 2012, compared with $388.0 million for the same period in 2011, all of which was associated with the diabetes collaboration with BI. We incurred $23.8 million of asset impairments, restructuring, and other special charges in the first quarter of 2012, compared with $76.3 million for the same period in 2011. See Notes 4 and 5 to the consolidated condensed financial statements for additional information.

Other—net, expense was a net expense of $46.0 million, compared with net expense of $11.2 million in the first quarter of 2011. The increase was driven by the recognition in the first quarter of 2011 of a gain on an equity investment and an insurance recovery, partially offset by increased interest income in the first quarter of 2012.

The effective tax rate was 24.3 percent in the first quarter of 2012, compared with an effective tax rate of 17.1 percent in the first quarter of 2011. The increase in the effective tax rate was driven primarily by the tax benefit in 2011 of the IPR&D charge described above, as well as the expiration of the R&D tax credit in the U.S. at the end of 2011.

Financial Condition

As of March 31, 2012, cash, cash equivalents, and short-term investments totaled $4.92 billion compared with $6.90 billion at December 31, 2011. The decrease was due primarily to the maturity and repayment of long-term debt of $1.50 billion and dividends paid of $544.6 million.

Total debt as of March 31, 2012 decreased by $1.57 billion compared with December 31, 2011, to $5.41 billion, due primarily to the previously mentioned long-term debt maturity and payment of $1.50 billion. Our current debt ratings from Standard & Poor’s and Moody’s are AA- and A2, respectively.

As of the first quarter of 2012, the U.S economy continues to show signs of recovery, though at a moderate pace. This is in contrast to Europe, where the Eurozone gross domestic product will likely decrease in 2012, with the “peripheral” nations continuing to weigh on the region. While worries in Europe persist, several positive actions this quarter were aimed at calming fears, including the Greek Private Sector Involvement bond exchange, the European Central Bank’s second three-year Long-Term Refinancing Operations and the agreement of Eurozone finance ministers to increase the size of the bailout package by 500 billion euro. This quarter also saw Japan announce its first trade deficit in more than three decades, while concern over oil prices created unease. Meanwhile, U.S. economic data in the first quarter generally exceeded expectations, with several key indicators signaling a strengthening recovery dampened, however, by the continued lag of the housing market. Given the fragility of the economic recovery and the continued anxiety regarding Europe, the Federal Reserve has maintained its view that accommodative policy is likely to be warranted through 2014. Fiscal austerity efforts, domestically and abroad (most notably in Spain, Italy and Greece), driven by sluggish growth and high sovereign debt levels, play a key role in the global economic recovery. We continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government backed agencies and suppliers; the uncertain impact of recent health care legislation; the federal government’s involvement in the U.S. economy; and various international government funding levels. Currently, we believe economic conditions in Europe will not have a material impact on our liquidity.

We believe that cash generated from operations, along with available cash and cash equivalents, will be sufficient to fund our normal operating needs, including debt service, capital expenditures, and dividends in 2012. We believe that amounts accessible through existing commercial paper markets will be adequate to fund short-term borrowings. Because of the high credit quality of our short- and long-term debt, our access to credit markets has not been adversely affected. We currently have $1.24 billion of unused committed bank credit facilities, $1.20 billion of which backs our commercial paper program. Various risks and uncertainties, including those discussed in the Financial Expectations for 2012 section, may affect our operating results and cash generated from operations.

We depend on patents or other forms of intellectual property protection for most of our revenues, cash flows, and earnings. Through 2014, we expect to lose U.S. patent protection for Cymbalta (June 2013) and Evista (March 2014). Cymbalta could receive an additional six months of exclusivity, based on completion of pediatric studies.

Zyprexa and Gemzar have already lost exclusivity in the U.S. and Europe. In the U.S., Gemzar lost exclusivity in November 2010 and Zyprexa lost exclusivity in October 2011. In addition, we face U.S. patent litigation over Alimta, and it is possible we could lose our exclusivity prior to the expiration of the relevant patents. Refer to the Hatch-Waxman patent litigation discussion in Note 12 and in the “Legal and Regulatory Matters” section below. The loss of exclusivity for Alimta, Cymbalta, or Evista would likely result in generic competition, generally causing a rapid and severe decline in revenue from the affected product, which would have a material adverse effect on our results of operations. The U.S. patent for Humalog expires in May 2013. Humalog is currently protected in Europe only by formulation patents. We do not currently expect the loss of patent protection for Humalog to result in a rapid and severe decline in revenue. To date, no biosimilar version of Humalog has been approved in the U.S. or Europe; however, it is difficult to predict the likelihood and impact of biosimilars entering the market. Our goal is to mitigate the effect of these exclusivity losses on our operations, liquidity, and financial position through growth in our patent-protected products that do not lose exclusivity during this period, in the emerging markets, in Japan, and in our animal health business. Our expected growth in the emerging markets and Japan is attributable to both the growth of these markets and launches of patent-protected products in these markets.

Legal and Regulatory Matters

Patent Litigation

that patent’s validity. The generic manufacturers have appealed this decision. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP, Pliva Hrvatska D.O.O., and Barr seeking rulings that our concomitant nutritional supplement use patent is valid and infringed. No trial date has yet been set. In January 2012 and April 2012, we filed similar lawsuits against Accord Healthcare Inc. and Apotex Inc., respectively.

Zyprexa^® Litigation

Byetta Litigation

Diethylstilbestrol Litigation

Product Liability Insurance

Financial Expectations for 2012

We have raised our 2012 earnings per share guidance and now expect to be in the range of $3.14 to $3.29. All other elements of our 2012 financial guidance remain unchanged. We anticipate that total revenue will be between $21.8 billion and $22.8 billion. This includes an expected decline of more than $3 billion in Zyprexa sales due to patent expirations in most markets outside of Japan. The reduction in revenue due to Zyprexa patent expirations is expected to be partially offset by growth in key franchises including Cymbalta, Cialis, Humalog, Humulin, and Forteo, as well as continued growth of newer products such as Effient, Axiron^®, and Tradjenta. We also anticipate continued strong, double-digit revenue growth from our Elanco Animal Health business. Both Japan and emerging markets are expected to post continued strong underlying volume growth; however, overall revenue growth in these markets in 2012 will be adversely affected by pricing actions in Japan and by the expected impact of patent expirations, including Zyprexa, in some emerging market countries.

We anticipate that gross margin as a percent of revenue will be approximately 77 percent. Marketing, selling, and administrative expenses are expected to decline and be in the range of $7.4 billion to $7.8 billion. Research and development expense is expected to be flat to increasing and in the range of $5.0 billion to $5.3 billion. Other—net, expense is expected to be in a range between net expense of $50 million and net income of $100 million. Operating cash flows are expected to be more than sufficient to fund capital expenditures of approximately $800 million, as well as anticipated business development activity and our current dividend.

We caution investors that any forward-looking statements or projections made by us, including those above, are based on management’s belief at the time they are made. However, they are subject to risks and uncertainties. Actual results could differ materially and will depend on, among other things, the continuing growth of our currently marketed products; developments with competitive products; the implementation of U.S. health care reform; the timing and scope of regulatory approvals and the success of our new product launches; asset impairments, restructurings, and acquisitions of compounds under development resulting in acquired IPR&D charges; foreign exchange rates and global macroeconomic conditions; changes in effective tax rates; wholesaler inventory changes; other regulatory developments, litigation, patent disputes, and government investigations; and the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals. Other factors that may affect our operations and prospects are discussed in Item 1A of our 2011 Form 10-K, “Risk Factors.” We undertake no duty to update these forward-looking statements.

Available Information on our Website

We make available through our company website, free of charge, our company filings with the Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The reports we make available include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents.

The website link to our SEC filings is http://investor.lilly.com/financials.cfm.

Item 4. Controls and Procedures

(a)

Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the commission (such as this Form 10-Q) is recorded, processed, summarized, and reported on a timely basis.

Our management, with the participation of John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, and Derica W. Rice, executive vice president, global services and chief financial officer, evaluated our disclosure controls and procedures as of March 31, 2012, and concluded that they are effective.

(b)

Changes in Internal Controls. During the first quarter of 2012, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We are pursuing a multi-year initiative to outsource some accounting transaction-processing activities, migrating to a consistent enterprise financial system across the organization, and moving certain activities to newly-established captive shared services centers. In addition, we are in the process of reducing financial human resources at various locations around the world. None of these initiatives is in response to any identified deficiency or weakness in our internal control over financial reporting. These initiatives are expected to continue to enhance our internal control over financial reporting, but in the short term may increase our risk.

Part II. Other Information

Item 1. Legal Proceedings

See Part I, Item 2, Management’s Discussion and Analysis, “Legal and Regulatory Matters,” for information on various legal proceedings, including but not limited to:

•

The U.S. patent litigation involving Alimta

•

The product liability litigation involving Zyprexa, Byetta, and diethylstilbestrol.

That information is incorporated into this Item by reference.

Strattera Patent Litigation

Actavis Elizabeth LLC, Apotex Inc., Aurobindo Pharma Ltd., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries Limited, and Teva Pharmaceuticals USA, Inc. each submitted an ANDA seeking permission to market generic versions of Strattera prior to the expiration of our relevant U.S. patent and data-based pediatric exclusivity period (expiring in 2017), and alleging that this patent is invalid. In 2007, we brought a lawsuit against the seven companies in the U.S. District Court for the District of New Jersey. In August 2010, the district court ruled that our patent was invalid; however, in July 2011, the Court of Appeals for the Federal Circuit overturned that decision, upholding the patent. The deadline for any further appeal has passed. Zydus Pharmaceuticals (Zydus) filed an action in the New Jersey district court in October 2010 seeking a declaratory judgment that it had the right to launch a generic atomoxetine product, based on the district court ruling in the Actavis case. Following the Federal Circuit decision in Actavis, Zydus and Lilly entered into a consent judgment under which Zydus has dismissed its declaratory judgment action and consented to the validity of Lilly’s patent.

Other Product Liability Litigation

We are currently a defendant in a variety of other product liability lawsuits involving primarily Darvon^®, Prozac^®, and Actos^®.

Along with several other manufacturers, we have been named as a defendant in approximately 150 cases in the U.S. involving approximately 760 claimants related to the analgesic Darvon and related formulations of propoxyphene. These cases generally allege various cardiac injuries. In November 2011, a lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana (Ballard, et al. v. Eli Lilly and Company et al.) against Lilly and other manufacturers as a putative class action seeking to assert product liability claims on behalf of U.S. residents who ingested propoxyphene and allegedly sustained personal injuries. We transferred the U.S. regulatory approvals and all marketing rights to our propoxyphene products in 2002 to aaiPharma Inc., which subsequently transferred all such approvals and marketing rights to Xanodyne Pharmaceuticals, Inc. We believe these claims are without merit and are prepared to defend against them vigorously.

We have been named as a defendant in a U.S. lawsuit involving a claimant alleging that the antidepressant Prozac caused or contributed to birth defects in the daughter of a woman who ingested the drug during pregnancy. We are aware of approximately 315 additional claims related to birth defects, which have not yet been filed. We believe these claims are without merit and are prepared to defend against them vigorously.

We have been named along with Takeda Chemical Industries, Ltd., and Takeda affiliates (together “Takeda”) as a defendant in product liability cases in the U.S. related to the diabetes medication Actos, which we co-promoted with Takeda in the U.S. from 1999 until September 2006. Under our agreement with Takeda, we will be indemnified by Takeda for our losses and expenses in connection with the U.S. litigation in accordance with the terms of the agreement. We have also been named along with Takeda as a defendant in a purported product liability class action in Ontario, Canada (Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.) related to Actos, which we promoted in Canada until 2009. We believe these claims are without merit and are prepared to defend against them vigorously.

Other Matters

We are also a defendant in other litigation and investigations, including product liability, patent, employment, and premises liability litigation, of a character we regard as normal to our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table summarizes the activity related to repurchases of our equity securities during the three months ended March 31, 2012:


Period	Total Number of Shares Purchased (a)	Average Price Paid per Share (b)		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (c)	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (d)
	(in thousands)			(in thousands)	(in millions)
January 2012	—	$	—	—	$	419.2
February 2012	—		—	—		419.2
March 2012	—		—	—		419.2

Total	—			—

The amounts presented in columns (a) and (b) above represent purchases of common stock related to our stock-based compensation programs. The amounts presented in columns (c) and (d) in the above table represent activity related to our $3.00 billion share repurchase program announced in March 2000. As of March 31, 2012, we have purchased $2.58 billion related to this program. We did not acquire any shares pursuant to this program during the first three months of 2012, and we have no current plans to repurchase shares under this program for the remainder of 2012.

Item 6. Exhibits

The following documents are filed as exhibits to this Report:


EXHIBIT 11.		Statement re: Computation of Earnings per Share

EXHIBIT 12.		Statement re: Computation of Ratio of Earnings (Loss) to Fixed Charges

EXHIBIT 31.1		Rule 13a-14(a) Certification of John C. Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer

EXHIBIT 31.2		Rule 13a-14(a) Certification of Derica W. Rice, Executive Vice President, Global Services and Chief Financial Officer

EXHIBIT 32.		Section 1350 Certification

EXHIBIT 101.		Interactive Data File

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


				ELI LILLY AND COMPANY
				(Registrant)

Date: April 30, 2012				/s/James B. Lootens
				James B. Lootens
				Corporate Secretary
Date: April 30, 2012				/s/Arnold C. Hanish
				Arnold C. Hanish
				Vice President, Finance and Chief Accounting Officer

Index to Exhibits

The following documents are filed as a part of this Report:


Exhibit

EXHIBIT 11.		Statement re: Computation of Earnings per Share

EXHIBIT 12.		Statement re: Computation of Ratio of Earnings (Loss) to Fixed Charges

EXHIBIT 31.1		Rule 13a-14(a) Certification of John C. Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer

EXHIBIT 31.2		Rule 13a-14(a) Certification of Derica W. Rice, Executive Vice President, Global Services and Chief Financial Officer

EXHIBIT 32.		Section 1350 Certification

EXHIBIT 101.		Interactive Data File

EX-11 2 d340670dex11.htm STATEMENT RE: COMPUTATION OF EARNINGS PER SHARE Statement re: Computation of Earnings per Share

EXHIBIT 11. Statement Re: Computation of Earnings Per Share

(Unaudited)

ELI LILLY AND COMPANY AND SUBSIDIARIES


	Three Months Ended March 31,
	2012		2011
BASIC
Net income	$	1,011.1	$	1,055.9

Average number of common shares outstanding		1,110.1		1,106.4
Contingently issuable shares		6.9		5.6

Adjusted average shares		1,117.0		1,112.0

Basic earnings per share	$	.91	$	.95

DILUTED
Net income	$	1,011.1	$	1,055.9

Average number of common shares outstanding		1,110.1		1,106.4
Incremental shares – stock options and contingently issuable shares		6.9		5.6

Adjusted average shares		1,117.0		1,112.0

Diluted earnings per share	$	.91	$	.95

Dollars and shares in millions except per-share data.

EX-12 3 d340670dex12.htm STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS (LOSS) TO FIXED CHARGES Statement re: Computation of Ratio of Earnings (Loss) to Fixed Charges

EXHIBIT 12. Statement Re: Computation of Ratio of Earnings (Loss) to Fixed Charges

(Unaudited)

ELI LILLY AND COMPANY AND SUBSIDIARIES

(Dollars in millions)


	Three Months Ended March 31,			Years Ended December 31,
	2012			2011			2010			2009			2008			2007
Consolidated pretax income (loss)	$	1,335.3		$	5,349.5		$	6,525.2		$	5,357.8		($	1,307.6	)	$	3,876.8
Interest¹		52.1			211.7			211.5			291.5			276.5			322.5
Less interest capitalized during the period		(6.8	)		(25.7	)		(26.0	)		(30.2	)		(48.2	)		(94.2	)

Earnings (loss)	$	1,380.6		$	5,535.5		$	6,710.7		$	5,619.1		($	1,079.3	)	$	4,105.1

Fixed charges	$	52.1		$	211.7		$	211.5		$	291.5		$	276.5		$	322.5

Ratio of earnings (loss) to fixed charges		26.5			26.1			31.7			19.3			NM	²		12.7

NM – Not Meaningful

¹	Interest is based upon interest expense reported as such in the consolidated condensed statements of operations and does not include any interest related to unrecognized tax benefits, which is included in income tax expense.

For such ratio, earnings were $1.31 billion less than fixed charges. The loss for the year ended December 31, 2008, included special charges related to the EDPA settlement of $1.48 billion and acquired in-process research and development expense of $4.69 billion associated with the ImClone acquisition.

EX-31.1 4 d340670dex311.htm RULE 13A-14(A) CERTIFICATION OF CEO Rule 13a-14(a) Certification of CEO

EXHIBIT

31.1 Rule 13a-14(a) Certification of John C. Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer

CERTIFICATIONS

I, John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, certify that:

1.	I have reviewed this report on Form 10-Q of Eli Lilly and Company;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent function):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.


Date: April 30, 2012

By:		/s/John C. Lechleiter
		John C. Lechleiter, Ph.D.
		Chairman, President, and Chief Executive Officer

EX-31.2 5 d340670dex312.htm RULE 13A-14(A) CERTIFICATION OF CFO Rule 13a-14(a) Certification of CFO

EXHIBIT

31.2 Rule 13a-14(a) Certification of Derica W. Rice, Executive Vice President, Global Services and Chief Financial Officer

CERTIFICATIONS

I, Derica W. Rice, executive vice president, global services and chief financial officer, certify that:

1.	I have reviewed this report on Form 10-Q of Eli Lilly and Company;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent function):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.


Date: April 30, 2012

By:		/s/ Derica W. Rice
		Derica W. Rice
		Executive Vice President, Global Services and Chief Financial Officer

EX-32 6 d340670dex32.htm SECTION 1350 CERTIFICATION Section 1350 Certification

EXHIBIT

32. Section 1350 Certification

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the “Company”), does hereby certify that, to the best of their knowledge:

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.




Date: April 30, 2012				/s/John C. Lechleiter
				John C. Lechleiter, Ph.D.
				Chairman, President, and Chief Executive Officer



Date: April 30, 2012				/s/Derica W. Rice
				Derica W. Rice
				Executive Vice President, Global Services and Chief Financial Officer

EX-101.INS 7 lly-20120331.xml XBRL INSTANCE DOCUMENT 0000059478 2006-01-01 2006-12-31 0000059478 2000-01-01 2000-12-31 0000059478 lly:PharmaceuticalProductsTotalMember 2012-01-01 2012-03-31 0000059478 lly:OtherPharmaceuticalsMember 2012-01-01 2012-03-31 0000059478 lly:OncologyMember 2012-01-01 2012-03-31 0000059478 lly:NeuroscienceMember 2012-01-01 2012-03-31 0000059478 lly:EndocrinologyMember 2012-01-01 2012-03-31 0000059478 lly:CardiovascularMember 2012-01-01 2012-03-31 0000059478 lly:PharmaceuticalProductsTotalMember 2011-01-01 2011-03-31 0000059478 lly:OtherPharmaceuticalsMember 2011-01-01 2011-03-31 0000059478 lly:OncologyMember 2011-01-01 2011-03-31 0000059478 lly:NeuroscienceMember 2011-01-01 2011-03-31 0000059478 lly:EndocrinologyMember 2011-01-01 2011-03-31 0000059478 lly:CardiovascularMember 2011-01-01 2011-03-31 0000059478 lly:EffientMember 2012-01-01 2012-03-31 0000059478 lly:EffientMember 2011-01-01 2011-03-31 0000059478 us-gaap:RestructuringChargesMember 2012-01-01 2012-03-31 0000059478 us-gaap:RestructuringChargesMember 2011-01-01 2011-03-31 0000059478 lly:ExenatideMember 2012-01-01 2012-03-31 0000059478 lly:ErbituxMember 2012-01-01 2012-03-31 0000059478 lly:ExenatideMember 2011-01-01 2011-03-31 0000059478 lly:ErbituxMember 2011-01-01 2011-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:EquityMethodAndOtherInvestmentsMember 2012-03-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember lly:EquityMethodAndOtherInvestmentsMember 2012-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:EquityMethodAndOtherInvestmentsMember 2011-12-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember lly:EquityMethodAndOtherInvestmentsMember 2011-12-31 0000059478 lly:BuyUsDollarSellEuroMember 2012-03-31 0000059478 lly:BuyEuroSellUsDollarMember 2012-03-31 0000059478 lly:BuyBritishPoundSellEuroMember 2012-03-31 0000059478 lly:AnimalHealthMember 2012-01-01 2012-03-31 0000059478 lly:AnimalHealthMember 2011-01-01 2011-03-31 0000059478 lly:ShareholderValueAwardsMember 2012-01-01 2012-03-31 0000059478 lly:RestrictedStockUnitMember 2012-01-01 2012-03-31 0000059478 lly:PerformanceAwardsGeneralMember 2012-01-01 2012-03-31 0000059478 lly:ShareholderValueAwardsMember 2012-03-31 0000059478 lly:RestrictedStockUnitMember 2012-03-31 0000059478 lly:PerformanceAwardsGeneralMember 2012-03-31 0000059478 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2012-03-31 0000059478 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2012-03-31 0000059478 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2012-03-31 0000059478 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2011-12-31 0000059478 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2011-12-31 0000059478 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2011-12-31 0000059478 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2012-03-31 0000059478 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2012-03-31 0000059478 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2012-03-31 0000059478 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2012-03-31 0000059478 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2012-03-31 0000059478 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2012-03-31 0000059478 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2011-12-31 0000059478 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2011-12-31 0000059478 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2011-12-31 0000059478 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2011-12-31 0000059478 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2011-12-31 0000059478 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2011-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2012-03-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2012-01-01 2012-03-31 0000059478 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2012-01-01 2012-03-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2011-01-01 2011-03-31 0000059478 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2011-01-01 2011-03-31 0000059478 us-gaap:InterestRateContractMember 2012-01-01 2012-03-31 0000059478 lly:HedgedFixedRateDebtMember 2012-01-01 2012-03-31 0000059478 us-gaap:InterestRateContractMember 2011-01-01 2011-03-31 0000059478 lly:HedgedFixedRateDebtMember 2011-01-01 2011-03-31 0000059478 us-gaap:FairValueInputsLevel2Member 2012-03-31 0000059478 us-gaap:FairValueInputsLevel1Member 2012-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2012-03-31 0000059478 us-gaap:FairValueInputsLevel2Member 2011-12-31 0000059478 us-gaap:FairValueInputsLevel1Member 2011-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2011-12-31 0000059478 2011-03-31 0000059478 2010-12-31 0000059478 lly:ChemgenCorporationMember 2012-02-17 0000059478 lly:JanssenPharmaceuticaNvJJMember 2011-07-07 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2012-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2012-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2012-03-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:EquitySecuritiesMember 2012-03-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2011-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2011-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2011-12-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:EquitySecuritiesMember 2011-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:OtherDebtSecuritiesMember 2012-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:MortgageBackedSecuritiesMember 2012-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2012-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2012-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2012-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2012-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2012-03-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:MortgageBackedSecuritiesMember 2012-03-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:AssetBackedSecuritiesMember 2012-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:OtherDebtSecuritiesMember 2011-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:MortgageBackedSecuritiesMember 2011-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2011-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2011-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2011-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2011-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2011-12-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:MortgageBackedSecuritiesMember 2011-12-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:AssetBackedSecuritiesMember 2011-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:OtherDebtSecuritiesMember 2012-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2012-03-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2012-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2012-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2012-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2012-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2012-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2012-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2012-03-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2012-03-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:OtherDebtSecuritiesMember 2012-03-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:CorporateDebtSecuritiesMember 2012-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:OtherDebtSecuritiesMember 2011-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2011-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2011-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2011-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2011-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2011-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2011-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2011-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2011-12-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2011-12-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:OtherDebtSecuritiesMember 2011-12-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember us-gaap:CorporateDebtSecuritiesMember 2011-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2012-03-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember 2012-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2011-12-31 0000059478 lly:AvailableForSaleSecuritiesAmortizedCostMember 2011-12-31 0000059478 lly:ProductLiabilityLitigationMember lly:ByettaMember lly:CaliforniaMember 2012-01-01 2012-03-31 0000059478 lly:ProductLiabilityLitigationMember lly:ZyprexaMember 2012-01-01 2012-03-31 0000059478 lly:MultiDistrictLitigationMdlMember lly:ZyprexaMember 2012-01-01 2012-03-31 0000059478 lly:ProductLiabilityLitigationMember lly:DiethylstilbestrolDesMember 2012-01-01 2012-03-31 0000059478 lly:ProductLiabilityLitigationMember lly:ByettaMember 2012-01-01 2012-03-31 0000059478 lly:ProductLiabilityLitigationMember lly:DamagesFromProductBreastCancerMember lly:DiethylstilbestrolDesMember 2012-01-01 2012-03-31 0000059478 lly:SalesNewMember lly:AmylinMember 2011-11-01 2011-11-30 0000059478 lly:UnitedStatesMember 2011-11-01 2011-11-30 0000059478 lly:OutsideUnitedStatesMember 2011-11-01 2011-11-30 0000059478 lly:SalesNewMember lly:ExenatideMember 2011-07-01 2011-09-30 0000059478 lly:ResearchAndDevelopmentAndMarketingAndSellingExpenseMember lly:ExenatideMember 2011-07-01 2011-09-30 0000059478 lly:GrossMarginShareMember lly:ExenatideMember 2011-07-01 2011-09-30 0000059478 lly:ProfitAndDevelopmentAndMarketingShareMember lly:EffientMember 2010-07-01 2010-09-30 0000059478 lly:ResearchAndDevelopmentExpMember lly:NecitumumabMember lly:UnitedStatesMember 2010-01-01 2010-03-31 0000059478 lly:ResearchAndDevelopmentExpMember lly:NecitumumabMember lly:OutsideUnitedStatesMember 2010-01-01 2010-03-31 0000059478 us-gaap:SellingAndMarketingExpenseMember lly:NecitumumabMember 2010-01-01 2010-03-31 0000059478 lly:ProfitShareMember lly:NecitumumabMember 2010-01-01 2010-03-31 0000059478 lly:UpfrontPaymentMember lly:AmylinMember 2011-11-01 2011-11-30 0000059478 lly:RevenueShareMember lly:AmylinMember 2011-11-01 2011-11-30 0000059478 lly:MilestonePaymentsMember lly:AmylinMember 2011-11-01 2011-11-30 0000059478 lly:MilestonePaymentsMember lly:TpgAxonMember 2011-07-01 2011-09-30 0000059478 lly:LoanCommitmentMember lly:ExenatideOnceWeeklyMember 2011-04-01 2011-06-30 0000059478 lly:MilestonePaymentsMember lly:BiCompoundsMember 2011-01-01 2011-09-30 0000059478 lly:MilestonePaymentsMember lly:LlyOptionalCompoundMember 2011-01-01 2011-03-31 0000059478 lly:MilestonePaymentsMember lly:LlyCompoundsMember 2011-01-01 2011-03-31 0000059478 lly:MilestonePaymentsMember lly:BiCompoundsMember 2011-01-01 2011-03-31 0000059478 lly:PrepaidSellingAndMarketingExpenseMember lly:DuloxetineBiMember 2010-01-01 2010-03-31 0000059478 lly:MilestonePaymentsMember lly:NecitumumabMember 2010-01-01 2010-03-31 0000059478 lly:JanssenPharmaceuticaNvJJMember 2011-07-06 2011-07-07 0000059478 2012-03-31 0000059478 2011-12-31 0000059478 2011-01-01 2011-03-31 0000059478 2012-04-20 0000059478 2012-01-01 2012-03-31 iso4217:GBP iso4217:USD xbrli:shares iso4217:EUR xbrli:pure iso4217:USD xbrli:shares false --12-31 Q1 2012 2012-03-31 10-Q 0000059478 1160415307 Yes Large Accelerated Filer Lilly Eli & Co No Yes 388000000 0 252200000 0 <div> <div> <div> <div> Note 3: Acquisitions <div> Acquisitions of Businesses On February 17, 2012, we acquired all of the outstanding stock of ChemGen Corporation, a privately-held bioscience company specializing in the development and commercialization of innovative feed enzyme products that improve the efficiency of poultry, egg, and meat production, for total purchase consideration of approximately $205 million. We have not yet finalized our acquisition accounting but we anticipate the majority of the value of the assets recorded will be marketed product intangibles. This transaction was not material to our consolidated condensed financial statements.    On July 7, 2011, we acquired the animal health business of Janssen Pharmaceutica NV, a Johnson & Johnson company, for total purchase consideration of $307.8 million in cash. We obtained a portfolio of more than 50 marketed animal health products. In connection with this acquisition, we preliminarily recorded $234.4 million of marketed product assets and $29.6 million of acquired in-process research and development (IPR&D) assets, with $43.8 million of other net assets. The final determination may result in asset and liability fair values that differ from the preliminary estimates, but it is not expected that these differences will be material to our financial results.</div></div></div></div> </div> 2498900000 3159000000 50 45400000 72000000 250000000 400000000 300000000 650000000 525000000 478700000 165000000 70000000 150000000 1200000000 250000000 0.4500 0.5000 0.7250 0.4500 0.500 0.5000 0.5000 1.0000 0.3500 0.6500 0.0950 0.1500 4565300000 4266700000 0.6000 5128100000 5266700000 5 520 115 85 15 115 100 20 100 -388000000 0 1771300000 1619800000

<div> Note 2: Implementation of New Financial Accounting Pronouncements   <div> There are no new accounting pronouncements that have had or will have a material impact on our consolidated condensed financial statements.  </div> </div>

640200000

529200000

1125200000

1246300000

3597700000

3402100000

261600000

388800000

1086300000

1158300000

6833700000

7011100000

-3858600000

-3549200000

4886800000

4858200000

37900000

30900000

110100000

108400000

33659800000

32238200000

14248200000

12602600000

11651300000

11881000000

2164400000

1877500000

975000000

974600000

801700000

802400000

4190000000

601100000

11600000

362300000

600700000

11600000

362300000

600700000

11600000

362300000

600700000

11600000

735100000

20400000

46200000

735800000

20400000

46200000

735800000

20400000

46200000

735800000

20400000

253200000

2093300000

479100000

11900000

901300000

245000000

2081300000

443800000

10000000

908800000

245000000

2081300000

443800000

10000000

908800000

245000000

2081300000

443800000

8700000

1300000

313900000

2362700000

506800000

11100000

976100000

306600000

2373700000

476200000

11100000

978400000

306600000

2373700000

476200000

11100000

978400000

306600000

2373700000

476200000

10100000

1000000

107500000

180800000

109300000

201600000

39400000

13700000

3500000

2700000

103000000

124800000

80000000

56400000

0.9000

4006400000

4029800000

4453400000

4521100000

<div> <table class="MsoNormalTable" style="border-right: medium none; border-top: medium none; font-size: 11pt; border-left: medium none; line-height: 115%; border-bottom: medium none; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="1"> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355">  </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 103.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="138"> March 31, 2012</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 99pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="132"> December 31, 2011</td></tr> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355">  </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 202.5pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="270" colspan="2"> (Dollars in millions)</td></tr> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355"> Unrealized gross gains </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 103.5pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="138"> $  124.8</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 99pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="132"> $    103.0</td></tr> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355"> Unrealized gross losses </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 103.5pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="138"> 56.4</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 99pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="132"> 80.0</td></tr> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355"> Fair value of securities in an unrealized gain position </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 103.5pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="138"> 3,159.0</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 99pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="132"> 2,498.9</td></tr> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355"> Fair value of securities in an unrealized loss position </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 103.5pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="138"> 1,877.5</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 99pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="132"> 2,164.4</td></tr></table> </div>

307800000

205000000

234400000

29600000

43800000

5993200000

6506400000

5922500000

4122200000

5922500000

5264600000

657900000

4122200000

4006400000

115800000

513200000

-1800300000

-53300000

53300000

-65900000

65900000

<div> <div class="WordSection1">  Note 4: Collaborations   We often enter into collaborative arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These collaborations often require milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the third party. Revenues related to products sold by us pursuant to these arrangements are included in net product sales, while other sources of revenue (e.g., royalties and profit share payments) are included in collaboration and other revenue. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments made to or reimbursements received from our collaboration partners. Each collaboration is unique in nature, and our more significant arrangements are discussed below. The following table summarizes the composition of our total revenue recognized from all transactions, including collaboration activity:</div> <div class="WordSection1"> <table class="MsoNormalTable" style="margin-left: 5.4pt; width: 463.5pt; border-collapse: collapse;" cellspacing="0" cellpadding="0" width="618" border="0"> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;"> </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 117pt; padding-top: 0in;" valign="top" width="156" colspan="2">   Three Months Ended  March 31, </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 1.75in; padding-top: 0in;" valign="top" width="168" colspan="2">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84"> 2012 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="72"> 2011 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 243pt; padding-top: 0in;" valign="top" width="324" colspan="4"> (Dollars in millions)</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Net product sales  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $5,413.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $5,689.9 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Collaboration and other revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">       188.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="72">     149.3 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Total revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="84"> $5,602.0 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="72"> $5,839.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="84">  </td></tr></table></div>    <div class="WordSection1"> <div>  Erbitux®   We have several collaborations with respect to Erbitux. The most significant collaborations are in the U.S., Japan, and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). The agreements are expected to expire in 2018, upon which all of the rights with respect to Erbitux in the U.S. and Canada return to us and certain rights with respect to Erbitux outside the U.S. and Canada (excluding Japan) remain with Merck KGaA (Merck). The following table summarizes the revenue recognized with respect to Erbitux: </div></div> <div class="WordSection1"> <table class="MsoNormalTable" style="margin-left: 5.4pt; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="0"> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 121.4pt; padding-top: 0in;" valign="top" width="162" colspan="2"> Three Months Ended   March 31, </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 109pt; padding-top: 0in;" valign="top" width="145" colspan="2">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="85"> 2012 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top"> 2011 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 3.2in; padding-top: 0in;" valign="top" width="307" colspan="4"> (Dollars in millions)</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top"> Net product sales  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in;" valign="top" width="85"> $ 34.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top"> 27.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top"> Collaboration and other revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="85">    79.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">    76.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top"> Total revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="85"> $113.3 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top"> $104.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top">  </td></tr></table></div>    <div class="WordSection1"> <div> <div> Bristol-Myers Squibb Company Pursuant to a commercial agreement with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), relating to Erbitux, we are co-developing Erbitux in the U.S. and Canada with BMS, exclusively, and in Japan with BMS and Merck. The companies have jointly agreed to expand the investment in the ongoing clinical development plan for Erbitux to further explore its use in additional tumor types. Under this arrangement, Erbitux research and development and other costs are shared by both companies according to a predetermined ratio.   Responsibilities associated with clinical and other ongoing studies are apportioned between the parties under the agreement. Collaborative reimbursements received by us for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated condensed statement of operations. We receive a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in the U.S. and Canada, which is recorded in collaboration and other revenue. Royalty expense paid to third parties, net of any reimbursements received, is recorded as a reduction of collaboration and other revenue.</div>   We are responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the territory, and BMS will purchase all of its requirements of API for commercial use from us, subject to certain stipulations per the agreement. Sales of Erbitux to BMS for commercial use are reported in net product sales. <div> Merck KGaA A development and license agreement with Merck with respect to Erbitux granted Merck exclusive rights to market Erbitux outside of the U.S. and Canada, and co-exclusive rights with BMS and us in Japan. Merck also has rights to manufacture Erbitux for supply in its territory. We receive a royalty on the sales of Erbitux outside of the U.S. and Canada, which is included in collaboration and other revenue as earned. Collaborative reimbursements received for research and for development; and marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated condensed statement of operations. Royalty expense paid to third parties, net of any royalty reimbursements received, is recorded as a reduction of collaboration and other revenue.      <div> Necitumumab The commercial agreement with BMS described above includes the co-development and co-commercialization of necitumumab, which is currently in Phase III clinical testing for squamous non-small cell lung cancer. We and BMS share the cost of developing and potentially commercializing necitumumab in the U.S., Canada, and Japan. We maintain exclusive rights to necitumumab in all other markets. We will fund 45 percent of the development costs for studies that will be used only in the U.S., and 72.5 percent for global studies. We will be responsible for the manufacturing of API, and BMS will be responsible for manufacturing the finished product. We could receive a payment of $250.0 million upon approval in the U.S. In the U.S. and Canada, BMS will record sales and we will receive 45 percent of the profits for necitumumab, while we will provide 50 percent of the selling effort. In Japan, we and BMS will share costs and profits evenly.<a name="eolPage64"> </a></div></div></div></div> <div class="WordSection1"> <div> </div> <div> </div>Exenatide <div> </div> <div> In November 2011, we agreed with Amylin Pharmaceuticals, Inc. (Amylin) to terminate our collaborative arrangement for the joint development, marketing, and selling of Byetta®(exenatide injection) and other forms of exenatide such as Bydureon™(exenatide extended-release for injectable suspension). Under the terms of the termination agreement, Amylin made a one-time, upfront payment to us of $250.0 million. Amylin also agreed to make future revenue-sharing payments to us in an amount equal to 15 percent of their global net sales of exenatide products until Amylin has made aggregate payments to us of $1.20 billion plus interest, which will accrue at 9.5 percent. Amylin issued a secured note in the amount of $1.20 billion to us under which any revenue-sharing payments made to us will reduce amounts outstanding under the note. In general, Amylin's obligation for the revenue-sharing payments and the secured note will terminate if all exenatide products are withdrawn from the market due to safety or efficacy issues and are not sold for a period of four years. Amylin will also pay a $150.0 million milestone to us contingent upon FDA approval of a once-monthly suspension version of exenatide that is currently in Phase II clinical trials.   Commercial operations were transferred to Amylin in the U.S. at the end of November 2011, although we continue to provide certain transition services. Outside the U.S., we will transfer responsibility for commercialization of exenatide to Amylin on a market-by-market basis over a period beginning no earlier than the second half of 2012 and that will not extend beyond December 31, 2013.   Payments received from Amylin are allocated 65 percent to the U.S., which is treated as a contract termination, and 35 percent to the business outside the U.S., which will be treated as the disposition of a business. The allocation was based upon relative fair values. Revenue-sharing payments will be recognized as income as Amylin records sales. The income allocated to the U.S. is recognized as collaboration and other revenue and the income allocated to the business outside the U.S. will be recognized as proceeds from the disposition of a business in other–net, expense in our consolidated condensed income statement beginning at the time control of the business transfers to Amylin. The amounts we may receive pursuant to the revenue-sharing arrangement represent contingent consideration and, therefore, do not qualify for recognition as income until the contingency is resolved and the amount becomes fixed or determinable. As a consequence, the note has not been recognized in our consolidated condensed balance sheet.   Prior to termination of the collaboration, we and Amylin were co-promoting Byetta in the U.S. Amylin was responsible for manufacturing and primarily utilized third-party contract manufacturers to supply Byetta. We supplied Byetta pen delivery devices for Amylin and will continue to do so for a period that will not extend beyond December 31, 2013, unless we and Amylin agree otherwise. We are responsible for certain development costs related to certain clinical trials outside the U.S. that we were conducting as of the date of the termination agreement as well as commercialization costs outside the U.S. until the commercial operations are transferred to Amylin.   Under the terms of our prior arrangement, we reported as collaboration and other revenue our 50 percent share of gross margin on Amylin's net product sales in the U.S. We reported as net product sales 100 percent of sales outside the U.S. and our sales of Byetta pen delivery devices to Amylin. We paid Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs were recorded in cost of sales. This arrangement for the commercial operations outside the U.S. will continue until those operations transfer to Amylin. Prior to its termination, under the 50/50 profit-sharing arrangement for the U.S., in addition to recording as revenue our 50 percent share of exenatide's gross margin, we also recorded approximately 50 percent of U.S. related research and development costs and marketing and selling costs in the respective line items on the consolidated condensed statements of operations. </div> <div class="WordSection1"> </div> <div class="WordSection1"> </div>The following table summarizes the revenue recognized with respect to exenatide:   <div class="WordSection1"> <table class="MsoNormalTable" style="margin-left: 5.4pt; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="0"> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 121.4pt; padding-top: 0in;" valign="top" width="162" colspan="2"> Three Months Ended   March 31, </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 109pt; padding-top: 0in;" valign="top" width="145" colspan="2">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="85"> 2012 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top"> 2011</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 3.2in; padding-top: 0in;" valign="top" width="307" colspan="4">       (Dollars in millions) </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Net product sales  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in;" valign="top" width="85"> $ 48.5 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top"> $  40.8 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Collaboration and other revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="85">    51.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">     61.0 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Total revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="85"> $99.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top"> $  101.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top">  </td></tr></table></div>    In accordance with the prior arrangement and pursuant to Amylin's request, in the second quarter of 2011 we loaned Amylin $165.0 million. Interest on this loan is to be received quarterly and all outstanding principal and interest is due five years from the date of the advance.    Cymbalta®   <div class="WordSection1"> <div> <div> <div> We were in a collaborative arrangement with Boehringer Ingelheim (Boehringer) to jointly develop, market, and promote Cymbalta (duloxetine), outside the U.S. and Japan. Pursuant to the terms of the agreement, we generally shared equally in development, marketing, and selling expenses, and paid Boehringer a commission on sales in the co-promotion territories. We manufactured the product for all territories. Reimbursements or payments for the cost sharing of marketing, selling, and administrative expenses were recorded in the respective expense line items in the consolidated condensed statements of operations. The commission paid to Boehringer was recorded in marketing, selling, and administrative expenses. In March 2010, the parties agreed to terminate this agreement, and we reacquired the exclusive rights to develop and market duloxetine for all indications in countries outside the U.S. and Japan. In connection with the termination, we paid Boehringer approximately $400 million and will also pay to Boehringer a percentage of our sales of duloxetine in these countries through 2012 as consideration for the rights acquired. We record these costs as intangible assets, which will be amortized to marketing, selling, and administrative expenses using the straight-line method over the life of the original agreement, which is through 2015.</div></div></div></div> Effient®   We are in a collaborative arrangement with Daiichi Sankyo Company, Limited (D-S) to develop, market, and promote Effient. We and D-S have agreed to co-promote in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. D-S has exclusive marketing rights in Japan. The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories. We record product sales in our exclusive and co-promotion territories. In our exclusive territories, we pay D-S a royalty specific to these territories. Profit share payments made to D-S are recorded as marketing, selling, and administrative expenses. All royalties paid to D-S and the third-party manufacturer are recorded in cost of sales. Worldwide Effient sales were $115.8 million and $56.3 million in the quarters ended March 31, 2012 and 2011, respectively. <div class="WordSection1"> <div>  Diabetes Collaboration   In January 2011, we and Boehringer entered into a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Included are Boehringer 's two oral diabetes agents, linagliptin and empagliflozin (BI 10773). Subsequently in 2011, linagliptin was approved and launched in the U.S. (tradename Tradjenta™), Japan (tradename Trazenta®), Europe (tradename Trajenta®), and other countries. Empagliflozin is currently in Phase III clinical testing. Also included in the agreement is our new insulin glargine product and our novel basal insulin analog, both of which began Phase III clinical testing in the second half of 2011; and an option granted to Boehringer to co-develop and co-commercialize our anti-TGF-beta monoclonal antibody, which is currently in Phase II clinical testing. Under the terms of the agreement, we made an initial one-time payment to Boehringer of $388.0 million and recorded an acquired IPR&D charge, which was included as expense in the first quarter of 2011 and is deductible for tax purposes. </div></div> <div class="WordSection1"> </div>   <div class="WordSection1">In connection with the approval of linagliptin in the U.S., Japan, and Europe, in 2011 we paid $478.7 million in success-based regulatory milestones, all of which were capitalized as intangible assets and are being amortized to cost of sales. We may pay up to 300.0 million in additional success-based regulatory milestones for empagliflozin. We will be eligible to receive up to a total of $650.0 million in success-based regulatory milestones on our two basal insulin analogues. Should Boehringer elect to opt in to the Phase III development and potential commercialization of the anti-TGF-beta monoclonal antibody, we would be eligible for up to $525.0 million in opt-in and success-based regulatory milestone payments. The companies share ongoing development costs equally. The companies also share in the commercialization costs and gross margin for any product resulting from the collaboration that receives regulatory approval. We record our portion of the gross margin as collaboration and other revenue, and we record our portion of the commercialization costs as marketing, selling, and administrative expense. Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration. Revenue related to this collaboration have not been significant to date. </div>   <div class="WordSection1"> </div>    <div class="WordSection1"> <div> <div> <div> Solanezumab <a name="eolPage65"> </a>We have an agreement with an affiliate of TPG-Axon Capital (TPG) whereby both we and TPG were obligated to fund the Phase III development of solanezumab. Under the agreement, TPG's obligation to fund solanezumab costs was not material and ended in the first half of 2011. In exchange for their funding, TPG may receive success-based sales milestones totaling approximately $70.0 million and mid-single digit royalties that are contingent upon the successful development of solanezumab. The royalties relating to solanezumab would be paid for approximately eight years after launch of a product. </div></div>  Summary of Collaboration-Related Commission and Profit Share Payments The aggregate amount of commission and profit share payments included in marketing, selling, and administrative expense pursuant to the collaborations described above was $72.0 million and $45.4 million for the first quarter ended March 31, 2012 and 2011, respectively.</div>    </div>      </div> </div>

<div> Note 12: Contingencies <div> We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as specifically noted below with respect to the Alimta® Hatch-Waxman Act patent challenges, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.   Patent Litigation   <div>We are engaged in U.S. patent litigation matters involving Alimta brought pursuant to procedures set out in the Hatch-Waxman Act (the Drug Price Competition and Patent Term Restoration Act of 1984). Teva Parenteral Medicines, Inc. (Teva); APP Pharmaceuticals, LLC (APP); and Barr Laboratories, Inc. (Barr) each submitted ANDAs seeking approval to market generic versions of Alimta prior to the expiration of the relevant U.S. patents and data-based pediatric exclusivity period (compound patent licensed from the Trustees of Princeton University and expiring in 2017, concomitant nutritional supplement use patent expiring in 2022) and alleging the patents are invalid. We, along with Princeton, filed lawsuits in the U.S. District Court for the District of Delaware against Teva, APP, and Barr seeking rulings that the compound patent is valid and infringed. In July 2011, the district court entered judgment in our favor, upholding that patent's validity. The generic manufacturers have appealed this decision. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP, Pliva Hrvatska D.O.O., and Barr seeking rulings that our concomitant nutritional supplement use patent is valid and infringed.  No trial date has yet been set. In January 2012 and April 2012, we filed similar lawsuits against Accord Healthcare Inc. and Apotex Inc., respectively.     </div>   <div>We believe the Hatch-Waxman challenges to the Alimta patents are without merit and expect to prevail in this litigation. However, it is not possible to determine the outcome of this litigation, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues in the relevant market. </div> <div> </div> <div> Zyprexa® Litigation  We are a defendant in approximately 20 Zyprexa product liability lawsuits in the U.S. covering approximately 80 plaintiffs. The lawsuits allege a variety of injuries from the use of Zyprexa, with the majority alleging that the product caused or contributed to diabetes or high blood-glucose levels. The claims seek substantial compensatory and punitive damages and typically accuse us of inadequately testing for and warning about side effects of Zyprexa. Many of the claims also allege that we improperly promoted the drug. Approximately 15 of the lawsuits, covering about 15 plaintiffs, are part of a Multi-District Litigation (MDL) proceeding before The Honorable Jack Weinstein in the Federal District Court for the Eastern District of New York (EDNY) (MDL No. 1596). We are prepared to continue our vigorous defense of Zyprexa in all these lawsuits and claims.   <div> Byetta Litigation We have been named as a defendant in approximately 115 lawsuits involving approximately 490 plaintiffs, primarily seeking to recover damages for pancreatitis experienced by patients prescribed Byetta. We are aware of approximately 520 additional claimants who have not yet filed suit. Approximately 100 of these lawsuits are filed in California and coordinated in a Los Angeles Superior Court. We believe these claims are without merit and are prepared to defend against them vigorously.</div></div></div> <div>   <div> Diethylstilbestrol Litigation  In approximately 100 U.S. lawsuits against us involving approximately 115 claimants, plaintiffs seek to recover damages on behalf of children or grandchildren of women who were prescribed diethylstilbestrol (DES) during pregnancy in the 1950s and 1960s. Approximately 85 of these claimants allege that they were indirectly exposed in utero to the medicine and later developed breast cancer as a consequence. In December 2009, a lawsuit was filed in U.S. District Court in Washington, D.C. against Lilly and other manufacturers (Michele Fecho, et al. v. Eli Lilly and Company, et al.) seeking to assert product liability claims on behalf of a putative class of men and women allegedly exposed to the medicine who claim to have later developed breast cancer; this case was dismissed in April 2012. Certain parties in this case participated in court-ordered mediation on April 20, 2012 which did not result in a decision. Five cases involving similar allegations are scheduled for trial in January 2013. We believe these claims are without merit and are prepared to defend against them vigorously. </div> <div> Product Liability Insurance Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. In the past several years, we have been unable to obtain product liability insurance due to a very restrictive insurance market. Therefore, for substantially all of our currently marketed products, we have been and expect that we will continue to be completely self-insured for future product liability losses. The DES claims are covered by insurance, subject to deductibles and coverage limits. There is no assurance that we will be able to fully collect from our insurance carriers in the future. </div></div> </div>

0.49

3013100000

724100000

725800000

1537200000

1320500000

1180100000

1197900000

-22200000

-49500000

-23700000

-70900000

-10800000

2200000

-8800000

900000

40000000

32000000

171600000

31800000

171100000

29500000

111800000

28500000

113000000

23700000

50800000

28000000

76700000

14800000

58900000

16400000

63000000

340900000

385900000

16200000

6100000

12100000

531700000

472000000

<div> <table class="MsoNormalTable" style="font-size: 11pt; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" width="740" border="0"> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="bottom" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 176.95pt; padding-top: 0in;" valign="bottom" width="236" colspan="6"> Three Months Ended March 31, </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 176.95pt; padding-top: 0in;" valign="bottom" width="236" colspan="6">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="bottom" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 72.05pt; padding-top: 0in;" valign="bottom" width="96" colspan="2"> 2012 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 77.9pt; padding-top: 0in;" valign="bottom" width="104" colspan="2"> 2011 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 72.05pt; padding-top: 0in;" valign="bottom" width="96" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 77.9pt; padding-top: 0in;" valign="bottom" width="104" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="bottom" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 0.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 339.05pt; padding-top: 0in;" valign="bottom" width="452" colspan="13"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="bottom" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 380.9pt; padding-top: 0in;" valign="bottom" width="508" colspan="14"> (Dollars in millions) </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Fair value hedges </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Effect from hedged fixed-rate debt </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> $</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40"> (65.9)</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">       $ </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> (53.3) </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Effect from interest rate contracts </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40"> 65.9</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 53.3 </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 102.15pt; padding-top: 0in;" width="136" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 104.9pt; padding-top: 0in;" width="140" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 99.05pt; padding-top: 0in;" width="132" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 104.9pt; padding-top: 0in;" width="140" colspan="4">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Cash flow hedges </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40"> 2.2 </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 2.2 </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 102.15pt; padding-top: 0in;" width="136" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 104.9pt; padding-top: 0in;" width="140" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 99.05pt; padding-top: 0in;" width="132" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 104.9pt; padding-top: 0in;" width="140" colspan="4">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40"> (32.8 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17"> )   </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 30.0</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr></table> </div>

30000000

-32800000

10000000

2200000

25900000

5300000

<div class="MetaData"> Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate the instruments individually as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.  For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized currently in earnings during the period of change.    <div>We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are entered into with the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other — net, expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. </div></div>

<div> <div> Note 7: Stock-Based Compensation   <div> <div> Our stock-based compensation expense consists primarily of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognized pretax stock-based compensation cost of $30.9 million and $37.9 million in the first quarter of 2012 and 2011, respectively.   PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain earnings per share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. As of March 31, 2012, the total remaining unrecognized compensation cost related to nonvested PAs amounted to $42.6 million, which will be amortized over the weighted-average remaining requisite service period of approximately 17 months. SVAs are granted to officers and management and are payable in shares of common stock at the end of a three-year period. The number of shares actually issued varies depending on our stock price at the end of the three-year vesting period compared to pre-established target prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. As of March 31, 2012, the total remaining unrecognized compensation cost related to nonvested SVAs amounted to $84.5 million, which will be amortized over the weighted-average remaining requisite service period of approximately 26 months. RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. As of March 31, 2012, the total remaining unrecognized compensation cost related to nonvested RSUs amounted to $91.3 million, which will be amortized over the weighted-average remaining requisite service period of 27 months.</div></div></div> </div>

542300000

0.95

0.91

<div> Note 9:  Earnings Per Share   Unless otherwise noted in the footnotes, all per-share amounts are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of all potentially dilutive common shares (primarily contingently issuable shares and unexercised stock options). </div>

91600000

56500000

804700000

533800000

42600000

91300000

84500000

P1Y5M

P2Y3M

P2Y2M

<div> <table class="MsoNormalTable" style="font-size: 11pt; margin-left: 0px! important; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" width="714" border="0"> <tr><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 193.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="258" colspan="3"> Fair Value Measurements Using</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="222">               Description</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">             Carrying Amount</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">             Amortized Cost</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="72"> Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td style="padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">       Significant Other Observable Inputs (Level 2)</td> <td style="padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="102">         Significant Unobservable Inputs (Level 3)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">             Fair Value</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 369pt; padding-top: 0in;" valign="top" width="492" colspan="6"> <a name="OLE_LINK7"> </a><a name="OLE_LINK5">(Dollars in millions)</a> </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> March 31, 2012</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Cash and cash equivalents </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,122.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,122.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $4,006.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $   115.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $4,122.2</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Short-term investments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   U.S. government and agencies.. </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $   46.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $   46.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $   46.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $      </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $   46.2</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Corporate debt securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 735.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 735.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 735.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 735.8</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Other securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78"> 20.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78"> 20.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 20.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 20.4</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Short-term investments </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $  802.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $  801.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Noncurrent investments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   U.S. government and agencies.. </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $  978.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $  976.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $  978.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $           </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $  978.4</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Corporate debt securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,373.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,362.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 2,373.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,373.7</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Mortgage-backed </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 476.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 506.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 476.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 476.2</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Asset-backed </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 306.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 313.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 306.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 306.6</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Other securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 11.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 11.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 10.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> 1.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 11.1</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Marketable equity </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 201.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 109.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> 201.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 201.6</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Equity method and other investments(1) </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">   173.5</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">   173.5</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">    </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Noncurrent investments </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,521.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,453.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr style="height: 8.55pt;"><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in; height: 8.55pt;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; height: 8.55pt;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; height: 8.55pt;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; height: 8.55pt;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; height: 8.55pt;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in; height: 8.55pt;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; height: 8.55pt;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> December 31, 2011</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Cash and cash equivalents </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $5,922.5</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $5,922.5</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $5,264.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $657.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $5,922.5</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Short-term investments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   U.S. government and agencies.. </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $  362.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $  362.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $  362.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $      </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $ 362.3</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Corporate debt securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 600.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 601.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 600.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 600.7</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Other securities<a name="OLE_LINK6"> </a><a name="OLE_LINK1"> </a></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78"> 11.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78"> 11.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 11.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 11.6</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Short-term investments </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $   974.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $   975.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Noncurrent investments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   U.S. government and agencies.. </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $ 908.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $901.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $908.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $          </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $908.8</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Corporate debt securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,081.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,093.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 2,081.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,081.3</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Mortgage-backed </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 443.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 479.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 443.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 443.8</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Asset-backed </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 245.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 253.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 245.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 245.0</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Other securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 10.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 11.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 8.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> 1.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 10.0</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Marketable equity </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 180.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 107.5</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> 180.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 180.8</td></tr> <tr style="height: 4pt;"><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in; height: 4pt;" valign="top" width="222">   Equity methods and other investments(1) </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid; height: 4pt;" valign="top" width="78">   160.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid; height: 4pt;" valign="top" width="78">   160.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; height: 4pt;" valign="top" width="72">    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; height: 4pt;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in; height: 4pt;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; height: 4pt;" valign="top" width="78">    </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Noncurrent investments </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,029.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,006.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr></table> </div>

<div> <div> <div> Note 6: Financial Instruments <div> <div> Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we limit the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.   <div>Accounting Policy for Risk-Management Instruments </div> <div class="MetaData"> Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate the instruments individually as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.  For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized currently in earnings during the period of change.    <div>We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are entered into with the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other — net, expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. </div></div> At March 31, 2012, we had outstanding foreign currency forward commitments to purchase 365.2 million U.S. dollars and sell 275.5 million euro, commitments to buy 871.5 million euro and sell 1.15 billion U.S. dollars, and commitments to purchase 380.2 million British pounds and sell 456.8 million euro, which will all settle within 35 days.</div></div></div> <div>   In the normal course of business, our operations are exposed to fluctuations in interest rates. These fluctuations can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.<a name="eolPage14"> </a> Interest rate swaps or collars that convert our fixed-rate debt or investments to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating rate debt or investments to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. At March 31, 2012, approximately 100 percent of our total debt is at a fixed rate. We have converted approximately 60 percent of our fixed-rate debt to floating rates through the use of interest rate swaps. We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted <a name="FIS_INCOME_STATEMENT_2"> </a>sales of available-for-sale securities.   <div> </div>The Effect of Risk-Management Instruments on the Consolidated Condensed Statement of Operations <div>  </div> <div>The following effects of risk-management instruments were recognized in other—net, expense:</div> <div>  </div> <table class="MsoNormalTable" style="font-size: 11pt; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" width="740" border="0"> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="bottom" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 176.95pt; padding-top: 0in;" valign="bottom" width="236" colspan="6"> Three Months Ended March 31, </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 176.95pt; padding-top: 0in;" valign="bottom" width="236" colspan="6">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="bottom" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 72.05pt; padding-top: 0in;" valign="bottom" width="96" colspan="2"> 2012 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 77.9pt; padding-top: 0in;" valign="bottom" width="104" colspan="2"> 2011 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 72.05pt; padding-top: 0in;" valign="bottom" width="96" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 77.9pt; padding-top: 0in;" valign="bottom" width="104" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="bottom" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 0.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 339.05pt; padding-top: 0in;" valign="bottom" width="452" colspan="13"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="bottom" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 380.9pt; padding-top: 0in;" valign="bottom" width="508" colspan="14"> (Dollars in millions) </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Fair value hedges </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Effect from hedged fixed-rate debt </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> $</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40"> (65.9)</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">       $ </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> (53.3) </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Effect from interest rate contracts </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40"> 65.9</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 53.3 </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 102.15pt; padding-top: 0in;" width="136" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 104.9pt; padding-top: 0in;" width="140" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 99.05pt; padding-top: 0in;" width="132" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 104.9pt; padding-top: 0in;" width="140" colspan="4">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Cash flow hedges </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40"> 2.2 </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 2.2 </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" width="192">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 102.15pt; padding-top: 0in;" width="136" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 104.9pt; padding-top: 0in;" width="140" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 99.05pt; padding-top: 0in;" width="132" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 104.9pt; padding-top: 0in;" width="140" colspan="4">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 2in; padding-top: 0in;" valign="top" width="192"> Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 17.4pt; padding-top: 0in;" valign="bottom" width="23">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40"> (32.8 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17"> )   </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 30.0</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" valign="bottom" width="40">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.3pt; padding-top: 0in;" valign="bottom" width="19">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr></table> <div> </div>     The effective portion of net losses on equity contracts in designated cash flow hedging relationships recorded in other comprehensive income was $10.0 million for the first quarter of 2011.   We expect to reclassify $9.0 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on floating rate debt from accumulated other comprehensive loss to earnings during the next 12 months.  <a name="FIS_UNIDENTIFIED_TABLE_7"> </a> During the first quarters of 2012 and 2011, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.   <div>Fair Value of Financial Instruments  </div>The following tables summarize certain fair value information at September 30, 2011 and December 31, 2010 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:   <table class="MsoNormalTable" style="font-size: 11pt; margin-left: 0px! important; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" width="714" border="0"> <tr><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 193.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="258" colspan="3"> Fair Value Measurements Using</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="222">               Description</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">             Carrying Amount</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">             Amortized Cost</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="72"> Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td style="padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">       Significant Other Observable Inputs (Level 2)</td> <td style="padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="102">         Significant Unobservable Inputs (Level 3)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">             Fair Value</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 369pt; padding-top: 0in;" valign="top" width="492" colspan="6"> <a name="OLE_LINK7"> </a><a name="OLE_LINK5">(Dollars in millions)</a> </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> March 31, 2012</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Cash and cash equivalents </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,122.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,122.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $4,006.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $   115.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $4,122.2</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Short-term investments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   U.S. government and agencies.. </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $   46.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $   46.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $   46.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $      </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $   46.2</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Corporate debt securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 735.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 735.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 735.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 735.8</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Other securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78"> 20.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78"> 20.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 20.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 20.4</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Short-term investments </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $  802.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $  801.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Noncurrent investments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   U.S. government and agencies.. </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $  978.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $  976.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $  978.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $           </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $  978.4</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Corporate debt securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,373.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,362.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 2,373.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,373.7</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Mortgage-backed </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 476.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 506.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 476.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 476.2</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Asset-backed </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 306.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 313.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 306.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 306.6</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Other securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 11.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 11.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 10.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> 1.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 11.1</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Marketable equity </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 201.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 109.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> 201.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 201.6</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Equity method and other investments(1) </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">   173.5</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">   173.5</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">    </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Noncurrent investments </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,521.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,453.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr style="height: 8.55pt;"><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in; height: 8.55pt;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; height: 8.55pt;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; height: 8.55pt;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; height: 8.55pt;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; height: 8.55pt;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in; height: 8.55pt;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; height: 8.55pt;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> December 31, 2011</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Cash and cash equivalents </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $5,922.5</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $5,922.5</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $5,264.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $657.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $5,922.5</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Short-term investments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   U.S. government and agencies.. </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $  362.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $  362.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $  362.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $      </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $ 362.3</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Corporate debt securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 600.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 601.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 600.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 600.7</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Other securities<a name="OLE_LINK6"> </a><a name="OLE_LINK1"> </a></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78"> 11.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78"> 11.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 11.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 11.6</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Short-term investments </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $   974.6</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $   975.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Noncurrent investments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   U.S. government and agencies.. </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $ 908.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $901.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $908.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $          </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $908.8</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Corporate debt securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,081.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,093.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 2,081.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 2,081.3</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Mortgage-backed </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 443.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 479.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 443.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 443.8</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Asset-backed </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 245.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 253.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 245.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 245.0</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Other securities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 10.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 11.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 8.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> 1.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 10.0</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Marketable equity </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 180.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 107.5</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> 180.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 180.8</td></tr> <tr style="height: 4pt;"><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in; height: 4pt;" valign="top" width="222">   Equity methods and other investments(1) </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid; height: 4pt;" valign="top" width="78">   160.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid; height: 4pt;" valign="top" width="78">   160.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; height: 4pt;" valign="top" width="72">    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; height: 4pt;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in; height: 4pt;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; height: 4pt;" valign="top" width="78">    </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Noncurrent investments </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,029.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="78"> $4,006.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr></table>   - Fair value not applicable <div> </div> <table class="MsoNormalTable" style="font-size: 11pt; margin-left: 0px! important; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" width="636" border="0"> <tr><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 193.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="258" colspan="3"> Fair Value Measurements Using</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="222">                 Description</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">               Carrying Amount</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="72">   Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td style="padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">         Significant Other Observable Inputs (Level 2)</td> <td style="padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="102">           Significant Unobservable Inputs (Level 3)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">               Fair Value</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 310.5pt; padding-top: 0in;" valign="top" width="414" colspan="5"> (Dollars in millions)</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Long-term debt, including   current portion</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   March 31, 2012 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">   $(5,413.8)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">   $</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">   $(5,845.2)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">   $</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">   $(5,845.2)</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   December 31, 2011 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">   $(6,981.5)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">   $</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">   $(7,451.5)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">   $</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">   $(7,451.5)</td></tr></table> <table class="MsoNormalTable" style="font-size: 11pt; margin-left: 0px! important; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" width="636" border="0"> <tr><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 193.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="258" colspan="3"> Fair Value Measurements Using</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="222">               Description</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">             Carrying Amount</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="72"> Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td style="padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">       Significant Other Observable Inputs (Level 2)</td> <td style="padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="102">         Significant Unobservable Inputs (Level 3)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="78">             Fair Value</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 310.5pt; padding-top: 0in;" valign="top" width="414" colspan="5"> (Dollars in millions)</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> March 31, 2012</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Risk-management instruments </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Interest rate contracts     designated as hedging     instruments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">      Sundry </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $472.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $472.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $472.0</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Foreign exchange contracts    not designated as hedging    instruments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">     Other receivables </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 12.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 12.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 12.1</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">     Other current liabilities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> (5.3)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> (5.3)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> (5.3)</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> December 31, 2011 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222"> Risk-management instruments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">   Interest rate contracts designated as hedging instruments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">      Other receivables </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $    6.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $   6.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102"> $    </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> $    6.1</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">      Sundry </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 531.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 531.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 531.7</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">    Foreign exchange contracts     not designated as hedging     instruments</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">      Other receivables </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 16.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> 16.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> 16.2</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 166.5pt; padding-top: 0in;" valign="top" width="222">      Other current liabilities </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> (25.9)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> (25.9)</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 76.5pt; padding-top: 0in;" valign="top" width="102">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 58.5pt; padding-top: 0in;" valign="top" width="78"> (25.9)</td></tr></table>   The fair value of the contingent consideration liability related to prior acquisitions, a Level 3 measurement in the fair value hierarchy, was $121.6 million as of March 31, 2012 and December 31, 2011, respectively.   <div> <div> We determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair value of equity method investments and other investments is not readily available.   Approximately $4.19 billion of our investments in debt securities, measured at fair value, will mature within five years.   </div> A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows: <table class="MsoNormalTable" style="border-right: medium none; border-top: medium none; font-size: 11pt; border-left: medium none; line-height: 115%; border-bottom: medium none; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="1"> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355">  </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 103.5pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="138"> March 31, 2012</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 99pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="132"> December 31, 2011</td></tr> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355">  </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 202.5pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="270" colspan="2"> (Dollars in millions)</td></tr> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355"> Unrealized gross gains </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 103.5pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="138"> $  124.8</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 99pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="132"> $    103.0</td></tr> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355"> Unrealized gross losses </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 103.5pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="138"> 56.4</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 99pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="132"> 80.0</td></tr> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355"> Fair value of securities in an unrealized gain position </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 103.5pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="138"> 3,159.0</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 99pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="132"> 2,498.9</td></tr> <tr><td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 3.7in; padding-top: 0in; border-bottom: medium none;" valign="top" width="355"> Fair value of securities in an unrealized loss position </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 103.5pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="138"> 1,877.5</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 99pt; padding-top: 0in; border-bottom: medium none;" valign="top" width="132"> 2,164.4</td></tr></table></div>   <div> Other-than-temporary impairment losses on fixed income securities of $3.7 million were recognized in the statement of operations for the first quarter of 2012 compared with $0.5 million for the same period in 2011. The amount of credit losses represents the difference between the present value of cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing the credit loss were the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.   The securities in an unrealized loss position include fixed-rate debt securities of varying maturities. The value of fixed income securities is sensitive to changes in the yield curve and other market conditions. Approximately 90 percent of the securities in a loss position are investment-grade debt securities. At this time, there is no indication of default on interest or principal payments for debt securities other than those for which an other-than-temporary impairment charge has been recorded. We do not intend to sell and it is not more likely than not we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and we have concluded that no additional other-than-temporary loss is required to be charged to earnings as of March 31, 2012.</div> Activity related to our available-for-sale investment portfolio was as follows: <div> <table class="MsoNormalTable" style="font-size: 11pt; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" width="703" border="0"> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" width="210">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" width="52">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" width="102">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" width="52">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" width="102">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="bottom" width="210">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 161.6pt; padding-top: 0in;" valign="bottom" width="215" colspan="6"> Three Months Ended March 31, </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 161.6pt; padding-top: 0in;" valign="bottom" width="215" colspan="6">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="bottom" width="210">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 54.55pt; padding-top: 0in;" valign="bottom" width="73" colspan="2">     2012    </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 83.7pt; padding-top: 0in;" valign="bottom" width="112" colspan="2">     2011     </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 54.55pt; padding-top: 0in;" valign="bottom" width="73" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 83.7pt; padding-top: 0in;" valign="bottom" width="112" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="bottom" width="210">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; width: 330.95pt; padding-top: 0in;" valign="bottom" width="441" colspan="13">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="bottom" width="210">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 346.55pt; padding-top: 0in;" valign="bottom" width="462" colspan="14"> (Dollars in millions) </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="top" width="210"> Proceeds from sales </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21"> $ </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52"> 2,383.4</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102"> 260.9</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="top" width="210"> Realized gross gains on sales </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52">  13.7</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102">   39.4</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="top" width="210"> Realized gross losses on sales </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52">   2.7</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102">   3.5</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr></table> <div>   Realized gains and losses on sales of available-for-sale securities are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.    </div></div></div></div> </div>

<div> <table class="MsoNormalTable" style="font-size: 11pt; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" width="703" border="0"> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" width="210">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" width="52">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" width="102">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" width="52">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" width="102">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="bottom" width="210">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 161.6pt; padding-top: 0in;" valign="bottom" width="215" colspan="6"> Three Months Ended March 31, </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 161.6pt; padding-top: 0in;" valign="bottom" width="215" colspan="6">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="bottom" width="210">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 54.55pt; padding-top: 0in;" valign="bottom" width="73" colspan="2">     2012    </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 83.7pt; padding-top: 0in;" valign="bottom" width="112" colspan="2">     2011     </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 54.55pt; padding-top: 0in;" valign="bottom" width="73" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 83.7pt; padding-top: 0in;" valign="bottom" width="112" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="bottom" width="210">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; width: 330.95pt; padding-top: 0in;" valign="bottom" width="441" colspan="13">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="bottom" width="210">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 346.55pt; padding-top: 0in;" valign="bottom" width="462" colspan="14"> (Dollars in millions) </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="top" width="210"> Proceeds from sales </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21"> $ </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52"> 2,383.4</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102"> 260.9</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="top" width="210"> Realized gross gains on sales </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52">  13.7</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102">   39.4</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 157.5pt; padding-top: 0in;" valign="top" width="210"> Realized gross losses on sales </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52">   2.7</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102">   3.5</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 15.6pt; padding-top: 0in;" valign="bottom" width="21">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 38.95pt; padding-top: 0in;" valign="bottom" width="52">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 10.65pt; padding-top: 0in;" valign="bottom" width="14">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 76.85pt; padding-top: 0in;" valign="bottom" width="102">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td></tr></table> </div>

500000

3700000

65300000

127000000

1273900000

1335300000

<div> Note 10: Income Taxes   <div> <div> <div> We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in major taxing jurisdictions for years before 2007. The U.S. examination of certain matters related to tax years 2008-2009 that were not settled as part of previous examinations remains in progress. Because this examination is still in its early stages, the resolution of all issues in this audit period will likely extend beyond the next 12 months.</div></div></div> </div>

218000000

324200000

-92500000

-132100000

595600000

698700000

45800000

45300000

9000000

2299800000

2424200000

15500000

26100000

33659800000

32238200000

8930900000

6553700000

11193300000

10861900000

6981500000

7451500000

5413800000

5845200000

5464700000

5403200000

1.0000

4029800000

4521100000

490

P35D

-6100000

-11500000

-713800000

-2057000000

-40700000

-652300000

1176100000

852500000

1055900000

1011100000

-11200000

-46000000

380200000

871500000

365200000

456800000

1150000000

275500000

<div> <div style="margin-top: 6pt; font-size: 10pt;" align="left"> <div> <div> <div> Note 1:  Basis of Presentation   <div> <div> <div> We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2011. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing. </div></div></div></div></div></div></div> </div>

2493400000

2093200000

481300000

309400000

<div> <div> Note 13: Other – Net, Expense (Income)   Other—net, expense (income) comprised the following: <div> <table class="MsoNormalTable" style="font-size: 11pt; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="0"> <tr><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 210.15pt; padding-top: 0in;" width="280" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 13.55pt; padding-top: 0in;" valign="bottom" width="18" colspan="3">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" width="40" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 13.3pt; padding-top: 0in;" valign="bottom" width="18" colspan="3">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.85pt; padding-top: 0in;" valign="bottom" width="20" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.8pt; padding-top: 0in;" valign="bottom" width="20" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" width="56" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 109.4pt; padding-top: 0in;" valign="bottom" width="146" colspan="12"> Three Months Ended March 31, </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 121.05pt; padding-top: 0in;" valign="bottom" width="161" colspan="11">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 37.05pt; padding-top: 0in;" valign="bottom" width="49" colspan="4"> 2012 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 42.9pt; padding-top: 0in;" valign="bottom" width="57" colspan="4"> 2011 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 42.9pt; padding-top: 0in;" valign="bottom" width="57" colspan="3">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 48.7pt; padding-top: 0in;" valign="bottom" width="65" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 0.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in;" valign="bottom" width="345" colspan="26"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 259.9pt; padding-top: 0in;" valign="bottom" width="347" colspan="27"> (Dollars in millions) </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="top" width="258"> Interest expense</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3"> $  45.3</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3"> 45.8</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="top" width="258"> Interest income</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3">   (26.1)</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3"> (15.5)</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="top" width="258"> Other</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3">    26.8</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3">  (19.1)</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr style="height: 3.15pt;"><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in; height: 3.15pt;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="345" colspan="26"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in; height: 3.15pt;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="top" width="258"> Other-net, expense (income)</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3"> $ 46.0</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3"> 11.2</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1"> <div style="border-right: medium none; padding-right: 0in; border-top: black 3px double; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 0.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in;" valign="bottom" width="345" colspan="26"> <div style="border-right: medium none; padding-right: 0in; border-top: black 3px double; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr></table> <div> <a name="FIS_MANAGEMENT_ANALYSIS"> </a> <a name="FIS_UNIDENTIFIED_TABLE_7"> </a> </div></div></div> </div>

2903500000

2754400000

121600000

1573800000

1533900000

160100000

173500000

19100000

-26800000

-7700000

-6100000

149300000

76900000

61000000

188200000

79300000

51300000

34300000

50900000

101400000

130700000

-539000000

-457600000

543200000

544600000

195400000

29600000

238300000

2156100000

300000000

30000000

<div> <div> <div> Note 11: Retirement Benefits    Net pension and retiree health benefit expense included the following components: <div>   <table class="MsoNormalTable" style="font-size: 11pt; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="0"> <tr><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 259.9pt; padding-top: 0in; border-bottom: black 1pt solid;" valign="bottom" width="347" colspan="14"> Defined Benefit Pension Plans                    Retiree Health Benefit Plans</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 109.4pt; padding-top: 0in;" valign="bottom" width="146" colspan="6"> Three Months Ended March 31, </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 121.05pt; padding-top: 0in;" valign="bottom" width="161" colspan="6"> Three Months Ended March 31, </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 37.05pt; padding-top: 0in;" valign="bottom" width="49" colspan="2"> 2012 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 42.9pt; padding-top: 0in;" valign="bottom" width="57" colspan="2"> 2011 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 42.9pt; padding-top: 0in;" valign="bottom" width="57" colspan="2"> 2012 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 48.7pt; padding-top: 0in;" valign="bottom" width="65" colspan="2"> 2011 </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 0.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in;" valign="bottom" width="345" colspan="13"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 259.9pt; padding-top: 0in;" valign="bottom" width="347" colspan="14"> (Dollars in millions) </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Components of net periodic benefit cost </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Service cost </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> $  63.0</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 58.9</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 16.4</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $ </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> 14.8</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Interest cost </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 113.0</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 111.8</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 28.5</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> 29.5</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Expected return on plan assets </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> (171.1</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17"> )</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> (171.6)</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> (31.8)</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> (32.0)</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Amortization of prior service cost </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> .9</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 2.2</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> (8.8)</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> (10.8)</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Recognized actuarial loss </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 70.9</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 49.5</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 23.7</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> 22.2</td></tr> <tr style="height: 3.15pt;"><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="345" colspan="13"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Net periodic benefit cost </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> $  76.7</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 50.8</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 28.0</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $ </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> 23.7</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1"> <div style="border-right: medium none; padding-right: 0in; border-top: black 3px double; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 0.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in;" valign="bottom" width="345" colspan="13"> <div style="border-right: medium none; padding-right: 0in; border-top: black 3px double; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td></tr></table>   On a global basis, we have contributed approximately $30 million required to satisfy minimum funding requirements to our defined benefit pension plans in 2012. In addition, we have contributed $300 million of discretionary funding to our global post-retirement benefit plans in 2012. During the remainder of 2012, we expect to make contributions to our defined benefit pension plans of approximately $40 million to satisfy minimum funding requirements. We do not anticipate making any additional discretionary contributions in 2012.</div>  </div></div> </div>

3068500000

2766500000

654900000

998500000

158500000

324000000

200000

-116200000

-12400000

260900000

2383400000

211900000

1423200000

14594000000

14765700000

7760300000

7754600000

54600000

1500000000

1124000000

1151500000

76300000

23800000

14897800000

15906700000

5839200000

104000000

101800000

5602000000

113300000

99800000

5689900000

56300000

27100000

40800000

5413800000

115800000

34000000

48500000

<div> <table class="MsoNormalTable" style="margin-left: 5.4pt; width: 463.5pt; border-collapse: collapse;" cellspacing="0" cellpadding="0" width="618" border="0"> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;"> </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 117pt; padding-top: 0in;" valign="top" width="156" colspan="2">   Three Months Ended  March 31, </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 1.75in; padding-top: 0in;" valign="top" width="168" colspan="2">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84"> 2012 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="72"> 2011 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 243pt; padding-top: 0in;" valign="top" width="324" colspan="4"> (Dollars in millions)</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Net product sales  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84"> $5,413.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in;" valign="top" width="72"> $5,689.9 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in;" valign="top" width="84">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Collaboration and other revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">       188.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="72">     149.3 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="84">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Total revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="84"> $5,602.0 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 0.75in; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="72"> $5,839.2</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="84">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="84">  </td></tr></table> </div>

<div> <table class="MsoNormalTable" style="margin-left: 5.4pt; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="0"> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 121.4pt; padding-top: 0in;" valign="top" width="162" colspan="2"> Three Months Ended   March 31, </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 109pt; padding-top: 0in;" valign="top" width="145" colspan="2">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="85"> 2012 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top"> 2011 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 3.2in; padding-top: 0in;" valign="top" width="307" colspan="4"> (Dollars in millions)</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top"> Net product sales  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in;" valign="top" width="85"> $ 34.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top"> 27.1</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top"> Collaboration and other revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="85">    79.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">    76.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top"> Total revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="85"> $113.3 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top"> $104.0</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top">  </td></tr></table> </div>

<div> <table class="MsoNormalTable" style="margin-left: 5.4pt; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="0"> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 121.4pt; padding-top: 0in;" valign="top" width="162" colspan="2"> Three Months Ended   March 31, </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 109pt; padding-top: 0in;" valign="top" width="145" colspan="2">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="85"> 2012 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top"> 2011</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 3.2in; padding-top: 0in;" valign="top" width="307" colspan="4">       (Dollars in millions) </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Net product sales  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in;" valign="top" width="85"> $ 48.5 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top"> $  40.8 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Collaboration and other revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="85">    51.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">     61.0 </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 220.5pt; padding-top: 0in;" valign="top" width="294"> Total revenue  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 63.55pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="85"> $99.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top"> $  101.8</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 54.6pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="73">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top">  </td></tr></table> </div>

<div> <table class="MsoNormalTable" style="font-size: 11pt; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="0"> <tr><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 259.9pt; padding-top: 0in; border-bottom: black 1pt solid;" valign="bottom" width="347" colspan="14"> Defined Benefit Pension Plans                    Retiree Health Benefit Plans</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 109.4pt; padding-top: 0in;" valign="bottom" width="146" colspan="6"> Three Months Ended March 31, </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 121.05pt; padding-top: 0in;" valign="bottom" width="161" colspan="6"> Three Months Ended March 31, </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 37.05pt; padding-top: 0in;" valign="bottom" width="49" colspan="2"> 2012 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 42.9pt; padding-top: 0in;" valign="bottom" width="57" colspan="2"> 2011 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 42.9pt; padding-top: 0in;" valign="bottom" width="57" colspan="2"> 2012 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 48.7pt; padding-top: 0in;" valign="bottom" width="65" colspan="2"> 2011 </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 0.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in;" valign="bottom" width="345" colspan="13"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 259.9pt; padding-top: 0in;" valign="bottom" width="347" colspan="14"> (Dollars in millions) </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Components of net periodic benefit cost </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Service cost </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> $  63.0</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 58.9</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 16.4</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $ </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> 14.8</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Interest cost </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 113.0</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 111.8</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 28.5</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> 29.5</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Expected return on plan assets </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> (171.1</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17"> )</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> (171.6)</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> (31.8)</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> (32.0)</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Amortization of prior service cost </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> .9</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 2.2</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> (8.8)</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> (10.8)</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Recognized actuarial loss </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 70.9</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 49.5</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 23.7</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> 22.2</td></tr> <tr style="height: 3.15pt;"><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="345" colspan="13"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="top" width="306"> Net periodic benefit cost </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> $  76.7</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 50.8</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48"> 28.0</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $ </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56"> 23.7</td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 229.5pt; padding-top: 0in;" valign="bottom" width="306">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 18.25pt; padding-top: 0in;" valign="bottom" width="24">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1"> <div style="border-right: medium none; padding-right: 0in; border-top: black 3px double; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 0.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in;" valign="bottom" width="345" colspan="13"> <div style="border-right: medium none; padding-right: 0in; border-top: black 3px double; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td></tr></table> </div>

<div> <table class="MsoNormalTable" style="font-size: 11pt; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="0"> <tr><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 210.15pt; padding-top: 0in;" width="280" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 13.55pt; padding-top: 0in;" valign="bottom" width="18" colspan="3">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 30.2pt; padding-top: 0in;" width="40" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 13.3pt; padding-top: 0in;" valign="bottom" width="18" colspan="3">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.85pt; padding-top: 0in;" valign="bottom" width="20" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 14.8pt; padding-top: 0in;" valign="bottom" width="20" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" width="9" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" width="56" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 109.4pt; padding-top: 0in;" valign="bottom" width="146" colspan="12"> Three Months Ended March 31, </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 121.05pt; padding-top: 0in;" valign="bottom" width="161" colspan="11">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 37.05pt; padding-top: 0in;" valign="bottom" width="49" colspan="4"> 2012 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 42.9pt; padding-top: 0in;" valign="bottom" width="57" colspan="4"> 2011 </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 42.9pt; padding-top: 0in;" valign="bottom" width="57" colspan="3">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 48.7pt; padding-top: 0in;" valign="bottom" width="65" colspan="4">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 0.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in;" valign="bottom" width="345" colspan="26"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 259.9pt; padding-top: 0in;" valign="bottom" width="347" colspan="27"> (Dollars in millions) </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="top" width="258"> Interest expense</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3"> $  45.3</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3"> 45.8</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="top" width="258"> Interest income</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3">   (26.1)</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3"> (15.5)</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="top" width="258"> Other</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3">    26.8</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3">  (19.1)</td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr style="height: 3.15pt;"><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in; height: 3.15pt;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in; height: 3.15pt;" valign="bottom" width="345" colspan="26"> <div style="border-right: medium none; padding-right: 0in; border-top: black 1pt solid; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in; height: 3.15pt;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="top" width="258"> Other-net, expense (income)</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3"> $ 46.0</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9"> $</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="3"> 11.2</td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 36.05pt; padding-top: 0in;" valign="bottom" width="48" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 16.75pt; padding-top: 0in;" valign="bottom" width="22" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 6.85pt; padding-top: 0in;" valign="bottom" width="9" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 41.85pt; padding-top: 0in;" valign="bottom" width="56" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; background: #cceeff; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" valign="bottom" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr> <tr><td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 193.5pt; padding-top: 0in;" valign="bottom" width="258">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 0.25in; padding-top: 0in;" valign="bottom" width="24" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 1pt; padding-top: 0in;" valign="bottom" width="1"> <div style="border-right: medium none; padding-right: 0in; border-top: black 3px double; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 0.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 258.9pt; padding-top: 0in;" valign="bottom" width="345" colspan="26"> <div style="border-right: medium none; padding-right: 0in; border-top: black 3px double; padding-left: 0in; padding-bottom: 0in; margin-left: 0in; border-left: medium none; margin-right: 12.8pt; padding-top: 0in; border-bottom: medium none;"> <p class="MsoNormal" style="border-right: medium none; padding-right: 0in; border-top: medium none; padding-left: 0in; font-size: 11pt; padding-bottom: 0in; margin: 0in 0in 0pt; border-left: medium none; line-height: normal; padding-top: 0in; border-bottom: medium none; font-family: 'Calibri','sans-serif';"> </div></td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; width: 12.7pt; padding-top: 0in;" width="17" colspan="2">  </td> <td style="padding-right: 0in; padding-left: 0in; padding-bottom: 0in; padding-top: 0in;" width="7">  </td></tr></table> </div>

<div> <table class="MsoNormalTable" style="font-size: 11pt; margin-left: 5.4pt; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="0"> <tr><td> </td> <td> </td> <td> </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 112.5pt; padding-top: 0in;" valign="top" width="150" colspan="2"> Three Months Ended March 31,</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">  </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="75"> 2012</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="75"> 2011</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 112.5pt; padding-top: 0in;" valign="top" width="150" colspan="2"> (Dollars in millions)</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444"> Revenue– to unaffiliated customers:</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">    Pharmaceutical products</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">       Neuroscience </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> $1,903.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> $2,405.1</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">       Endocrinology </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 1,690.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 1,589.0</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">       Oncology </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 803.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 839.9</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">       Cardiovascular </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 638.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 581.8</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">       Other pharmaceuticals </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="75"> 74.4</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="75"> 53.6</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">    Total pharmaceutical products </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 5,111.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 5,469.4</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">    Animal health </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 490.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 369.8</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444"> Total revenue </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="75"> $5,602.0</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="75"> $5,839.2</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td></tr></table> </div>

<div> <div> <div> Segment Information <div> We operate in one significant business segment—human pharmaceutical products. Operations of the animal health business segment are not material and share many of the same economic and operating characteristics as human pharmaceutical products. Therefore, they are included with pharmaceutical products for purposes of segment reporting. Our business segments are distinguished by the ultimate end user of the product: humans or animals. Performance is evaluated based on profit or loss from operations before income taxes. Income before income taxes for the animal health business for the first quarters of 2012 and 2011 was $127.0 million and $65.3 million, respectively. Revenue by Category Worldwide revenue by category was as follows: </div></div> <div> </div> <div> </div></div> <table class="MsoNormalTable" style="font-size: 11pt; margin-left: 5.4pt; line-height: 115%; font-family: 'Calibri','sans-serif'; border-collapse: collapse;" cellspacing="0" cellpadding="0" border="0"> <tr><td> </td> <td> </td> <td> </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 112.5pt; padding-top: 0in;" valign="top" width="150" colspan="2"> Three Months Ended March 31,</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">  </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="75"> 2012</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="75"> 2011</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 112.5pt; padding-top: 0in;" valign="top" width="150" colspan="2"> (Dollars in millions)</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444"> Revenue– to unaffiliated customers:</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">    Pharmaceutical products</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">       Neuroscience </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> $1,903.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> $2,405.1</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">       Endocrinology </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 1,690.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 1,589.0</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">       Oncology </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 803.9</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 839.9</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">       Cardiovascular </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 638.4</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 581.8</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">       Other pharmaceuticals </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="75"> 74.4</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: medium none; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 1pt solid;" valign="top" width="75"> 53.6</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">    Total pharmaceutical products </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 5,111.3</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 5,469.4</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">    Animal health </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 490.7</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75"> 369.8</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444"> Total revenue </td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="75"> $5,602.0</td> <td style="border-right: medium none; padding-right: 5.4pt; border-top: windowtext 1pt solid; padding-left: 5.4pt; padding-bottom: 0in; border-left: medium none; width: 56.25pt; padding-top: 0in; border-bottom: windowtext 2.25pt solid;" valign="top" width="75"> $5,839.2</td></tr> <tr><td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 333pt; padding-top: 0in;" valign="top" width="444">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 0in; width: 56.25pt; padding-top: 0in;" valign="top" width="75">  </td></tr></table> </div>

369800000

581800000

1589000000

2405100000

839900000

53600000

5469400000

490700000

638400000

1690900000

1903700000

803900000

74400000

5111300000

1785700000

1847500000

37900000

28200000

1522300000

10600000

974600000

802400000

13535600000

14822600000

<div> <div> Note 8: Shareholders' Equity   As of March 31, 2012, we have purchased $2.58 billion of our previously announced $3.00 billion share repurchase program. We did not acquire any shares pursuant to this program during the first three months of 2012, and we have no current plans to repurchase shares under this program for the remainder of 2012. </div> </div>

3000000000

95300000

94300000

2580000000

<div> <div> Note 5: Asset Impairments, Restructuring, and Other Special Charges  <a name="eolPage13"> </a> <div> We recognized asset impairments, restructuring, and other special charges of $23.8 million in the first quarter of 2012, primarily consisting of a change in our estimates of returned product related to the withdrawal of Xigris® from the market during the fourth quarter of 2011. We recognized severance costs of $76.3 million in the first quarter of 2011 as a result of the 2009 initiative to reorganize global operations, streamline various functions of the business, and reduce total employees, as well as other previously announced strategic actions to reduce our cost structure.</div> </div> </div>

EX-101.SCH 8 lly-20120331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00200 - Statement - Consolidated Condensed Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Condensed Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00600 - Statement - Consolidated Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - Collaborations (Details) link:presentationLink link:calculationLink link:definitionLink 40604 - Disclosure - Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Retirement Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 41304 - Disclosure - Other - Net, Expense (Income) (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00410 - Statement - Consolidated Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10001 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Implementation of New Financial Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Collaborations link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Asset Impairments, Restructuring, and Other Special Charges link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Retirement Benefits link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Other-Net, Expense (Income) link:presentationLink link:calculationLink link:definitionLink 20602 - Disclosure - Financial Instruments (Policies) link:presentationLink link:calculationLink link:definitionLink 30001 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Collaborations (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Retirement Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Other - Net, Expense (Income) (Tables) link:presentationLink link:calculationLink link:definitionLink 40004 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - Asset Impairments, Restructuring, and Other Special Charges (Details) link:presentationLink link:calculationLink link:definitionLink 40704 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 41204 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 lly-20120331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 lly-20120331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 lly-20120331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document & Entity Information [Abstract] Document & Entity Information [Abstract] Document Information [Table] Statement [Line Items] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Consolidated Statements of Operations [Abstract] Statement [Table] Revenue Revenue Cost of sales Cost of sales Cost of Goods Sold, Total Research and development Research and development Research and Development Expense, Total Marketing, selling, and administrative Marketing, selling, and administrative Selling, General and Administrative Expense, Total The amount of purchased research and development assets that are acquired in a business combination and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition. Acquired in-process research and development Acquired in-process research and development Asset impairments, restructuring, and other special charges Asset impairments, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions, Total Other - net, expense Other - net, expense Nonoperating Income (Expense), Total Other-net, expense Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Income before income taxes Income before income taxes Income taxes Income taxes Net income Net income (loss) Net income Earnings per share - basic and diluted Earnings Per Share, Basic and Diluted, Total Common Stock, Dividends, Per Share, Cash Paid Dividends paid per share Dividends paid per share Consolidated Statements of Comprehensive Income [Abstract] Other Comprehensive Income (Loss), Net of Tax Other comprehensive income, net of tax Other comprehensive income, net of tax Comprehensive Income, Net of Tax, Attributable to Parent Comprehensive income Consolidated Condensed Balance Sheets [Abstract] Assets Abstract Assets Current Assets Cash and cash equivalents Cash and Cash Equivalents at March 31 Cash and cash equivalents at January 1 Cash and Cash Equivalents, at Carrying Value, Total Short-term investments Short-term Investments, Total Accounts receivable, net of allowances of $108.4 (2012) and $110.1 (2011) Accounts Receivable, Net, Current, Total Other receivables Inventories Inventories Prepaid taxes Prepaid expenses and other Prepaid expenses Prepaid expenses Assets, Current, Total Total current assets Other Assets Investments Long-term Investments, Total Goodwill and other intangibles - net Goodwill and other intangibles - net Sundry Sundry Assets, Noncurrent, Total Total other assets Property and Equipment Land, buildings, equipment, and construction-in-progress Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property and equipment, gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property and equipment, net Assets Total assets Liabilities and Shareholders' Equity Current Liabilities Short-term borrowings and current maturities of long-term debt Short-term Debt, Total Accounts payable Accounts Payable, Current, Total Employee compensation Employee-related Liabilities, Current, Total Sales rebates and discounts Sales rebates and discounts Dividends payable Income taxes payable Other current liabilities Other current liabilities Total current liabilities Total current liabilities Other Liabilities Long-term debt Long-term debt Long-term Debt, Excluding Current Maturities, Total Accrued retirement benefits Accrued retirement benefit Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent, Total Long-term income taxes payable Other noncurrent liabilities Other noncurrent liabilities Liabilities, Noncurrent, Total Total other liabilities Shareholders' Equity Common stock Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Additional paid-in capital Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Retained earnings Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Employee benefit trust Employee benefit trust Accumulated other comprehensive loss Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance Accumulated other comprehensive income loss Noncontrolling interests Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Noncontrolling interests Cost of common stock in treasury Cost of common stock in treasury Treasury Stock, Value, Ending Balance Treasury Stock, Value, Beginning Balance Less cost of common stock in treasury Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance Total shareholders' equity Liabilities and Equity Total liabilities and shareholders' equity Consolidated Condensed Balance Sheets (Parenthetical) [Abstract] Accounts receivable, allowances Accounts receivable, allowances Allowance for Doubtful Accounts Receivable, Current, Ending Balance Allowance for Doubtful Accounts Receivable, Current, Beginning Balance Consolidated Statements of Cash Flows [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Net Cash Provided by Operating Activities [Abstract] Cash Flows from Operating Activities Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Change in deferred income taxes Changes in deferred income taxes Change in deferred income taxes Stock-based compensation expense Stock-based compensation expense Share-based Compensation, Total Research and development assets that are acquired in a business combination and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition, net of tax Acquired in-process research and development, net of tax Acquired in-process research and development, net of tax Acquired in-process research and development, net of tax Other changes in operating assets and liabilities, net of acquisitions Other changes in operating assets and liabilities Other changes in operating assets and liabilities Other changes in operating assets and liabilities Other changes in operating assets and liabilities Other operating activities, net Other Operating Activities, Cash Flow Statement Other Operating Activities, Cash Flow Statement NET CASH PROVIDED BY OPERATING ACTIVITIES Net Cash Provided by Operating Activities Net Cash Provided By (Used In) Investing Activities [Abstract] Cash Flows from Investing Activities Net purchases of property and equipment Net purchases of property and equipment Payments for (Proceeds from) Productive Assets, Total Net change in short-term investments Net change in short-term investments Payments for (Proceeds from) Short-term Investments, Total Proceeds from sales and maturities of noncurrent investments Proceeds from sales and maturities of noncurrent investments Proceeds from sales and maturities of noncurrent investments Proceeds from Sale and Maturity of Other Investments, Total Purchases of noncurrent investments Purchases of noncurrent investments Purchase of product rights Purchase of product rights The amount of purchased research and development assets that are acquired in an in-licensing arrangement and have no alternative future use and are therefore written off in the period of acquisition. Purchase of in-process research and development Purchase of in-process research and development Purchase of in-process research and development Cash paid for acquisitions, net of cash acquired Cash paid for acquisition, net of cash acquired Cash paid for acquisition Cash paid for acquisitions, net of cash acquired Payments for Proceeds From Other Investing Activities Other investing activities, net Other investing activities, net Other, net NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES Net Cash Used for Investing Activities Net Cash Used in Financing Activities [Abstract] Cash Flows from Financing Activities Dividends paid Dividends paid Payments of Dividends, Total Net change in short-term borrowings Proceeds from (Repayments of) Short-term Debt, Total Repayment of long-term debt Repayment of long-term debt Repayment of long-term debt Other financing activities, net Other financing activities, net Other financing activities, net Other, net NET CASH USED IN FINANCING ACTIVITIES Net Cash Used in Financing Activities Effect of exchange rate on cash and cash equivalents Effect of exchange rate changes on cash and cash equivalents Effect of exchange rate changes on cash and cash equivalents NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Net (decrease) increase in cash and cash equivalents Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] Summary of Significant Accounting Policies [Abstract] Basis of Presentation [Text Block] Implementation of New Financial Accounting Pronouncements[Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Changes and Error Corrections [Text Block] Acquisitions [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Definition: Description of a business combination (or series of individually immaterial business combinations) OR OTHER ACQUISITION (e.g. license or asset) completed during the period, including background, timing, and recognized assets and liabilities. This element may be used as a single block of text to encapsulate the entire disclosure (including data and tables) regarding business combinations, including leverage buyout transactions (as applicable). Acquisitions Text Block New Acquisitions [Text Block] Collaborations Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborations [Text Block] Asset Impairments, Restructuring, and Other Special Charges [Abstract] Component of Other Operating Cost and Expense [Table] Asset Impairments, Restructuring, And Other Special Charges [Text Block] Financial Instruments [Abstract] Fair Value, by Balance Sheet Grouping [Table] Financial Instruments [Text Block] Stock-Based Compensation [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Stock-Based Compensation [Text Block] Shareholders' Equity [Abstract] Schedule of Stock by Class [Table] Shareholders' Equity [Text Block] Earnings Per Share [Abstract] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Earnings Per Share [Text Block] Income Taxes [Abstract] Federal Income Tax Note [Table] Income Taxes [Text Block] Retirement Benefits [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Retirement Benefits [Text Block] Contingencies [Abstract] Loss Contingencies [Table] Contingencies [Text Block] Other-Net, Expense [Abstract] Other - Net, Expense (Income) [Text Block] Description of Derivative Risk Management Policy Schedule of Segment Reporting Information, by Segment [Table] Segment Information [Text Block] Products and Services [Axis] Products And Services [Domain] Products and Services [Domain] Erbitux [Member] Erbitux [Member] Erbitux [Member] Revenue from External Customers by Products and Services [Table Text Block] Derivative Instruments and Hedging Activities Disclosure [Text Block] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Fair Value, by Balance Sheet Grouping [Table Text Block] Available-for-sale Securities [Table Text Block] Gain (Loss) on Investments [Table Text Block] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Axis] Defined Benefit Plans [Domain] Defined Benefit Plans and Other Postretirement Benefit Plans [Domain] Pension Plans Defined Benefit [Member] Pension Plans, Defined Benefit [Member] Schedule of Net Benefit Costs [Table Text Block] Schedule of Other Nonoperating Income (Expense) [Table Text Block] Business Segments [Axis] Segment [Domain] Segment [Domain] Revenue to unaffiliated customers, Neuroscience Neuroscience [Member] Neuroscience [Member] Revenue to unaffiliated customers, Endocrinology Endocrinology [Member] Endocrinology [Member] Revenue to unaffiliated customers, Oncology Oncology [Member] Oncology [Member] Revenue to unaffiliated customers, Cardiovascular Cardiovascular [Member] Cardiovascular [Member] Revenue to unaffiliated customers, Animal health Animal Health [Member] Animal health [Member] Revenue to unaffiliated customers, Other pharmaceuticals Other Pharmaceuticals [Member] Other pharmaceuticals [Member] The sum of revenue from pharmaceutical products. Pharmaceutical Products Total [Member] Pharmaceutical products, total [Member] Segment Reporting Information, Income (Loss) before Income Taxes Segment Reporting Information, Income (Loss) before Income Taxes, Total Segment Reporting Information, Revenue Segment Reporting Information, Revenue, Total Business Acquisition [Axis] Business Acquisition Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisitions Business Acquisition [Member] Business Acquisition [Member] Disclosures related to the business acquisition of ChemGen Corporation on February 17, 2012. Chemgen Corporation [Member] ChemGen Corporation [Member] Animal health business acquisition of Janssen Pharmaceutica NV from J&J on July 7, 2011. Janssen Pharmaceutica Nv J J [Member] Janssen Pharmaceutica NV (J&J) [Member] Total purchase price Business Acquisition, Cost of Acquired Entity, Purchase Price, Total Number or Amount of products or other assets acquired pursuant to the acquisition of a business or of assets. Business Acquisition, Products or Other Assets Acquired Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets Business Acquisition, Purchase Price Allocation, Intangible Assets Not Amortizable Business Acquisition, Purchase Price Allocation, Intangible Assets Not Amortizable, Total Business Acquisition, Purchase Price Allocation, Net Tangible Assets EX-101.PRE 12 lly-20120331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ZIP 13 0001193125-12-195656-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-195656-xbrl.zip M4$L#!!0````(`$1[GD!"ILI[F=P``&VD$@`0`!P`;&QY+3(P,3(P,S,Q+GAM M;%54"0`#3^>>3T_GGD]U>`L``00E#@``!#D!``#L76U3X[BR_KY5^Q]\J%N[ M]U8-$">\#,S+*0@PRRP#'&!V[SE?*,56$MV1K:QD`]E??UNV$SLO3FQ(',O6 M[M96L&6I^^FG6ZT7RQ__^>)0XPES09C[:IRU?;"-A$;+U MS\\___3Q']O;_WMZ=V78S/(=['J&Q3'RL&T\$Z]OM#D3HDLX-CI#XXX\8<^X M9UWO&<&5J'YC?\?<,??>[S2,ON<-CG=WGY^?=[@L*Z*B.Q9SMK>CUDZ1@-KA MN:#9YHXYOM..6F;NL;&WVVKL-AMFTS"/S<:QN6_"DL>4^+^6%!_!;GAS5-3&4^4$MG9Z[&D7;@2Z;C?,[9:9K)GDT9$.)TI3`E+JH[+#%Z`"C30V@P?J"+1"\"U@`=RQHLO$_K1UYG,D[SV:\*]$_O&!/9K-QU;X5R@3/`/\)MXP^@O^ M)K:\TB68&X&L>`*2D7G:E[]O?6[(?_:/]@[??]R-'QM5O#M1\\X+!LD\1KXS5YZE50;.;2;.;.KLO479O9B.$ M61)"Z.Q>4T!G]W4QM<[N:V=RG=W7T.@ZNU?9["F#NBB3O>'WF#\1"\33237J,VC39JVDM[:9,V`N2'_3#88A-U`[/.?VVDQX)ZY]_C(` M#/$7[,)U&AA]].@=%AX','TNB\/PI8<5&9/E5WKK\^C9=*WK$PLT:=0@3:DB M37H'\H)=J,!69*BWH`N95*2"\2"W:7F'>/Z+\H9-JE%!L^9.^;3'JA*,VP9S7HB'F^ZS+[:B/,AI"!W>,"X MA^T3A_FN-W[RC`B+,N'SR!_&SWU#_\?XPW"`Q4WW#'>"=.6"7.G2?8(,*)@F48-9V7"-$[R4*$H@[%%XS?(XH3*#E@.O(WMF5"KQT@FP-(4N6" M5%/_+=0?[1Y/=.6Z"]!=@$I^8([>(-B,'^@^0/?8-CW!):Z M1A[$F#$13_WA=W'&*$4P2*+TW.=,#?+-URDT8ZI29>^^\YI.:B8U'&E;"=/- M5ZIJICN5L4?T;R$)L"OE>>F*E=>$*]N/?N(2!]'?,*)>7PUK9MBO,JM4?>:X MM1:+Z`:U'9"*;."7S?= M.VRQGBN3V=M`(IG2BM-A..2[`JS'K`GJZC-JXS!O/GE&W%8D[U\W0"$%%R%4 MP?BS23(&VP^(Y6'[WF/6C^_N"%#-1,G$5'@T#5=*0[C?9=R1!Z:$SA[ME=%< M3+P5MA"C"A`R;32E>^52\*_(7GG]0W3=NVZ>487UKA6AD^XER]9+KI]8IXA* M7>[[&'M7$2`3J[;!2L4501U"@R6-J:6I>,KNTI4[C:5R=T3\F*CC@G%,>N[Y MB]5';@_+,]TXLJ97N7(N)X_+7+H#WQ-!@:8:5$T#/5[2G8_Z*E>O%ADNEF.A MY58I3MXU[P76UTY8G!.>"X\XD(K?=,>E4_<=:*^LO%?FH8-VT^+<-.<.(>VI ME??4%>\9V[2SSMF5I:ZWZLRVSIZYFVVE55 MR6W7M.LZF[.>"(&]5_GI)8C`L?#N(-[IE#:;0R;1+MX7TRU6OU1VH[,_97*Z M&F:PV@M+F[EJMZQUPJH]L\R)JJ+.J:=?%?3%THX;=;JZ:=?3&:OV19VTEM0Y M==ZJ_;.JJ>NK5T3*-+#4B6L=!Y%UW"]0)J_3.:MVP_(DK-HO=;JJ7;.LN:JJ MWJGG615TQM*.'77&NG'?TTFK=D:=MY;5.W7JJAVTJMGKO--,N\3%]BEVX8=W M"UP1L5)BSMT)7[D-\0T?FRBKAG.\2ON8'\;SP30[%&)'>8^9>QN- M@O[IED'O@3W"PQ-.DS75CUFO0*2"9$LYVE?'+%5C5JD^E:=C5K5C5JG.IG[C M*DWYJ;/>]0L%.Z_7$$$>$_@;MGO8OB`OV)8XR4_?5($#\G2_5-4J:/[43D?' M@4W%@9)E'SH.%!L'E/J@K\*KMVJL5V[V@[6+S&S6Q\QF3]A%WD(5]CUCH^NGKUPK8;[%J:XV:C4/XK[SCWW&9 MC!^"C[ODJ9MJL*3`K"N/6!G!3R0%<]$O^\"NT!&^9G9A::6F^NJIGG/'K&9[ MD?N/->%71_C@(_%/B%#4H?B"\7M$<0(:!^PE/VHG/V>GJ;Z`ZL%WZ?/@J$F> MF^1KG;'4O-:I>$7G9#6U=2ZN,M=U,JZ3\7HP7F?C.AM7A>5KF1=OO9'6P?L9 MLF!5F;TH'V^5@,NI!BC[X'*=NUE?3>=O$*AZJ(=/D?4#VW7D=,;-5&OE]&(K M:&*_@MC!01V:U9MD]0(35)[2AU"MX*S.+4O-H7@CU:Q3>E>%]G>-]43.( M]0KY*LTDUCSJ%^4`-0K\*K&_CK&_N+GT>D1]M>;4:QKOBR-]#2*]6HQ7.,:O M9V.77DO2:TF;61I=ZROT.DU1>MI]8XE)A9E=@URD[+3>3/91$D[KY:3Z3JO7 M/9[K]:2:$K_6$5\O*-5]2KWN<5^O*-6:_K6,_GI)JZV7E,HP3:E?3UHEG4J$1:DGKMY[H\OW^"WO"W)6XG/2P M:Q'Y9;!Z,KP,9[QDM4?ER5[(7'M=V:_,Q+MVAR+=H38INS+\KV\.7PCA:Y74 M*T/Z>F?Y12TVU37W46GE2:<_!3M%;3(@E;R@ODE04;2O51ZD$O7KF0H5MPI; MMR1(K279VJ<_Q3E"Y1,?M9A?OY2G.*K7(ME1B^Y*ISGE?$^P\@&]['L5]!O= M>O]-U3B]J3A=8E[K#3AZ`TXUV:YWX.C%6.T/>@M.S1V@QGF\WH-36];7/-/7 MFW#6ZPB:4O)-;\PJ;B]B58BP\EBU:0H4/O:O"A/*%Q)4 MRXJJPH0RQ80W4+"-!!Y;_Y8SV[>\*X(Z MA(*\<;&I-#@J>,/O,7\B5ES#Z1!['IHJ?>]!MB7A^()9CZ-!GU@HIEP;4=)E MW"5(#5;-8A`+W#L#$:)^TX3_ MH([QU7%![-J)8F'W.KJFEBO]9SC@^$4[Q0J<8@+*VE/SFT\]`FF-QXFTS-@@ M-JT5-9?!H*FI8M0\(]CK#ZGP".U@L"VC9ZI,MY4[ABX`5M-VI7FSYFE1";`F MYOAY)D0;FB5NM/AY.KQ&GL_Q33>^/(RC+')0#XL+SIRHB5..D?#:R+4PU[&Z M$!_(;K,H@F)A^V@C")1?\DDV*Q"VM@C8]_XG@!S5,[FJ7I5 MR?2'".,Q$\L:16B2_PP++-4AX]$RN M0K)!L.W4M;\A_@/+Q!U^WV,*.4/O_&4`UIG>=J_]88X_O!I6[3K*N,X7#H-> ML&>/N/=]-/,ZBO:+.7XQ'S--^M60OI$D?6,MI`=XN\1+#VOY/*$+-'45V<&S M4C_(`6-!SI$TQ5I=HY'--1HK<@TSX1JCN>KUN,;\/A]Z]ZSN<(T!:M_Q'=3) MM6M)O8%L`;G6&/=B_&?&=@5N>"IXP-_(-G/=6.UB4Y4=6-D)*>W'J_3CSL78)A21U3.T7Z^"W7**V^'A"/U`H?CU6; M[@5N1O@^Z'*0X18-G?'X5F])2*7[/+CTQ@15R'X'>;/KXUSAO;94GP5+$UT5 MHG\C%`N/N3@*5$*S?0G;4Q#3E%=CL?'5A'\8]$Y>F&9\P8R?@+U*2XU["8XQ,N3N8]7>6]<"_^)\0\ZK"'WYV%7\"K[-/[K=H*];$YPL,)% MQ3+'_5,"]A\PW[7KN):PT=@_`_VZJ9\MY5GI>KJ9G*HL&?6OZ/!F(.M"=&0( M[0+%ND"J"4KB"JN&QHVVB]4>EO#X>/!."4Z MA'\G,J)37X#'"W%B_>430>0#8T)^!3L)[-[V$7>0A7V/6.CZZ>M7-=B9HEEH M\,6J%3`Q?I`A*X!BAZ^U_M3AUVLWUN;.="Z3:BL^FG9R%+-Q13>0W(;&W@/] MRTCCO>UF8SW'$&]R/*[')$\`1:R#+7?L.!GNPB<1BNK7O M]V>3K87:S7\^J/8,N\PA;EK%LI1J]%]1>ZFUI34H9>0RI!37R,E'KRL"@QOCG!+C%^0, M/AAMEFQULN+I9O]@U'>A?P^%RX?P]40[4S5--_0GIO1WESV[]Q"T83?9^LYD?Y9$DZU%AK:BGB!Y.<(@' MD.F40ER]QL^Y'.H7ZGV`M/*7GO?!2/S^^:>??UK^Y\"P*!*@SC?!KAD'U;8, MX0TI#$ZZ(,.V('_C8\-L#J!R)SAEY=AH$-=H[#3E_P>>_.N#$93M(H>`4L:O M#\3!PI!ZW#$'N;]^V))-7C/HV5O'1E)I*<+N0-Z5OV0M(WD>'6^N)`TIR>+F MWOTJH._O1LV&>N[*1^(_7X>"F43!;.WLA^H;@4R4N'B[CTFO[QT;;E#)M*#R M.R(=3J2`R!7;22G7IGX2;8-UC='<&A83L!1@B#=4?,()HO-@FS+N'$N_QK1' MI;!KJM(WKG&!.]R';MHP#]\9,@R\,YZQ@:(X9"!*I:V]/C98(AT4,FV3-]I] M['S!KC'Z6B20XYV!C`$G3Y#9T"'H2VVC0YBP"'8MF4D+7B;I<$C0_EXP/F4X\/WQFXUWL7M`+#1F_T>"!^EW'#8QZB!HQPK3X2 M0?XE7W_G8RG0`)YX@0`NE0SR++Y*?]!K]`7)AP(ECBW$;FGD&28R.?$BN.\*%"`M`&LS=(QV*Q8[Q MT">`;;QJ8SPC$<@L(9#\`L@"B254C!([2'KA#UNN8=J!6JXT)7`G.FE`[,0Z MQ+^,E&CRE@B[#C>4[7S:@HY\RM)3\L<:CC4!K_OJ0XH>.IPYZ7"!A5R9&1A] MC*C7!UN'<5;:+UJR,";6+(SK/Z3/?65]0-X-L_X@\Q]=B7PN&[-3*0SCMYWW MWLS5=9:C3M,)%G MR:"27N71SD%JC6,6$'=[$":`(&68`0;5)B)D#.-_7][>C8U^]C^1&.]"'%(% MV6NE61,$8?)CUX:+1SI)_\?KZ('"<`=Z01`)9CBE``Z2QA$0J"6S`@D"[>GH M1K4HX-NDVP6)NYPY@0O%EAX:6'A!H`9((&X:`W$*Y)=E4A$QLD0%\>R4$H(9#,Q*\H+L_PVDG\DQ@%STOE$PI_Z(<;P MHP8^\\5WE^.P+_D"+GG+P@K'WWB<,ZF36%%;.NC:.WI_E!QUO5V@=6N7?3C6 M,O>/&NM2;LZB=+0K0=SPX#/S)X'3C0:#\\=PZUK1GX*FE82FL?5Y/T(DKQ*Q M^FD[1BY=Z*?P^!RBM@PR!%*W0%T8_X8?G%T$Y5SXF!O?R]AY#<*5HR&.><5 M#IN-(C6\DUF5W/ISTZ'1!UW$LED(M;9C+9^+:F1!/`4H91%>YV[0A9`?@!Y6GO/IQ#>F^D.-<)O?;5E6=PX*&'<*#G$*2_2+4-Z?Q2BRX:T,F_K+DVK M#M\?E@9A=0\%6`:S>5`B(BMWW,C2S+E,\5BYXXN6_NOP3:"2%E\UWDD]%+(]U]% M9]4AI^4\5'^IM0Z;^]I:&_^&B7)QK!)?85J$>BL*924$7:'OO2G7653R:Y3: M"JE6>.N';Y=`:^Z\+KE?8_^ZIL])+^58JV3!=.4?45^*P(%B")1YFF(6W<91 MR1+9`M'-&\7R(6NNBK?"N^D&HMX,@@V"XXXM>%3N\;C&*WU=9F__8+\U,;^2 M2835RIQSA\5>\^#@\"TRGV%A<1*L9=UTSW"P!YU%VRJ6E. M0!L+F:?-6-(OC-ER3]Q(C%]>2N\VM?NNU-MXV``3F8-PX+5\2+G%16D1QHR6AQ-=H4&1>;"BN3 M\A`L3H?7R/,Y!IEB,>,=&,A!/2PN.'.B)DXY1L)K(]?"//,^#H*]_I`*C]`. M%AYG]"Q3SRNWF(5P+X)Q.=@4087Y-E.M#/#TI=0A]CR4$85F8S$.(PT5Q>(- M!#'-)111`QK5_/+]JE"_0L_")RL%_9M//7(FWVPF$OHQXC;-"LQ_A@..7S(Z MYQ("CA3[;KH%GG6P/778068A5BWWZUZ]?X6XP2#O#G?DI)(L0X0UNX$_ M]TC(/#PTDX/@M%9>)4=V6,P#\^A]9C%&!RZ>C-]1;??E;(,L>LXYXVW&>?A^ M7OQ"TYL.)RCZO('FL7'I#,+SH@)!Y7MRLN3%^&VP6'D#&.3";RN<(GKU6ZRK MD'[>*ZAO.\-!I5?<'V9>S3%`C?/

`.\CVR#\?"MP^`"BM\\),X`69[Q_^W]:W/C M1I(V#'^?B/D/M1K/;G?<$DWPS![;$>I6MT>[?=IN>?SN\T4!`D41;A"@<9!: M\^O?S"J`!$F`!$B`+)`YWK5)"H>LK*PKK\K*RD*K6]UCO7L#=:M+VH=>U0C>L(%T)RQ.A?%YP/(+-[CUJ$>AKJAXUGYNKM=IQD5["KVU M'$&+1`&')0Y2%!LLRKW9WV.]G M2)3VMKWD*K"Q&*Q>VT7YDH9;,U!FH5GOFTON0H,/*T[V$NL0`B-%)"A;_/R=4WKG> MC1N.@G%HKQ.4DOAK7!KIU'I=;8W>K;RBL`!% MV.4@2LK)__Y"E9+0?99=ETKK==:&Y_Y"':*5!3IFT.]WC]C(',8]7PR;/_WU M\_SC/RWNX\ M9\MYD,7I>51]:7XGKKS8+IYTD5L/G34$JUX/ZVNP1S.$05-;FU\JK("J[� M;!4`QF)JN.&CX`,F+\E.&@?<^^3PNXGGA@^3=S!=PA,[_!+`KP_3"BVJS9>K M(04E*])@Q0!Q_H(/6/X7SQ3Q,;EW%$<(@N?$[4N&%A5OYLN-RENYJ+D>SBBF MMG/4N0@H[*1O;3U82^K>IN[?OO[J/G+/$7OVHG3+G;3?[K76"'E=U;^CHSD: MSC3S>W'2/*'-L95.F+.A$]Y&1;D_C>=7$^"*N9/WA*VB[92W9Z M:ZN_-55^O6(N@#%K:06D>$(:175.>%/G>,L)@HWBX9;30YIZ15M.#V:4CK6< MA[J/&VDY01!7*]!R),S.F=*J[EQ4I*V^UHUOW"RN\VY[5^0HGB=[8GK?#TY: MS6%[U_CXV:O^`SSJ07_@.UI]IS_<-W[13(VR?M5^!S!V3^Q_6\G?:NDRCJ@'W];\&]!:3ZZKSP>AF0T^B* M@T0IR077=!WDA/WO0;1/SK>>JU$GZWGKM2AUNFY7Z<6I\U+[ONLG1&[JL1QX MPERF"F43=:G%&NQ@U\T$-=1R^WA\4$G@J$':]3[.L:VUE5Q_JH':]_24[5Y+ M25BI@>;W=)O=YGHE3=)\Y>O<2B87U$#GY4TY^[W3ZH,ZK7*WF[U==TR2\LMP MM_WUHN.D_T-FE^VV4 M`YE.5LM'7-<^7/;1:@MJO\5O]8^Y55[@N)QLI2FF]D/'O795_J"9?WFU=LH_ MR/R'-'^@*<\)*KH&*]H[H_HP?XI87;1>$U"'IN6?:=9-]RIC^DDK7B%(/["> M?_5T[GNF\3!__&U=DHK:4/!\8ZU`N*6D-N`AF;SIMML9\Z\\[R]7,&+G$'\B=WE?+)\1R7]M/YU+P`K:R]O[2I<^O^&ZO(&KF%7ZMUVZ=])-Y_?\-X<<` M!NMC@GB(T--G[AG@7_0'8"G@;F;<@Z=.@3"FG/%=;+RWDWKH7/S2;`QS&E_Y MSH%6K*H8[6^L'UAU*'0D<4=SK=]M',0KF3BCO= M5H%LB>+:N(/VO[9=XUL1E/SE/^W@'Z;U^)\/P3\8?@[PV:Q/+?OY%?NO-X#) M(\_ZK\O_\G7'O_*Y9XW_:_X`P[5M?>:#$/&G?UPP@]NV/],-Z.N?+YKR^TPW MS?B[O/?G"^T"M?37OP@U>?A9?#)SJ"5Z7/RW;J.34,&ZLN++I7*BJ^,?8R4T M+6>3%I\L,YB\8NU&'Z^+;Q;O2MZ9IM(+]@A:?'!^OH#++^23?KYH=[N1`J0* M9@DK>>V:SVA_[;F-H`%>_1'Z@36&;K'`(+TKR^3N@Z?/)LOFT,36377OP7*$ M;/+_\<>5KG7!TKG'/O(GZ%'Q`B'F*X;-!ZDCH?&;D/0_]>GL'\[(GXF.^G$6 M=]F/@9GH2;7[#_A]HYN\/;,'GRS'=)]0+0P&&/-=VS(SNE)K#U3M2N1-W%MT MIOQ^$7?=*/Z`SXNEOI\&SEA;]%JMG)ZB^T] MV.HC%W*1&L%?SG3TO[A!GNCYT`H&U]HX[W])"'"B"+"_O2Q"1>P!@V?L0:P8 M;+>86L!+?C*ZW3P4YJ`;S*,L_OG#PMLPK=5I#,Z5@N8Q%&5]3W4XDK"/M$]B M)#;)#Y$?RNN';+E@2HZ('-&2H71[C0[Y'O(]"9,8-,FUD&O)-`]<`4-MA)RY M8^;/UY]PBJP[+$QX'DP2F47+Y>1ZR/4L&U+[4NL.TZ"&O,\9>Y_696K' M**LJ3[+7/'5K.=?K=>A;#O?]:^//T)(@AMEWG\;B!X^;;YW`"IX_AYXQT7W^ MV;,,GI()UX=_EM(C4YX[SP#\;U"'SYW/$]V;Z@8/`\O0/S[^]W_GKM717\U\ MW*45E>BA=:_UES,"-RGBS81/'[@3U].`/^5100_WV*R=Q%&)"I:NOK;!?(24 M4:(FVMFM$^C.@P6?4M*G#V\;K79G-1NTE&;MJJG5YWQT@\1;CJVLX>I&K;(: MMJNZ/O+@3B5S6C\69(^V+"OEC>Y/KAT3_X.;X,`UFTYDN;?W-7KKN?V'U#0`MMRNL-6:W4GVA%4NGT+3D=KM2KK M^Y0$=<5WC^3OMY2VJ:"2JG8,G(QBBFP]/Q^M;-@7OET)K5YGE2":M8W@<)F(W7/ZWS/H372WG5"I=E(H:4;#^Q)4&O;!:^6F/9DQ@ M?LN3>]>Q:@+N7__D+"R*FP\`L[>.'W@A%D0N4A9D;GPW(,ZCV`:_>-`7R_\V M=W+X&FZ^L[YS\TM4F3:G;5YUVVLJV:UA:FHGON@6@^7<#U`];^`=GF[DGCW5 M1T/+(^(@]M/KKC'$4])."?93E89PW\Q(1,X?^;7GX2/QLH7O*&>_.GR.UWI^ M=STLPHQW:YG+5G(_^_*:4');>KPHI8E%UL6ZU-*F=$<\)-_6\XU[RS8N5277 MRI;?=&=-N8^+8NR+.]4=?&/B91_=@+/.*Y;H`M?QU]:S\KR[5?3=3&I\_J*H M`[)TL$\/#4OLGMV[(G,9\7?,3@BXP\1^-%P.=671@7A0,'TQ*GP&?S61M;DS MICLF7#F=CB^[1!5^XP$,7_$GG]LV?GXA;\2/,\^=NF@VNIU\.EX]FSS[%@CF MP",#F+S"Y2_QB4XXABMA\NH\7,HW6@`-UBC$QS38W80+OI0TR4A!'A>+8+B_ M#B#,=;BXW7.?=3MX9JZ'THRM@/D3':Z:Z<]"8Y<"-N!M6/XCG+D."R:@'_4?BAE)%C\YF%@>Z$OW@N<&^X(O#T&''K>A#\7K MH5UF:,`-OFN;;/3,0I_-X)&A#DV2#_%7S`0U$/6OB5(Z(&ST&(9EBT`M3Q/0 M(W.Q#A$\./2@==@X3PK`7O#&0^,R4N^\4],T_'+M;4O=)VZ4KXF>W6"?9AS_ M"!84J+!?7Z`Z3FB;\P\;?2BF3^^%2ZQ\!W^#,$=[#WN`ASTS`KX]%+H M`1JI.\^+;ICJ,`C@%:ZWVED>-S@\R&1CL',&.EII&?:9PST8:&]U&#_+?[1\ M=*E_AESH7T?+D@:/SYFZ(+QO/3C6V#*PB6LM@V%AA&!DT.%@7T]B9("2;/B, M>I/U5_QP"F,4AKXO+`G08)[%!*W$%P5N`&,S[E1HD`OO_'?<)!UL%4B`X^O" M'8)5+,;V2B?*T?W\:E.^0^1P8[3.XW/SU)&12+Z<\1*EL'1Z49+3/H5;HBR6 MGC98%'%I;BGBLI*UTTPFZDE!EWY:2LQ9R[C9A86T%I@E[RX77WX:U.NB5E[%9M=1*LKSIG?<294LYZ@?MO M;#XKVU;!KWY<76E9WT],7G:#Y>3W$"=F.#\46WF/G[SRX-4&92Q.;Y7WYO;C MU0>Q\7=UT7I5[NYE1VNG%28\NMUE3@;VY?ED>8I87F\P3"D!H@R^$M@JPT#K MKA8B>RHBYYO-B2Y$_8X903@Q6]MU^F]N\RO;,^_'(;3!H)%RULK1C?FX MP>5S->=ZV[]\.FK=,3_9$S'^8F'LQ15G8-/UG!)-X.BOL[HQZ3.RFGKA\L M;&9>S[[^F=H MC4;LC3N%"Y]?_D-<^N1ZM@E`AYM1#0[JC!^X]*`/W#.^L?_Y5;]^*:73'SR> MV`N*&UF-:#,P?+:D;*VF-KB46YJ?)A;NW[;M>'NR`/I,%21;EA3$XT'H.7AA M*/?[QANCMSS.#0,?VYC:.&AXM*-4J/`E/&"*SQ0/6[0\TL++7!M=4_:S9LBV MOE^UFF&YB=)$*)GF/*K<(KO/EEC:!IN#1E%KJ;7[M?:`.>`GUGT'B15OB0VK MII.J]NRUM.6+MF[::U6Y:4^%R,SZ1E?5`^,GU@%B:RVC';4X8TH_Q2=C;':Z M)[ZAEC!;1NH:W7R'?Q59,LX^1*[&4'+>^V;+L(_3-`K:'=OM-'IE8TB_??(0 MK."0(K]\;*.8'^G:*K`CJ=WLTT;8[?!WGO:K@INDS:X%F/>^I/K$;.>'NFY/ M:'?2#J-7B,(3,@&![S?6";Q:+'I?@JQR`9ER;++,%A))H$V2M:,,!PG656%N MJOOPU.V2_;0M6R<;CJ-NC[N]EU)#0BVJ<)"`6ZWX1'7C@DC'*9`.VK6V/\7( MD[Q_MM$+36MG;?`N?8/.:>\>*\DDS]4.F]O#40K3ESS[_\Z.P>QOY161&/DQ M;3?4UL&P[(.//S]19O/45K>QZPZEU)U")>S8*OG(2Y#"VE,/F3N$-NW06>_! M0F*4MD5DW\US5ZV&)OI#]HF*&[4^)P[RTQ-G5B[V.Y5=%@C7K!E*Y24Y\/7 M2R;V+_G16_`*N$/L9)I?(WX5NY?DYB5#2(QG)HKM:7^XEA/8S[*Q\1XNO`7? M:SF/W`^$"B))7.?!10$-Z$?+`"4E3IAD,QO>BTT-D,KN(!]Z9@GR83X>#&^8Z)%3@H>>]F393P MA?LSU_&MD65')\?ZO@O($,0;^N:#8&%X\?CP@]`4MX`)ZC,\!A0,71R7&3QQ M+L<2'M")UX21O2=V5JX>CIMU]*<\;A6'G!_.9C",\;S86*H`&P9*!ZN&#_X_ MQ'59@T?N",4K8"Q(9AH?>XHC"Z33X3M\ MPP0,?%QTHNRF,U!]%AV!:X#BD6`*9<,7$Z]#N@L_B+&.)XC*`]BS[HX`UN[(Y.OXY.D1XG M^5;@>A'O0:;S9($HLQ#03(!)`HXE>=5\2A07AH`K)8U9 M*PD1U:-8\^@2=:[6GK0TIPK]^62K$;T:6)8+TRI_ZBYJ@A0"*"*PU;PL=(U7X@]KW+(N5'('8A;= M<5B"IA@\E%O>*!,R$JD1NQ4;4JPJ5`4J^L@-`(=I.-5']3"="G001;JR0GD` MX2;W#9@DXH@:/U;CT>OL]!V`F^-T/.X"*R!NCX+ M/GI[>YN8FW-?1`*%*_@SU*=659PG" M+9!+0KV"(>>[=DC\@`G]!>%&D))GH@7S;B M2+-Q,B_5OVBCGD>*?JN1(0>^[L%V1]!_T5L7+1QMFS:A\N748V7"DG+G\ETB M=($N<@*-BB8*XL6&&]IF@BW,].?8H?V0U;I6M[FR(AOO;)+%NO09O.%1S,L6 ME.(V(_(Q;X/T;A$_$:7%^/P/*-S>?0]"C:VHQU=''"@M?AW*#GQH^^NZS8VO MBP@*XV-X82`4$)58>^++O2<'8Q1O=LRYH.B[[6?ANW7FZ%/`,N[:G_4'WNLD M6+^^;4T\I3Q7UN<\RWM'6<];< MJ/SZ*7C%P*I9/5:. MT6`OY%]?BLF,6.F"&1!,(;WD#`0=R6+1;>['Q#)AT@-?)N=S(B`8028@Z.MG M'@3Z?\Z+C[[@\>``K_*'A*.7B8D.1@?%M'9QG1_B5-*'1YDP9>,4V\C#4Y MU4WTK"Y80@#FB14MQQ[V:NQK93G*W3QN(WZ+B!LL5F"G^C=H2BAB!M$D\`K] M#*HW>J\?O1AOAO\#^@@OYD`D@5JZV]V?MM';6G.:LUC\6.J=B(3@TE5@V7$K M,/`A]?4`37E`XUJ1=I.:M$9K14NCB)?,;-%0Z"@@S3''%LY7-PP/`Q;!]A8/ M,TC=O`\LWP]Q,@"&#.0=/CG`HF,6%"EX-_EEV^4J7U0+5:SF9'2L4*&\)Z)0 MH.M8!%^$?`(8.WC/8N40A14TY8$[6&XV-N#_@AM&MO4@[3L>S9GOCA?^EW0@ MI%@`AB5#_BG6@$P(8(EH?D"N#)>):JER_' M1\!+,;MLOAH)`.B:J/LQ8M4SUSU_WFO2#'#X0!O@XNSNR>:]\%\P+!CBD=8- MN`"T@N-!4.)W-]<+6BR6#UV8DUU-X;()S#`6(,,>N>='T\*%>L3$)&M*N+): M"PVK:,JNL%>K?NE-X<:_600I%D%(<.LXPP&O?=H&3BM_;12-/ER/L6*I5I, M6C$]XGEEH2L1($F,A'DCQ#J[Q(6KT?-5A!`CW8=Q`JU(#/L1AUYT1.3"Q;"T M;0G$TYT8IUQH_$2WQ_@JK)8585@<#$`PD30!'O6,%]_`E%2HJ0U*@CO:-.;. M;,Q]CMW=8@4#?55,QCRQ=NP:N&"PG5CT,JA4M$01#9XX+AAX7*Q#B%4`')6> MCFM9"PZ:,TC5WOS64>B#UGU_K?CY$GT:\:0\(L1FP9B.P$!XNOA!4>5WJ1;\ MZQ/<(7-FA(^4J8TP>1CKP![!48:((E^R>,8B\#4OD:Z+12IW*M:?HJZ0824_ M6A47(L37Q!V4U'.\SK)XXM:EKGFB8_I3,_68T0+`5@-(O+\@/YD:12`7PD13 MFY:F_0/H]N5\W0G_+N9FJ`>>7]^5SVY`3CFA93SY;$$CT1JZ-0SGNTHBRCSC>!QUB?<>0 M,*Y+1J,-)HA`(Z-QZ,/<"1[%+^=L6DQG4*@1YNLENGESO\"L"2/VS)]P'M3& MLZ3MBTC=D"`P-2L$53\GI?Y"UF=@05XR8A,!B1P""72;AZ;CF1&76>4`25-7 MK#7)L,P2@8ROU?TM:Q`RM&WA,1`!D4R`>#`P;4`:[QFC3$A"A12Q3\8E!43<))$%T(!YW](DL1#O MNP0TL1$,EQ4GXC`2FI\LG\NEMY2LN)@_KR]+"6_#`S9FOD-8%O&[@EA*21=+:9O3P9A6/3#C5"W:PR'9;2^?C<.\2HYL+[$W?-8Q<)!:/W6:TM)M* M>6-A9=L3>YOPP;+5$9B7:Z'SK@"C3':3)`,8%EWDG6$$\[N%VT'LY[T6R(6^ M8Q^7N1EKL20^7RA:6B>2?X_&32*1KW@"G[^:P9=C/3W76OFV9>O,.P^SEEW. M461S$SK*861K;&%;+Q3>R$P'E"E:I9I:2ZVEUBK86OFQXKI@45665JO9*%*0 MNC54[T!F.MEL^8(*ZZ;1R69TLED>M1]@=-+)9H3G=2JD7">8H5//#E1.MF9& MH?JA"0>IA%R.4S@#HR6O6`.OJ.:98T>$N=1ZCAL_L7S'E"GK/VDDJEB[ETY/ MH]/3=J[[O*'G-BXJQ>\H7(2\[),\.H.5_4)*V?MQIR-4V7S9PN>?.NNESNMA M[8T!V7JN"1X=&ZT*"-#DKGZ@26?MJ1TB/C%S2YTK=]=CB(?RLOOQ@:VG_YUJ MC/H,K#)AGS5ED#TMY9P?9>!;*0YYD$6"TR&:M0`68J/U`V(ZA'%_[JG\(8RJ ML[H?AL.4X(NZ7$[-(PZ5[^4$P=.:VM%[7)4C$<^"I2@U9$HX3/'X8WS?V5;V M>-LXQ"LKB1D_)]I]6VR_;>$-6'NT,W,C[Z;BG-E?]CA71).#2N$B0[=.=,2< M*`YME:85$>97Y+F,\M494/+26BEW]&>I>@$>-B7I7&N[TM%T= M#Q>+]O!FU\#K=3,K4=Y&]17EIDO+%\\4%8OP9M'!/7'-1GP,5O\;X_Y.4;\O41\G4=5`-Q]168HIR/= M3E9P/5`GS%N^334%3K#-][7,L@NU..=+[,<7&_ZSB__*LQ)>5LE-+E7L3U7H!`Z/"IUB04Q[Y*:KARFJ;>>H6Q^?.1#)C381$T^7!L)8O MRWLZRU4?%E5V$#RCHWSBTP$2U7#,N)2]2*H2A6MD9=7%#5^6CY"!2^8UTQ8% M$7Q9`<"2U9:+GJNS5HEA^TDZUHX;\>-3."*]Q2?I)/0J*P\M9"G8&%'R5FY* M`E_8O%PZ5W-14'E1O%:>*KLPG.BL`H_KAC@B3G91VF$7D0TE*AJPA1G/.Q-H MOV5$U29$D8O0";!G-UKY+5[H.!+$%E1AJ1C%$U^WR61%AVROWUDM)A+7O9T7 M59K7SUWNF]5:($OE11)ME]8A*GW$K0TFGB@]*@MR^BO5W^9EB*5R8]7'9U_A M21+)TB&B^ALPC`=1>@G:Q@-_M8ZA/L4S2_\=U\\N-B*P*)X\9@/_AD)=">.? M\F""E8%\WOYCE?,\]GM8[AJVX^4_SDA?$8 M3X]<)BM'/8%A9RI79:>55#WO),B/GI/[W.@6C&B+?=6=;\]N?-C[)7MO32WT M@2]NKKZ^3#B'=-X3&>C\#">X29Z]OG!0&U,V.9D07[GJ>7@6 MW;@X4Q()GS6VC(A;^WSYB9^%TJ,>7#N<0#QJY8#&PMSM&D\W$-*@K<3L4#PZ M*N*:K"^9+"NY_.[U:F([N8!"(.)ZMOF$A"X:W5&W"7*='8`!.C#()F.9]W5[ M*]D_\]LBXXZB,CX3QZ&P^3;]145T61-^0?.CLZD.6;^UC%F\FHZT,FYS8^DC M'L`%2ZF3!R(XNYVO>58%+&_1ZSDP^)X3YS$Y2[,TL;U0@!1@FQX?K+,HVKH> M/5DY]!RDPJD8S&_&,/EVA;.+S0*NFJ'ZA`>(3OA%:$R\_[]@.O($=WGPUOE] M.M;D!L<`&M4?;&L61#5V.1`<^#ZVW7_#+R]>WX(Z^OWVRP;[&HYDC>SH`!/9 MW.3].)67QZ1$5;AM/72,R2+&(#C+"W`#)L<#\=@=?/H#IY?_N3C<"3B+H!$K MU_U[<1DR?+A*DIV5R_Y8NVR19#R?G#;8VZ56YC^M$ST6S)239RDOQ:'P4>B% M'1A1EN.'&(Q_L(5!+$^<:%.!_1D8PE]<=:BO%B'":4+7G,$(F,_RPGEB#_H M&P\1M;(.P]#DR>?IB@TXU"NY=">/%0*G9T5B#J@T6ES#(.@8(V[V@,\X\+,%N/W\1-H7_?\,,($0/?!Y_T!-G:PN&/"_>+^FAYP=K M*S9B;<2'X2Z*/,^/"]6_XSK0S/53&.>DAB7 M0+++^$10[$V)1I>E\<[-0D?P.X$9H?^^H-&/Y,X^J%A<-^_DL=X>/PAM'4\ M@WYQ(!9.N6Q[@42R.+D^LP+=7AS:L1*:FY_C->((3DN1N16:_KL\9`+G)N$, M_QYA=VN0JCPQ@)N9YW@ERN[B";W;6R>&W9++6SK/E]N6;)>LX2O.P9!BZO"O M0%I'INY[V0>.Y=,]+C,@[*+W3G,3XH25KQ-Q!G"2;]A185>`?&&OA"A)Q:%^I<:RIS:MK#5I,06>!5<1-=FNL?DL=;[P M`.-S$85PG0<7#7*]2'&T4K1ZFPB+RWOG,83TJOHHWU*5;+$FCI[=L+I"<6/K*>F-G6HA-] MX%LZ8(?4ZW-BQ0$M!>PGL"4V+.QPQCT\$E0D3LPC#_-%MTB^J0N&'MJRT'%T M^H0U"@,>6_R2"LH+"6R&YB_S@LOVXAPA:[4_1#1N?K:,;STX&(B)UCEQ>6U' M1%#\$4U6!KXZMJZP_^-)\N7 MN*!S>+VLGCC?30QVO2KE_1ZM,NC)(VD$H\9?QF/+MJ)"4]> M/APW?F[BUOCLBN@D,%S`P-;+4(F3"`'(>5YRYBU"\OP[S!:!E<4KWI8G7B$< M)K8L><+:,K^1KBY!!@7A%'PZWZI_/Y-]BM41R[S"16\;#ZA[L()$&%XP$=U+ M'+`6'8,K0@Q2R'%H;U0X\JC%$^79@+APY2XI=\X7Q21&4*:EMHD1$.4+ZF.< M0,N(DCQ'+Z)6.\^4U8PD?Q7G-SQC$Y="OE=?(D+Q9I%.@QT9K=)\%2PU/M?R MKW]AN[=QJ'9:K3BC<'Z^^.)<;F-9+[/4U:MDY*X8B5T[`'&)T&$LQS>`?N*4 M>.3";0@9V6.SM;I9=FX)N9:#.MU&9\O]<8K-<@!JK]6A[$-4-IA9=++&?/-$ MEE%E+ZUD4:U2>.K1@U['W?41Z7#IN)J??@S]JP==G[UZDTR.N%[D1MQ8/DS_ M_=#C=_Q[\-IVC6^_`.2PGQ8WPE@,Q)"[=LPWL1\QP!FDW"L<#7SYPL<_7]R$ M_)"@J6]7?.]<-\.1.?'(%6OR(V1E:ZQ5;:E`J MTR\`?GVY6W=O&K\+U'<.FA6V>ZJ.'J5F`/0^ZI[EACZS`?^!AQG1(848?\$T M/4/FP5&`U)-91HJ7@U,)YPFXA[@ M:\308'%^I.".\/BY#+8K#PX&8BE.)1[/S^O5#<,+N3F//*T*]0\V<9^`LGDB M5`>MM#AFB0#9NQ1/FXGC(^.<$)$XC6,I4LC:J5$HWK5M39/+;>R?>F!,KG[7 MOX/-LFNX<*8'(LH&Q-CFT!;_,DXV=NUP?B2R+8*UD[GZYN=WRNE$@G:;(#\T MB8_'*(:;.[(ZP!@Z0]RKB`R%R(PL^P&DM.&@\Q*\'G_4X5)/)*``M.%&=\,2BWJWCM%@+_""E_]@ MUY\_8QP%NL3@`,J`_7#%^_=OV`OXRTN90?!:]SSV7I+!**=0/@/_\))Q#/#[ MX0A8'P+F]<>;:VPE_S8/6#Q*;(TV3HB].I;!$,[E<9[C6'6S^7G78A_&S/*6 M5J(\;H/4T/A$ETB'"UBM1\&3&;14#_`%<3XD0']\1/2+.&=FT:&&W,$\/[Y2N1L M9LMP6(@S2?G:Y?M;K9?QADK^$"?YSILG5J!PX[C8(X&+LBY<(GSR7+Y+\'VX MDF+K3WYH![%]+9]$+NG$;,9U6QY= MCM-VP_*C_:_LDQ&X>#ZXW$GTQ".%ZK%*\VCT*XSK"?#0)=7>.F"/CIZFV<^V M!:/TG]ZC'OC?=';3^`3_;%-XQ%`*&%M&=R3*4GQTY='DR MXQ:9;C)J<`V#U19?$^KR+4!@W5O88=SJ:[$;FOT3U!],#+0T`2'R04`UOXOO MJU&(O#7P4V,".0&_HJG+@F2O8/R"#R]3Z:4!CZ,;G<04'AK$B!.Q[YD'%F39 MTB!QK_;<)S78/V.:;Q6=PBP]*`J&&='1Q;9G,0\LLDRY<[(U:G M`F(-/=*B+N=2X@SEA8_`81SUA8Q.RU?)S2*>/HM&D(\:QEFC84<;X"(QH^7U MQ+G&D;N2CB\M6)V^_E:%26Y:JRQO%;`F#/C_>P8K_9Z;@+X]^&+R M,7=,7?KB@L>(MU86H2*USQ-C;$L?638.O53>8F!09VW5:_MK!ZNGE]O@@P)K M/(ZB00OGA'P+&XF!)1Z(N(GE_!&*/5=S0HB>%/X0"7^YR!,4&Z\$(USPMH@1 MQ2TT]!#)I>LE4E3$(N8\&1O^-`%;8"/;=I$E"DDZHA@BNPCEM68ZNA?Q$::YUD4T0$XQZ:$OFRF;F+FDUAK MBU.)9?C(9,`$':'W$?H@L7-91EW\A"(:[,,BU!0+*5)[(K7&7@$@'?,CL6I( MM,U-+M^:,,IDP&A2^^`,7QG+)Y/*1%\@UQP^8Q'4U MIW8+Q&`O/MR\?RGG>%S0TQ$'57+1>_]TG<@!_K=N?`,?A'2(+[))WW%33-`R M*.5;':Y>8908(/D_U_O&7KR]^?A_+\7K@<(UF-8=]E[*G88HN<=GHA:"2+W$ M"%4H4[D?K0?7PSBJ&-M+UBT&.98E$-'#Q4#!K'#1PXT=-X:#\?HJT.T(2KB`,O!1_9&68ZB$L,08"V+:PD$LV^9`*P MJ`,0`^M8E.9P#(_K&)F1F?_@-8`,FVR$.[281DPC!W063?N_Z,#=XX)CC\C44@1E/HIY03F+BY"_\2NJ<:!7EI)W- MYYSPA.D<[/(M:F_+&RD!QJI9=\NJI5M>O+Z2A,,3!,$;8)*39QL8E3T"7N6Y M=OU\0C61]D+:WEJ^=6/MO3T13DP_UF)8H;]XU,[.9\V?S4'[,N&')-M/\3S` M-D<\3C4T)I9M>ERL8XZJ#;M-20*U8:_I%_8@@U32'J.[<%C).8-(Z8]*E)D6:`!W$HKE M<>E"8`[EN7'P;!HM;$2;3C'1*4I.1%>,R^\X"P/'[$DN@K$DL975X"*N><,- M/I6!W^;P,A'OQ22NN4]+B_K"S[_K_@0T)@+P-XTWC;FIO+?LJ$BBW'FQ'(M^ M@>JP4!4?+&,"CA!F`<;$O63@J'&SQV.#O;6MQ$/FM4?D!4*;XOZ729:".["\ M(&5V'3G1)=N!67@8R"PWT5NBF!B/ZD()TY%=8B9TOZIR-"[Q;/R+H!L;.^`? MT6X(S-I%[9J6CUE[4L.+<'*#O8F*D<2%1.)(I[A3_(AE)H.X^`-TQI4HP`L_ M3,7J3U2G+7YFE.LFM[&9ELED9D84W%O8K[Y8$MANU.]`=2LC6?=YDI;&P7"A MR"AQ`"F+C_NB0SO*UY"!=VLIPMZNF`GECD2JYIC*7`6/ALG[^3"Y=:*`=DV\ M=)F35RXB57$X!=AZ*&`.6`K2Q^I4?J4*N,66M!&%E MOJ@?QB%J"-.F\?DBM(IZ6FC8T#V8/WMK75YPSI:9S%HD)W4]G]5UO@;PAQL+ MU[X?>9<)&0L"7SMWW\:WX.< M&3IM)46\ZE[\T@:7"B0?_IIR9-P\ M+M=E;+>:W=UE].'G7UW7]+^Z]CX`MRZ7-FBNF]32ZW:7I:B.M&%_6$26&SX& M\F:^Y@Y\"#[;NG,-LSH=>=6OP#3>8UI!?EW=1X^]7W]LPC'Y*7^]_F[Y\[L_ MX1SS,XCM\0#FR^CGEIZT=/L',=W=JIFK5FO5P'.TO0;*^HS&[SI[:*8S7!U6 M!]?,LIDK;4;M_DDJ:W\SZC=7D:<,S+8,CK+T!SF\% M)P)06G.5&NRFCGJJ=&_[RP/O*FBO/E`WJ(D]JHF'.<"P!.6]C3;AF>]$@"&: M1GEOXNPL#-+>.F]D_.8=-%^W_X_KWJ9)C!(*[%W\TFDVMZIPQ^9OU:J(8''S M"X>G.I]$(ZYE/;B3\#7M5@[59NJ@3MK;>QAK?:VGGJYJXT3:VG8GHJ/A,/?^O`(`QQ`'ZQ_&]+ MM[]S/6X]P"Q=ELH5<4C="%8>]4ZW/)'K\?IY_O&?%O>PE.7S>TPV7GKH&]WS MGBWGX0O'JO8<=1,ZP?S.Q1C)/>K7ETI2=7KNBH^CRY_&\ZM)ZY5K?7[-K3,+ M`U].\Q2ZKDKOU18(C#P[CZ\-+I MIZ12D>ZK1Q=2_&'`I10]+UJ+^U7_R4VL+GB-NY*MH()S5`*Q37=U4_L=_IJ] MLWUK@9;T+>QL)$HU7(DCE&8^/"[^A"I/\\.*\$?QOE>L ME;P@<&?RKW-QM&'K8M_Z`-D'/#0;S91#8G8H$?IC8"8T5:9^M'ZC@R*FJ`@+ M3S\X/U_(V^8J:[7/6V,=K3'H9J@L4E&W=]XJ:C<;KLJBGE6=Z7.*`;NZZZW7&&8!6:;F>A<8 MX_9G.ORQ'$?0+4F-#)<,KH32DV-:C[$\T0ZE2!P\43:<@A(DD!=)J0+Y@3<+`'SPT=\Q7[FV%P/A[OYP[@IPI]@28XC1A2EF/" MZ'G%KK3UV7MQC><B0:21A9HX7,:B/7K1I%KM^.Q]P(V-ASIS)T;;*Q]9V; M5YX><&;R45#W4#9%K57,JU-#<558,\.;XKSJ'XYBUL>;L%2QDBX4L5A(%U\K MP\,7O6YCN+YN3@O:ZH(138@(Q$M&@41G%/ZT#ODG1)B..,]3W69>=-N--F5< MD8,B!T4.2MF"WR?%_VD3:$T,DA"0$%"9RN)UXJF$<)153VL3[I19T6F>3*Q+ MX*F6>)XGY=G3BD4]5_]/4)OG,NNH`.EPT4$AC#D'#D#I6C54)@'VB21MJ1[, MQUC^^7%+PGW"?2652;A/1%V1Y0%"54+5$U$FH2JQ:56U>1:H6>8ZQ"Y+#@"LSIEDM95981GA&>$9XJJC.@9P1G!F9IZ(S@C>D9XIE"@E3;W5+RYQWKD M;.9Z@>4ZS!TSV_5][C/XDK'?AWE2_9A!9C9:K3.#\G.(1&(TB=KJ$QR"Y0^ M>1"J3+!/L$^PKXHR"?9I-D![D1:H6>:RR2XK)+07 MB?8BT7Z12K5%>Y'(MI3`>MJ+M/K,CSQ@+QYTR_%?)A;!QZX'0CK,"#V/.\8S MX]^-B>X\)!?$'3=@)O?A,K$"KOMB-Q,HG,'#`B^<0L-KO_Y-2]TGE6Q6;\6= M2\BJ`IA[T6XU!B<-1J.7TDA*MX>5A^U$L1O_ST8^A? M/>CZ[-4-//I1Q_U=MXLP]+5C_E,&IZ]QZY<56-R_L7S#=OW0XW?@P%[;KO'M ME[_^A;&?-C[I5]URWKN^_X4;[H,#^C%OG5O'<*<<(^D8'8>'?>'CGR]N0D_' M[67W&OS3:FK:_9U[W[YORR\7+'0L>>%O\$%K73"3&Q:H#KKCJGOQ2[LI_[>E M91OEJ;0]K61[6EO;<]5N#8[5H$^X.^]-?.)\*^!GN1.PY"[4=N_"`A+G MT$GT]/G^Q7>>.[U>[%[\].;VU@G<]#>4J9!6*X\^]I'VF,HH."".IXSWECZR M;`&";\0"W[+57_OWG\;WT)RH6^^C)]R_UFW=,?C7">?!>]<0C;_^;OGS"X35 M)I[^@4]'W)O_.:V!7RS_V](SWLFEQ[?1@N.;:+UQY5'O=,O[EVZ'_/7S_.,_ M+>[IGC%Y?L\?N;WTT#>ZYST#^G_AN.>7F]=3-W2"^9T+5R!?L[WONL/,SEO7 M+O5#?/E;/P`M!OS3>'XU=<*A.V%^S:TS"P%A\(*6>CJ?(^D)J+QL_.FVJ1>. MC#[4!8?&GKTT[AN>-4,]?1HO;L,V?]`=_8&C!CZ[MF4\%Z%XO^`4%&:@\VDT M#_0;/=#W74[:O*HLY^[S%:6M4_EXYMYI=.6,/27-+YJU+PN^Q]I7LM'XS$^A M![T9ZYWI\UDXTSW.+.AO2V21/5G!!`0$\V4/H65R%-+'`BVF:P@SA6L,UP,4 MQ>HL'O3?U73>@6R&/2@>ZIAPATA1,SR.EV*(!'M2M\5=;,0-/?3A+9CZ)JY? M9+\E!%VDN[GCL0_3P^@JO$'>ZDIIH;4\\"]!JW-+O!17P>V.C^UUX>(1Q_PX M4?7;;+!K/_U52RJY9$]\D6JV_8PY>-P2E6AT-H:1AF&@ MD,OW,1=_-99+CS?8POR9QQ\M_N2+5X"./6X+VQ>MX/'4`KI#](>[U*%"#3K[ M,]3!NWD@R4CW+;^1GF6Q;V;%JFUMR.J0T:0-WA*X,I/@1AVZT/!FPM;CY9J.&=,],VIH+YF"&!D\,4>SML1T:00B6"7:PGGB.#M]G+V9@)H8U$^Y.W!YZ MKASKKSWPF``",]Q@%_E>^/F_]9GNX.!^YLY+@3'+\B6=&!`"$P6>VSS:N6A< M/'SGUBW&+5JW]8W'#YLSCX@UXNC)`#M?2+*B&'Q;LGU"'`'2Z*,7]\*%EH]/ M$V7H_'#D6S#HO6=$#9-'R*8[;*8_XV+)'(HX-%1\-[GC3BTYPJVU;'\+I;M; M`<1]1CS^*E`2K=*:6_#?!BVM)4U8_,@<'EQB*P%%P1OL9%O8TOF?_2=]YJ?Z M1V%NEC=%W)Y:@0"UM!YY`&3U1%],]$>4)P@]25L1)\$V.<>5-T`>-H6;)O"0 M=?!(#,FTY:K<,Y.5*HM82^DO?X1^`(0D-TQGHC8(]?-%^R)S[AC+LR+.;A/$3*^UE0T? M-[D2)Y6^,(21,`0C80@QCJ"=PU0$QC(@*[0+'HF#'SC&&)O@@!?2<="#:_E\ M[;^\9#Z.F8EK`V1'D!'__>N_Q`423($+60;BIQ!`A"[@DB]??_-?"NA*P!\0 MPT#_GBVI`4,59?HA34=1$NEP&5;FE@4JLN,Y6O;]_:WW1VP4,!%DB:9Q*!.. M?_%PC'U?)DB^_;Q.R_:G2548G!Q+K>UC2=A9:N)^1H8"#=7<0Q7&EJ`0#S"O M"22K@;FC97!/^NQ$$`>_"B8DV0N:IAB3\[`#^FPP63&>!%%A3H@!1/S[Y^OX M8AVY)'INR_=##*-8,&]SGB]A4'N6X$`P`H7SCB,XQL3BCU(&G'MP+]"3,Q2` M#/EL%H#..8:$'D6D)7ARKY[ALFCBTD@*X>%S#0SV1\QRF3I)-`AGD0CHT%$B MB2D`6(!.T9],#/[@Y!45*'0T#K%UCUBJ6)=3<&@/7H(?IUQ':B"C8I%8UT*# M'S`RR]HPF'%L2^H"+Z.%IU%+X M2R8:=5J-WF8TNF1/$PN$?(*O;,3QL3!Y%]$#U#A*_"2,FYM70,L\),<+X3W^ M9PCT&-0%!OB(*EQ,*/79S'._BT4`^WEY6*>)JO67!(TYWH:$?B4"OG4%"72P MI:!$$B%6!@<,UXG'^?*`7<:0=`!)Q0TW9B#18%T?B(FWX4#!^R)SQ'&E>[*5 M0!&NX*_0$IC!XD\"8>1#?3D5D@-:>ND%@$1O`1` M'&!J*06%P3:2X7!!NA!#_/%S'.>)8H]`T&1H'C1IS:*H6L1'!/5*8)ZAVX:X MPL]0A+BA:JB3=IH'ZP:=1KV^\RC M"$X!4@0/K9B"2,@0RT3^S)6`&$^Y+#_-C)?A#T;C\\PRHC@>8"1#C/27AN[" M!LL?PU+M><;P4&NT5VA`Q4,WQV`M3$S2HE#)SUG9U/M%F59#5H^6";[1_RRM M.$^^U?:L@$YK+2\@_3V["I,_I;.H#&^CN<5G[L5*M(QKQ[RQ[%"N=.^:>MM- MBM8"R1K#[D*X+>\M3\C-*;$I0FHE"5E.G/-XL4,1YQR^6B`!BUO(H(E,M+'$ M6&?Q0.S&F(BR7*#<9;@*V,!OCBT2+'"YY,GRQ7KL@@Z/73?`'S"U!'P..(PK M&9&0CBQ>0>*^3)01.1EF-$Q%1L:E9.GX0?K]R+6O^:G%;,@-`YB82`T.'? MN6=8_CS6ZHK5$O]EQKKPH8IX9'C,3"1:`2RALT_C.+WN"^8E.F]T?P(0A_]Y M"_0`&)I8;B]Q"\90ZZUXRR*25-2&@CLGNKUN>6V(*'9$:`IF@V\5==#L]%=E MW?;&_04LH,IV>W57UH[R?94L=D$&DW3Q8\R[K\5:RAT2^.3?D4>"R_L_'GQ) M,OGMF;!?C0DW0QO8:2XYKFT[2I?]-%Z\Z;,@WH++OGZ6*=KOP3.(Q%5`L?O/ MB\4B*?^O\T[1JKKG>M%/^%U6@&'J!3:_?)9^[_NAP-T3JK6J,<* M@>`OGUO_UZ;.4JFS-F(C]E=+D?Z:;]6Y%EL;/L@%*/.3`[<`$80Y#D9D2LHH M$U4=UB;T=_CKMEE]7"UC]OT_F#5%?>M.G@37C&I&(TQQ]*X,U[;UF0_OBC]A M]BNWL>2V`6W_^:(IOT?%-\3WJ,I&7^M<1,_!GQ/5/Q+5KE."*,N%0NI]0:)L M1^Y*W]WE>LJR7U=^3*V#TNLUMA6025;\;K7*JOC=[";C9L>L'[.K[KJ#0JKK M5WF$_+,=TG[`Q#+3$?->VS"PP MZ`X21RF44Z#]JMD8EE];;U-_5!"*1O_/!`%@'Q;99#[[#=>'-ZTTTLBJ;F2I MX5;W&6ZU\;TD(4E($M9*PGU`MGZ-J,#G)W:CJ>?A]_`Z)T$#2'J2GJ0GZ>OD M4.+"9TQ6/".G0N9)TI/T)/W92%^!4[F>;[3`IG?_PU%TO-GL?N165E3T?-6TK6L:_9!;*+T<6,7J2E%3;=X_C+N,V,RC8&4 ME'8ZJJC#RK2796%I!(`"$5/1KSC:]M(/)=H#:P=5GIM.3("D5TCZ"D#C*[S$ M&@.TPF-%O6F"UK0:52/R`^A6LAFM-5?C^*8`<24_2 M*P-I"?=(D)^ZT]F=NT924-K,E>C"%KK0+HTNT'K2&8(^24_2D_1UD[X"=X*9 M[N1G4Q0CLO^W^UCY\=A)Z77/-Z^>M+1[PP*:ZPQ;B8TQ)9U4?]#AH#-'GX)( MG]Z_O7]_^_%_^HEZ/GK61=W*1E,E3/@&=Z=ZXCBAJ"RAG\**E[[H50F352F) MH&+/*F.C^$-85=A)9>4E\RB>IW-$E66LR"N^ MV'Y$A66N(-5V<8B@;!^5$1G:A0R537VP/&1TN`!\X(F2E;6*+K<:K6Y=`LR5 M]>4/G4NM!9J@GJ.>.RL"6$V/-)N]1N=H/5)G?EE%?R38Q*(LO*9U&X.C=5'- M&>VA>BG17^IY)O(X%+0\C?6-NIKXTIJ&T,%B24-\)9V>E$[K2C55UFD]R:+* M&JTMMU.[B&5=`94"FG4):'Z=N%YPA>>P,DM4!A=U.VGB<4+83#HE5E8'G1(K M(U9&K(Q8&;&R9`SXM\;7!GO`0Z(=I&;R<.\'[A@6]QL-"A$KTV?I2RZ=GHH+ MS-1'RO1179GD.?51/9GIL98MU5K*K"T')H*KN,7GQ"1BU"KT8*+;WKC>S/7T M@#.3CP+FXPF%XLAJ(M/*=%>_?J.E.[0B"+7QX,38U4(3HB"$@0?RH2) M;:K060FV*:J=JDTR3Z$,565=V6H><5<#=5GMNHS(*I'5&ILO<57BJ@>R8**J M*O15@JJFYX+6B[#2_NCEY0HV:+9J1F"I"]>Z4&OTB=#6AQ#4F=!2HFI-=%9O MUDE9J+2)6FT;))6IHC)B(,1`B(&HI[-3AC)B("K,@C^ZCA%Z'NY[H=W)A!'G MH3*B.T1WB.ZHI[-3AC*B.RK0'=KV6^^%FF%_H.):&W4-=DV/=C"HVC7''#5U MIH[5=DQUGV@W<&TZG)B&BCV5%S.)UJO0<;3WN%;CK'79[K>/F'!%';+>(;T6 M9<#5*59&K%HI2*DY[:5P;ZV,F%BG"MV58)T?7"]XT!_XU4@WOG&3N*8RG=3I M4WU(A;JCV^P=L4X(\4SBF76&$V*9!,&',F'BF"IT5H)C7OL^#XA@JM9#;6`T M/>H.9;I#:S>&1##KXY^)8"H$)T0P"8(/9<)$,%7HK`3!K$$AQ7,=4IIVQ-Q* MZ@V5>H,H)E',/43SK3G#K*([&DV"=F4Z(Q>T$W55H:^2Z^^Z]XT'^LCF MC/\96L$S<5=ENJG5U"A`JDYW:,UAHTWL597N..[HJ#,SIFW]-=$90?!N8_[, M6*;6:O3PS^)D>LLQN0.B7\6_JL(TWTIZ.>7!Q#5%T0`7PZ;XUI''?L2K5PHI M^:'HV!?:2]&AT5<%">KI''F2`G.JB%8%H^NW&UTR)S*G4S"GNDX0I-L2$KYB M!F`_]T#D2&+YG2+@]>&LQ///C>CTFJKU(OQT1`P\\X?.9;>E M9.8%]=S6GNMTVW1(99WH`W%4XJC$4X>D""R51GJ1!C5 MLM5\JJR5[9(*555A)I/)J4)R.EG,)I\"B>EL8#KY5$C,Y\R@D$)BNTS"1_&' ML*II^0TW^'3$/=;6+EFKJ:5$5N;O_G$NSM%'R`F,"%*9*BJCR!!%AB@RI)[. M3AG*B`^IL"CQ1O_H!"&E>RJW MG)""@G506,UY%4$9!06/S4`J8(Q?)ZX77`7([A#= M44]GIPQE1'=4H#N)J.5OC:\-]N`^T3-5>BNQ!AZ MXWHSU],#SDP^"NA(&!6[J]=LYCDJGKKC4-U!A\+4*M9%K%@A.*DYS:5@;8U, MF-BF"IVU/&;$T_$I/U_\O^9%\CUX[=K)A&N=K#-'G\+-G]Z_O7]_^_%_>LMR M9S]YW5STK&=JF;K8]'O*&Y)?=A=/+=IW.L6>*[!U36W)G=(QY73,3XK(@QY0W71&?GQUXIUY@V M=]-0)Y41:R'6HH+"B+4H!&7$6LZ%M50P[TX_/4Z]^`GY>U(9422B2+51&%$D MA:",*!)1)-I$KBH'J&(YB0V;@\:`.D29#ADV-=HOKE1_''-\U)E.'FKUNYQ/ MM)F\-MU\@OQ!6>)]1$@E5J_"6*3]Y[6"SM9E?'%"&N*U'-;?C$5%7`J013_>!ZP8/^P*]&NO&-F\1/E>FD3J=-X6:% MNJ,_I/I(=7+LQ$T5@A-BI@I!\#DQTYQF3[Q4!8Q*\-)KW^JC5.>;V M6>J.U>[HMALM(J7U\>E$2A6"$R*E"D'P.9'2G&9/I%0%C$J0TM4RGD1,E>DE MK4F\5*'>T!I#HJ7U\>I$2Y>>.:!*\@KUQDDF:9T3W- M!_K(YHS_&5K!,]%=9;I)&S0I.4"A[FCV&UTBO,ITQU%'1YW)-!4VJ(G.B)@> M#B=2F&G\YKB-V%]S,0](5]F2`(?BKEJKT<,_B\ZR'),[(,%5_*LJ_/6M)*U3 M'DQ5%5P,X.)K1Q[[$2]?J5#EAZ+O7V@O19]'7Q7DO;G.OLEA'(I1LQ0H M546T*N"GUSQB2BG9EC*BG9QM9\\U>XV.>M2^KFR>%@244Q@M""BT(*"`RA)$4'[$I(1%9-:T'O'+3S^&_M6# MKL]>O=,M[U^Z'7*QB\S_P'4_]+CYR?F"J;L>J.>U[EO^'7B5U[9K?/OEKW]A M[*>UNU\_O]9MW3'XUPGGP:^>&\[@UOE=S(#FP9^?=^67RY^04$C.870,J]B5>EW^.LVS4N%^C.:@]H M6O?O.=EYY'`-U[;UF0_OBC^!Y1C`X10>1(XGE]R-J51NV]UDLR##;[N`"P08` M!O[2+J4CKIJ-(9KOWB:_9L/JE=ORG8>(TL-![#/ M<*N-ER`)24*2L"0(HT8-<-9IGHD8`_'=!),@:0GZ4EZDKY. M#N6-[GG/@.+L>NJ&X$N46U+:QZFHLB1PS`[^W]`-N,D^>Y;!?69ET8;S5M*U M$5B//-KMZ,-='JDI14VWF.5O&;HM2_-E'>A\WDIZ\9X_4G0._NPNJ00K0\44[$X@FZ4\*TA+ND2`_13^_.>[<-9*" MTF:N1!>VT(5V:72!%I3.$/1)>I*>I*^;]!4E+I*?35&,2.;<[F/5R#&L>_I@ M]:2EK34+Z:ZC=1*9SMVZL9,JB.<-;C+Q<%&2P;6VY3I^#A)*`V27/:BC^$-8 M57=^T#UC`L/BDN%NI_5^G+_XQU%FWU+:NBKP1EM\:8LO;?%53V>G#&5GYMF' M^+?E\IG#$G1<@6O_8OG?KJ:ZHS^(76A`V/S`"U4M_'("(X&=Q&[1NI-5)-VB=F\ M>]UG$VX^9&_:/WME)<@D<!HHOI9!DD"RBNN%U-%$VL9=2BWC2?HHEU4%C-*3%% M$RF:2/0QSXJB**#"/&YP2^R(IB0U=;I.:ZEX)"VQC%-D&:=FOD1@%`)@90G, MT:R>N)$*")6+&\4GN-J6/K)L*["((RG4A2^ZC2-68R&21"2ISO9++$DA"#XG MEI33[(DFG?F8.%T8(>IP5M2!5G%JHK/S<^^TBE/'$D(WW.#3$??B*D(I0:>4 M*D)E2T&1D!I!&U$.HAQ$.=33&5$.HASJ128W%#(BIU\?<"&G3TZ?G+YZ.B.G M?]9.?]`0?UTN:1C]J!X72"1%9)0WRMYO,_+8C_@,X@^UQ"GB#\0?B#^HIS/B M#V?-'Q0-&N2N74/[3M3-2=M6_:%'VU+JTUE'ZZDZLZ!#]=-1AU+-6=<9D_L M2`6,2F5"5#NPZ/9OJB)(IY.<@X,D4GQ6I)A6>&NBL_,CKK3"6W<.0"N\M8AB M:+U&BX)P]7$%=>8;IV:^1&44`F!EJV7O_Z%L9_6[KJQ?,-V M_=#C_OQ2L1P'7[[P\<\7-Z&G!Y;KW&OP3ZNIM>[OW/OV?5M^N?@%I8J$8HG/ M<>^O?,TY?EKK+*N5)%G+.K^SIL!1/O(G]L6=ZDZD\(]NP%GO%7MG.:`5Z!5V MNU@38NM+9>F"[V$*JV*!423L0;YE;@N[P\M0*D55O%^H/[$DQX*)'K`9])`3 MP)_L9^:'HS^X$;`0_N8RP^.F%3#/\H4Q^I8/5WL6/&!JQ'6X_@%^>(2OXJ4-]OO$A0MUFS,3GNA9HS!P/1^?9EMC?N4;%H?Q MX\.K7#/$C:2Z8;@AZ&/L>DQ'&?U`%Q*#[!Z.BE1)_@$RV[8.DF"K??;`'?P( M.E#K&"$)_O M@U@SN`6)/\P"F`W&A1MK#72:^7+;+=`W1_]"$Q8TSU[9`\?XE>X+W6M!*(8$^%9J'UT;&P+_/ M!$ZA?>@.:,#AZ6UAT,C%XRW?#[D'?0^/A)O%4^#]-PM?S MQZC1CNO,N#?&H83M`-4+D^#>3/?$W`B>Y&67)V%@8]!NT?/P;C1Q%'[]&6/= MLO&_4P!OE,""_AW9V.&B>QXL$"CZ?0+#>SY$X._.@]^H(`]`:Z/;KY*ZK&#M MM1QM:-*?T2B>Q;@3M5\^+)1[N[RRGP>O6D7!.67"N^X>YBKE@7ZC!_J^$%JN MOXA[L;.]$Y<%WP/ODXW&9WX"P##A;X]@I(\P_@SXCPPHX%"T'/@\![UHW#V$ M0`!12`'+J8"Q.MIB`!%P%PTU&!UX*1)6'#\`$`)H1]S00Q_>HL,0%=='HQY0 M(R'HHI*`.Q[[,!ZCJ_`&>:LKI876\@"0*Q$KN117P>V.C^W%L3OB:-*8L(.H M?^VGOVI))0(,YPD_XEU)4+$8:T]Z#5^\`G0LT!!!%%O!QV..?0;^R_=C#[`07JA!9W^&@&+< M`TE&.GCJ=2C*,JM"PW+5ME;P9"?HRTVA*ALA[UPOW1H$04*32&9]09>`LH&K MB$Y?[6LP/>S$Q.,6)B/X@^Y]DYY/?`JD3UX;"D!DW`<'FF7&H4#H65`.L"]W M*KQO-"CP94`99M)$UL=(XD'1<`D=$^T$1T/LS1ML'Q6L&':D@;G9)EE:VI"' MB_WD&RU!@^`>F6*G+],?8#/A-)1DP96A4OBSQR<<"&JD`/$":#CVLC6VN&"D M+@,RZJ";CMF%KX,F@598KBF^2VQ(H@;312/\^:T-]D\QH,$ZET8ER&Q-I\`% M0"[HJ(32X5V+FV\V:C@SO7`)=?!*?+YGXC5!T@`CVBJ1%4%'*"/+E.;J`)J* M+\$;(VT@WQ,YH36"D4P&E=.Q5S4@D'O/4?S3XELNL-F^O-B/IR<'YO<<:>6'.%@DBM])N9L=RN` MN,^(QU\%2J)56G,+_MN@I;6D"8L?F<.#2S$U4)X@FM=$LSN`]N][LJZ+P/9;+3ZWQI?&\"^;5OW9(?XW+:W/['5 M[S:ZZ4^4@WQ%UE'XO/VA@[ZVZ:$%Q-,:VLJ#1BGME;BSNU8'S2RM+L%;$;UV MNKW&8-DJY_'A\$-H^F9#ED7U&/J3]G!B.RQD7&_#K+ M^[YVS6>,5;=SAHYC][LE:+RT'(!K(^#XHM4-_+9Q_:62&?^A0@GG$8>^EACM`'&L`BI`@V-(FXKT<(Y3\&_B>E0HO;@W'4N766`-WX4 M'EK,K?T@\D`B9ND\7$;!5/$11W;T) MF*:`ZP(H`DEG'JZ>3?%:$?%(Q$D$VP>>88Y_+9`GH6T1QK>E,7^%YJ?K#V=ABLH)Q(Z!$4]3=TG6R3?-(,/P> MVJ!5P8@D8Q3/]B>@L2NX;YJ$Z;4NPPBU@U04KDXPKN4WSOF7<+&X:O`H0]#& MQ.(8U!)A;CX3ZW1L))?@V(@'3YP#R;*^1[-6F*5*DKN(ELOP?!Q/AV[VK>HD19*W1*G,&5`DL;-8KJA&,_9&#B2!`B`Z]6O2AN[PD@H:QTM6K$8P, M8KHR95@:?D6$3+&S5!F%868(N!I624@0$?4XHB.>#X->-W$!72)E!#%R5J\_ MRY=.<8[BQCGX<*%HJYQ407N8_N!Q'C4WA=WJ,P"V[X`(&.3(0=N:S65:`LAJ M)%:Q`C<`B)L+'RPI1*"O8/Z13E$IQ=[?V_SZ52,2[B71;0ML3Z!T"@)DQ$@. ML!JR-S0HSA92IZ$IL\ZE$/TT;>PL^\/YDC=[=#'0;EN!6,V>1\3$1&+^B-6% M89S1P5_Q>Q+&W]U^O;_]^.;3A[?W7^^N[]Y^>/OQ[KZUBNFX\"V@1G_4+1O= MU14\[TJLAR<6;LFFUF?G[>VS\Y7FIK9R>P1O*6W6V)4DGZYG8X#%X M2_=)A..BT'K$D;-6[I]X%/U:"6@EPEC)V-6K/&O&AQQ3&S4WG[I">UWG(3$M M7/R0M%*16"@H[NJXO,-?LP?GUI!S1G+>"(..WI7@.#/0+HL_83R:V[8/$POH MS)\OFO)[E)PHOL>)B!WX+)^#/R<:LGT;0C.9Y2PS)9=^2LN3;&5D1L>YI,,J MMX:T5J._64-:_\PUU&ELVZ2Q`DS:\+PU1L"T'9AZD8P;D*G*[6HU M4!$A$R$3(1-1)N4T1,!$P$3`1)1)/16=&#+)C\4JA)09FLO$JK**@PQP3:*D MVB!G%+"KN]YZC>&V+?-KFNM=8(S;G^GPQW(<0;_%UF) M[3=2,"1S*?9NXO%$$N4'D7&[^/[6,;E9WS7+D^FF><;&MN4@Y.AN)6<'*S[&.3 MHD:7BS>.;-WXQD"[3&RKR]\.V1?)RZ+'RE^6A(BNC67`GDMI>/R`^#7)1^0U MF3TTD7IQHGEKUKA!+2N#.ELSJ69;2#,E&'FR^$UU&57M86&:W^FV$GQ`:Y^& M_8._I@%P?@/@S*1/X1<+`'#PM+OF)_,PS.Q^/]W,'2P5FE^P)9YD0, M*0L+D$`SKE*J&BM1/NC=:H6ON@^\PK9"3K!$9>X?MCC)"%EA/6[8^)@U%SZ# MC9#%Q_;1/.UIJ9%6N`@B5=/CIBV861AY!ELR"2,)(PDCR2B)1A)$JJ9&@DB" M2-7T2#22,+)&"YG51JY;-8I<1V7!Q8DJT:F4*Z<5U#V435%K%?/JU%!<%=8\ M+TJ/;_CA*&9]O`E+%2OI0A&+A73QM3(\?-'K-H;KZ^:TH*TN&-&$B$"\9!1( M=$;A3^N0?T*$Z8CS/-5MYD6WW6A3QA4Y*')0Y*"4+?A]4OR?-H'6Q"`)`0D! ME:DL7B>>2@A'6?6T-N%.5TY#GA_*6_?I%N79G^GJ_PEJ\UQF'14@'2XZ*(0Q MY\`!*%VKALHDP#Z1I"W5@_D8RS\_;DFX3[BOI#()]XFH*[(\0*A*J'HBRB14 M)3:MJC;/`C7+7(?89Y8V:[OL]]!E\R]OLPCPL9K+&%EBS7/)/JP`,UN- MUODAV3DD`E'Z9`V526Z!TBY%6G_F1!^S%@VXY M_LO$(OC8]4!(AQFAYW''>&;\NS'1G8?D@KCC!LSD/EPF5L!U7^QF`H4S>%C@ MA5-H>.W7OVFI^Z22S>JMN',)654`1^KJL0Q,"$@*JHC="P#.GCX1P%2\/ MRX_ZR.;)1IC68\ICHE_36OK:-9_OP&>ULR?YJ>LBFV?^RWX0>W#A!O';QK;N M..W8''VHWX-E7RW/E5*_[&Z^0VFT*2M=N\\7\3T_7^#Z988^XJ>MM#XU2+2+ MA6R?AZYH-L^@$.;\1^@'UA@>+;9%7EDF=Q\\?3:)U)3LZ!QCYHT;>A;W4`,Y MQ\O^+;^;<,;3MGPZ/$BL>/$_0RMX3BQO00L2JUO&4LD^7.3RN*WCH_R)-1.[ M0UW/A`OAMK2]H)8#WSE[TGWV0UJC4%)M-5;`H&VV)9?C&#R4C2W/#]B?H>Y! M9V`;6DU-:V3$%_)!7ZUZ671RWE%S@NW/MO+?PD`?4@K<(AT&H<<7VZEG^K-8$1;+ MR[8+8P<'$>ZQ-ODHR+^C&AO(=<^!VWUF@J;A,2B'`WH&[\VFT*")?P*#(L,1 MZ,S1IR#CN]NO][]]O+UY^_'N]MWMVYO[N^O7[]_>]Q.C0S_@XD:-%+O_:+M9 MF-T2)/L1)K>8[I@"G"^3HTBX##!ML&`@'K%/ M68[N&"`TNUU8RU__PG9GUEJ[T2V17&?-"N/I7E5S$.2+8]>&`2&&.,XV?>:' M4V@F/)$9W`MT:&)B6%G.&%LG1B8,G:]\%O#IB'N+)K2;EP(-!"S<<&/USYKX M@*11KIO+8,)CEI#][QG M_+,^=4-0&3X;/@*6_!NIK>N+T1RW3#I>RWD$KRVLXM4Q%LOG&+&-WHD>6C/7 M._QUF\W&<9;9]_]@UA3!57?6\A^U[M]SQL%'.`/PK@PP'GWFP[OB3P`L!G2' M/],-Z(6?+YKR>Q2V$=^C^$Q?ZUQ$S\&?$W&C1)YDBD:60TSUOB`1\,F=(]I= MSL23_;KR8VH$K==K;`L])G-%6ZVR;W* MX,@K%IY??B>MGIA6M6$[0ZTQ:L=W@=6&FYUG^%6&]]+ M$I*$)&&M)-P'9.O7B`I\_@WW#<^:81!$/0^_A]'\B8. M6E^+H#4Y%3)/DIZD)^G/1OH*G,KU?-7SC>L?SZ6KZM*_ M_QNZF"[SV;,,CBFJ)PK=1+4__!16O/2E4$&) M(L+D*)1-4+%+?:I1_"&LJNL^Z)XQ8=$6]O7C@G^5%9> M,H_B>3I'5%G&BKSBB^U'5%CF"E)M%X<(R@Y]CAJ1H;*ISQLLG36OH845)$$? M8J=[K:++K4:K6Y<`"EJ>QOE%7$S_$V4ND4W5T6E>JJ;). MZTD65=9H;;F=VD4LZPJH%-"L2T#SZ\3U@BNP\FFR_C=-/$X(FTFGQ,KJH%-B M9<3*B)41*R-6EHP!_];XVF`/[B/W''$(DSC)Y8$[AL7]1H-"Q,KT6?J22Z>G MX@(S]9$R?517)GE.?51/9GJL94NUEC)KRX&)X"IN\3DQB1BU"CV8Z+8WKC=S M%\<0^WB4HCQQD8B:*MW5;Q\S4XFZ(Z4[-*+(]?'@Q%@5@A.BH`3!AS)A8ILJ M=%:";8IJIVJ3S%,H0U595[::1]S50%U6NRXCLDIDM<;F2UR5N.J!+)BHJ@I] ME:"JZ;F@]2*LM#]Z>;F"#9JMFA%8ZL*U+M0:?2*T]2$$=2:TE*A:$YW5FW52 M%BIMHE;;!DEEJJB,&`@Q$&(@ZNGLE*&,&(@*L^"/KF.$GH?[7FAW,F'$>:B, MZ`[1':([ZNGLE*&,Z(X*=(>V_=9[H6;8'ZBXUD9=@UW3HQT,JG;-,4=-G:EC MM1U3W2?:#5R;#B>FH6)/Y<5,HO4J=!SM/:[5.&M=MOOM(R9<48>L=TBO11EP M=8J5$:M6"E)J3GLIW%LK(R;6J4)W)5CG!]<+'O0'?C72C6_<)*ZI3"=U^E0? M4J'NZ#9[1ZP30CR3>&:=X818)D'PH4R8.*8*G97@F->^SP,BF*KU4!L838^Z M0YGNT-J-(1',^OAG(I@*P0D13(+@0YDP$4P5.BM!,&M02/%BKY/J[[GWC@3ZR.>-_ MAE;P3-Q5F6YJ-34*D*K3'5ISV&@3>U6E.XX[.NK,C&E;?TUT1A"\VY@_,Y:I MM1H]_+,XF=YR3.Z`Z%?QKZHPS;>27DYY,'%-433`Q;`IOG7DL1_QZI5"2GXH M.O:%]E)T:/1508)Z.D>>I,"<*J)5P>CZ[4:7S(G,Z13,J:X3!.FVA(2OF`'8 MSST0.9)8?J<(>'TX*_'\<^/Y"H,\51:K53`ZO:9JO0@_'1$#S_RA<]EM*9EY M03VWM>OVCUA#J^;DM8H.2=`[.D%(Z9[*[5R(DM.T\-C30E*9*BJK-R>D MH&`=%%9S7D501D'!8S.0"ACCUXGK!5A.(FKY6^-K@SVXC]QSD/.(E5']@3N&Q?U&@X*:RO19\EAT/"?X M>-7CJ&N4[9IZ4[J3[IHZ4\?#KZ:IM<)6 MS/7T@#.3CP(Z$D;%[NHUFWF.BJ?N.%1WT*$PM8IU$2M6"$YJ3G,I6%LC$R:V MJ4)G+8\9\71\RL\7_Z]YD7P/7KMV,N%:)^O,T:=P\Z?W;^_?WW[\G]ZRW-E/ M7C<7/>N96J8N-OV>\H;DE]W%4XOVG4ZQYPIL75/R`!SJ,E6[C-@\L?D:FR^1 M>87(O"A+_T?H!]88&FYA'?HKR^3N@Z?/)I%:#E05/Y+BV%9/_%\%A$I$F]-3 M8!4,-=/6ZAV6YMBP?\R]O=29)7=F]XC'%1,Q/BMB3'G#-='9^;%7RC6FS=TT MU$EEQ%J(M:B@,&(M"D$9L99S82T5S+O33X]3+WY"_IY41A2)*%)M%$8422$H M(XI$%(DVD:O*`:I83F+#YJ`QH`Y1ID.&38WVBRO5'\<<'W6FDX=:_2[G$VTF MKTTWGR!_4)9X'Q%2B=6K,!9I_WFMH+-UV1P[H M#ZD^4IT<.W%3A>"$F*E"$'Q.S#2GV1,O50&C$KSTVO=Y0*14M1YJ=8ZY?9:Z M8[4[NNU&BTAI?7PZD5*%X(1(J4(0?$ZD-*?9$RE5`:,2I'2UC"<14V5Z26L2 M+U6H-[3&D&AI?;PZT=*E9PZHDKQ"O7&225KG1'?S^69BNRH,MF1J@.Y]XX$^ MLCGC?X96\$QT5YENT@9-2@Y0J#N:_4:7"*\RW7'4T5%G,DV%#6JB,R*FA\.) M%&8:OSEN(_;77,P#TE6V),"AN*O6:O3PSZ*S+,?D#DAP%?^J"G]]*TGKE`<3 MU_1%9047`[CXVI''?L3+5RI4^:'H^Q?:2]'GT5<%>6^NLV]R&(=BU"P%2E41 MK0KXZ36/F%)*MJ6,:"=G6YDSDCQFHSR[4UBTH\UNV]YS MS5ZCHQZUKRN;IP4!Y11&"P(*+0@HH+($$90?,2EAY;X%2[EB[W3+PU:''$0) MF#Z;V9:!]_SU+TRVU[0>4]X;_[H[;M]94^ZSC_R)?7&GNH-M3313OGL.V[NK M?BCI8AFJCV2:)4Q3I'RL"G6'OVZ3+#+7YNS[?S!K.G.]0'=6)=2T[M]S3APB M+F"XMJW/?'A7_`F,VN"V[<]T`VS]YXNF_![9OO@>V7FOW;N(GH,_I\\E4DQA M>:PJ?0%-DPBA#S9_-SA&#T#D2&+Y_8A:U8;M?=8Q,LRV.[A`L`&`@;^T2^F( MJV9#P/;>)IR[/RJ8?@C/^B_A63]PW0\]+D,`O_F@>O5FD^E)>I*>I"?I M#^4.W^B>]PP^B%U/W1`\H7*KB?NX1%56@\@\=S7/_PW=@)OLLV<9W&=6%F4[ M;R5=&X'UR*-MNC[I*>I*^Y,\1L9V()*8H1&>#;&8+\ M>.S$Y+KG'%=/N=I:LY#N.EHGL3VB6S=N505MOL&=:1ZN53.XUK9'T=KLI8M8F+# MZUP5<7$.W'@9)[J&Z:*.,FV2]NBH`LM4:H%*+5"I!?5T=LI01HQ$B94]Y:N" M?=`]8P(3ATO6:FHM!4N`U74LJB):!3;SPXON94=K-P;'6UPX.4JEBFA5F,O1 MK.3$6*0JHE4$*8-.MU%>YA4Q:&5$.RE,(:)2(RLI@"HT85+"F)2?,-UP@T]' MW(OG3!K-F=2Q'I6AJ'JE,+Y7I)8@FZ566OEKW2)!/M7"I%B[5PJ4% M)9*>I"?I27JUW`E5DZ5JLL=/VZJ>M%`UV;V))U63/:5JLLNUTM;[,:5L[-$G M&(K/'8X(;R>W';YZE9W8WO#J%79Z^Z,)RJ@J:V[//L2_"?YE.9A8\XI=#4O0 M<06N_8OE?[N:ZH[^(':A`6'S`R^4&]+4BQJ>P$@@IZZ*RLBIDU.O+Y0)[_)' MZ`?6&!INX73^RC*Y^^#ILTFDE@,%%R(IB`C4II;?HI/8+5H.]P/FZ0%G!MSO MZ49UZZDU4DW:)V9R'^Q&Q[Q[W6<3;CYD;]H_>V4ER"1QR?KX+.*2Q"6)2ZJG M,^*2Q"7KQ@$2;.!KZ)C>,T65E.FY'SK]5J-YM/ZH-\VHHC^V#*"C]52=VX\4'0QG2R#9`'%%;>K MB:*)M8Q:U)OF4S2Q#@JK.26F:")%$XD^YEE1%`54F,<-;HD=T92DID[7::V& M1L'$^CB`.K.,4S-?(C`*`;"R!.9H5D_<2`6$RL6-C-#S,)'?MO2195N!11Q) MH2Y\T6TB;D[:MNH//=J6 M4I_..EI/U9D%':J?CCJ4:LZZSFDLG1_94]6M$L:\)#B4[J6CO(6?NF`%5$JN6,!Z0+,%''RS7 MTP/+=>;4Z9EYW!8+=H'+9I[E>DPW_@PMW\++_$NFL_?\D=NLS:9<]T,OKFX@ M'I]XX<2"1WO&Y/F2/>D^^R&MC8*6M[1&;\G&-1IG@-A#[`SXE+M/48KIC MLK7B39<@M3_C1F"!:,^-;2N,VXS"M!Y3ON[12W?6%"CI1_[$OKA3W<'^*J?[ M-S]8BK^LB?C+B9O_[YR9',!Y"I(ES-)G(]T'XT;KP@9]XP'39S//U<'&0A^& M!OLS=-'\HS_*NRX9KF-;8\O004Q73#K<$;Q/A&;!^F=AX(-H'K-P+S)<9C/X M8KC3F>Z)2Z!A'"Z!'Q.3E$O\;EJ^X88.OM/0_0D;V^X36+EN/_O<;[#U<UTU0&M,?=(=&7+D#$RF!PES!>R'QX#&`O@;?`XF<.\80)H]<]WSR0+7'M_> M_O@5S$]]454>)26LLN(L<_99:TN?;1:J8K]YS?QP"L(]Q[1I&8#G"'H%B'_E MZP#OBZ&`HT-W6.@`WMKP?I,]Z/`3`K_K^VSF2B8EL!H?K4\1_/&Q*[=(.,>; MX*$O9AX/].\OQ=,-(YR&DJ1)M$<_X_$)!T('0TN\9^S:X$?\5SN91:NP6:0Q MC5EB?B=\X*IAW.&O@!!NA:G_D@1/P)IID&MVU_IAM`*7Z^:,KO MT6Q4?)?WPG0]P=328LT;U)(^5\Y45OY)=+86H^EUN]%/#:EM4FGZS+O=[69. MO5^[YO,=3'C;N\R^FYFS[Y6N!>\&4Q4T[97Y-38?I(Z$QF^[!#24[#^MV MJJXCXF@9&^MF-<-A^2:3':M4VV3VM)08GL/ MMOK(A5RD1@Y.IA3MS6I'_XL;Y(F>F"M$P4Z_K.-\E+2@LT:`_>WEM\3,T,/9 MG9P?%E^15-(X\I/1[>:A,`?=8!YE\<]$B0:8Q'<:@W.EH'D,15G?4QV.;"OA M@2.Q27Z(_%!>/Q1%)\D1D2-:WN_>:W3(]Y#O29C$H$FNA5Q+IGF\6UIAV[J< M-E]&(]=#KF?)D-J76G>8!C7D?<[8^[0N.\-!8T@.B!S0W@YH.8^#'!`YH.5] MAI>#?K_1)0=$#FC)`6F]3MJD./=F"O%M0[+=NNHVY]NEZV8MTV[71<[:)\_/ M'RP3,_]?:D-9V!1Q6; M0Z(HH8NIO]\YIJP;[G0I9Q(\;F9J\@3]S@62'$?'.&7HSTH?J`' M+QF<=]D5>-]YO6>`SM<@S.1CQXXEPV M*KIF05#F6P5\QK_CSA>Y8V?$10ZB_.Z*>_TE32?23KU`J,UP_:#!WNE&X'K^ M?%>0U"?N6O#%K@BQ>6@AN%2^D"PF0I'Z#7UF!;K-L):=@6G?E^P14%M_X.+= M"37@&CAT@6Y?,I.#5?\90K.?Q<%H_N5\3W?T4C^<@6$%E^(A#Q'\6P;*BVOS MLI.KR">G?6C[[T/+SZ8!&NS0Y!(HKL09>2M;#=!T'@%@T"C%O@+QJQQC\]&1 MA3.6#]\T^6]PVT?(>>6(O3;03""S-E)O@&FQI5\5RMZ:A MQG`Y'('X8$0`%:RK9S51W..)W1=78/CFFE)`H@`>!: MEB$W^<'[3#[60SM@0M?1480`73,/E&7-8-S.]&>YRP,1;4WW0B&(]/`O%Y`% M+WJ"<3C!7G6W^`'0M@&FH/&L,M`Z];9664&J@( M^$%_LX:T_IEKB)"IJ,IZC<&683<\;P7UMVNHVII--=`1(1,A$W$FXDSJJ8B0 MB9").!-Q)O5T=&+(E$A\.%J`+@.N2@O8-088/"]IL>Z<@+[FBNMIF4PTT^2Z MB7WRO5*TV"U)BZ7ME)>"1L,Q]WJRQ_FB"S_`71-_\?VM8W)3C?6:L^ZF^;+D M8?IB94P7RL>MUA5G`6-)KKGFP$@>A3Q*$:A2B62?SL@FZJW\>">@W$UQW4ZC M6U!Q_7:N"E5%E*B=`J7;7#QD\4G4/MQ\[5'Y.3D,%0\9V"<-;"(Q-+"/;9_G$,ZJ;=("(62DD&3-CI&M M&]\2IR64F.F8:8BDU&W)D>UF=G9DAEH['2WAE;1V.6ZII9B6E4U4(B=#:R;D M:O957+O3*SS-[O22=+PD/6KM4X@JYCOM@\*"]1IW9>+_"(C*@^>&COF*_R-NVARS"&LO;4J6X,K^F5J^9I[X^(7T- ML8F0GB8/BBKS5-BW&MHDU"345%2;I\&/U=#ER?!8-=1Y%JBITGHW+6W$S_R2 M=BZ\ZYS&(@441&UG0QE)(13/2Y- M>?B'#%8OCH4^B6@UK0]35LVI*/-4)A4'BM*T*HQZTVHT8?2I:)-F0.7I\F2F M195B-&LWN@3-)SD`")J)/BNJS%.ASVIHDU"34%-1;1*A)4*KJ#K/`C43P7_Y M41_9/-D(TWK<F#![_#`8,*9Y<#MN@VW^@'3S3]"'^^'%X`4S\R%2[RK8*([ M5P&?SEQ/]YZ9R0U4H2@W-M8M#X=[R.%I>L">.(CA<0.K9)IX`=<]!]#!;V1, MDO?IU:&$@%)ZM0J#:[2D<*I&,;:/.?$I`7';/K/DEY]^#/VK!UV?O7H'5O(O M-)(;RS?`LD./^W?\>_#:=HUOO_SU+XS]M';I>TL?6;:P[0]\3URL;UV[R)Z#OZ_N`PM?5WMLAA.T.M M,7S$=SU9CND^86,2):HSS+8[2-16+:>F]%6S,52QM&HA#XG>B`EWQ"(G-(47 M^NPW'U2_=]B?1M9.(TL-![#/<*N-ER`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`\1V%8NNT@-[.4RVK_JEO/>]?U/SJWSR/U` ME"T]8KWL(Y;$[C?;VTMB9XSD9L9A&1MGK1N.;"[[E.;4\8&3PW5+5NO@\.,= M$E1;E66?GU;R>6EUU="F0]%*/@2MKBK:<&9/R6?TU%9#A$Q%5;;A6*URSR2K MJX(V'3QVD"E?#71$R$3(1)R).)-Z*B)D(F0BSD2<23T=G1@R[9):4G:`+O,H M^I("=NJ?`ZPHT-=<<3TMDXEFFEPWL>FX5XH6NR5IL>2MQ]%PS+GRX:^(OOK]U3&ZNK9_FV9%=\ M.H>ADT=12'%GZE%4(MFG,[*)>BL_W@DH=U-D5GF9W>DDZ7I(> ML7IF_:.*^4Y+H+!@O<9=F?@_`J+RX+FA8[YB?S,,SL?C_9W"4FFTTCV"K)8@ MAI7EF#""7K$K3=%B#9\]%W1J^FSLN5/FZS9?/PVQ9L.ON,60,RQU_)W$?*N" ML;9>/N?41]:F/709QE#6GCK5C:%UV1ZT&QUU^NHLF`FYE#IJ<\.&MPQEEK1% M4'40V;\@6VE]M&E78I;%E[5+4?5N:O6:C:$Z745(3TBOJC9/8_*@AC)/A7VK MH4U"34)-1;5Y&OQ8#5V>#(]50YUG@9HJK7?3TD;\S"\M1A-&GXHV:094GBY/9EI4 M*4:S=J-+T'R2`X"@F>BSHLH\%?JLAC8)-0DU%=4F$5HBM(JJ\RQ0,Q'\EQ_U MDL0O/_T8^E]=W__DW#J/W`^FW`G\._X]>&V[QK=? M_OH7QGZ*K[V=SG3+PRL^C1-7,P-DASN^\/'/%S>AIP>6Z]QK\`]6A;^_<^_; M]VWYY8*%CB4O_`T^8,%:DQL6:`"T>M6]^*7;Q/\MQ,MXY?YRM9)RM;;*U>[O M))ACN%..ZGWGN=,W(([EA&!ZGV9<2N._YF/7X_*Z._T[]]]^#SS=]_Y M-N!3_Z/K8$,\UP;#>;C%RESPM@)*OX_$N?\:Z/!`$/-UZ(,-^OY7_B"DOOYN M^?>V_7Q_[6";_\EU.YA\X-,1][9JIM=MKZJFNE:KH=YEVZE6O5I+6EY-]/O! M`D"S@N?X@=>.N?R4MW^&\.>&/YANWZHY$OQS^#!<[ M#]QC?CCZ@QL!"]RE=UW*9XIG18]UO<53$P+S[]!,1PY_4.93]'`B=8J]GL-ZHX,[A&-G`7]W)"D!#9`:#"2U]S00Q^Z=V(M7[70],*&#@,RS5AE@47V-8W#D\!".=@;"/^[,)_\%D. M_`3]Q:8NGF?=V+1FD<"JM,\94Y]-;B7#`;W]/N..SU]SAX^M(AQ\J\-M:8-T MGK?VUOU%*SKW:75:.XKF<=WG-US^]]:YX6/N>=Q,,(0R=7@U;*W-'_/(4+;8 M!?5[I;5;6A5R?X)AY$7LS'EXH\^L0+<_\E+MMCOL]K;*GB5()0THJ/W><+`V MM]^Y`9+E1H.B3#5WNH,U(9=>MKLD!?7529D7Y)#D"WBO-[H_>6>[3__DY@./ M`T]W[FO^A0O_:HTM;H)XH.*/(*W6^B"@?[7#K_W[3^,"$@_7@;4,F5;;^0@3 M%]=[3I<6M)S;$[2&P_7.7CR]T'OS:PE`/@7F-[U6SM4D'NT0EMH^!^VNHWGZ M6TN0K>`H:/76$3N/;.\M?6395F!Q'^;"7P.@&A/7!L[MRYGP?J;3;O>Z:[:S M[95["UB$2;3:@U4CVUF^-R'X0V?/T388MINKP:+U=^P@0P$/U.VNA9<+B("1 MO#(TH6G:L+V*[:GOV4V4`L&GYJ"G;>B43$E@3GO'O>D-'VW6Q3QD^TZWO'_I M=LA?/\\__M,"-^\9D^?W_)';(G8;7_Y&][QG\`1?^,SU8#9V/75#)YC?N9A' MY(V=#P?:*L8E&W'@YKV%V1W,-_FG\?SJW=O6[W15:MO\FEMG%@:^N*!UC*:L MKQL[>DK+<0[?3ZZQYJ=3W["A+ M?O_0[33;FY211Y3/W,-3CO0'_IKKR.[?6=]QK)$MW?8W MITN=M=)3N"<[S=8Z25Q_R2Y2%)E&MK15"IU#"-^7ZTX/W#&>/X8X=CZ-/]LP M;PNL\;A(6&8^+-\#IW@0%\)902+:SZ8MARR\_L_>ZX9 M&L$G[ROW'BUC\83_[WGF\>]Z^@A?LI@F3G:2>MC2S.-I)6IL3,:>$XK)J977 MSSP(B58*VA#B`BVX6]?CUH,C9QO& M\PWWK$=H`HQ$K=`:Z^=V]V8AWD[O6Q%Y90UY/_"[6INXKSZ_\-N+1'K7>.3F MMW_D`0:HP&P>+9.;KY]_\]%5O+,JO97];FLUG%!R"^81^6JZ0-/Z:VB1 M7Y)*6E"P#P;=M16Q/1JP2-TI5,L0K.L0[O360S2L>OE:W9?!B`QOX',)D&K@6/2#D2_#-\?@T.UX(A@+GC7[EMOPT]-YUY]=8BV(/F>H?LVA2% M5((J0%7\YLNC>=/5T5G#E_X:H3D)=<1JV&P=Z^L;O;4@S<'5\56WCS18UJRC MT^VMTXRZLVS#A,) M@_/CUG%3T\7V5-R,KSLG#C=:79DC*;[*"292,^F=H M>=$U8(P`+E,0^.I_,:U9Y*MZ(@]9?'QFIBMR9RW'L$.3R^159XQZFR=1U:RSL6YYV*ZYM>,+%\+.7-_"7R\Q0S:TI3SN?-^$3-HV M8%K&QK;[)%H$;<:78\J%:!&V,!1Q/G@/"&G-;)#C@3N8KVT_X]_Y#)45IXX[ M0H\"ZGSVXM?KZ\\O&^P6!`L]>+7E"''PRE2=@FIL3`Q'->@FCG?Y^PNI'Q0C MF+@B2U@/HJ1R-#'1$H_C^@M<\S+QYSP:BW*(US4D;L*_RM1AG_D3]\D1[9'6 MA`)E&<>J*E$7E^R)LRDT"X;/-\YXM.SH"_G!XL/I3+Y8-F`\%EGR0CRY[,IT MX;.$G'`]#Z`7[46.`O;T(W="_,3E#"CJYCB3VYR['GBI?#9:>ZR&U,;@_:9( M1DO((DQ"J*7!8/8>PBVQ#L%D;'P3B.^QL>=.HTZ;-W<]K?J@-0;W@;NAVF"' MB?U)_(APQ9RGPO]OJ(,=80:]7,G'LH\+B`+[QJX;82?K9F3%?X2.W/TAS!@' M\A),9IK,$L9*`$N*@P^Z=APTG'51_F<^]'#/`>,.WG0#@QDY7Z(LOW;),*0A M]IB(I']3/#=5IM$S;GQ!8>9@_14A0\:_4.*WWV$RY#QP]L:=3N%QV.@77]^^ M>2G^*KP(?]3M4+3;#T<^8#TN*^.8@Q>$,[%1`IX+=IX84OC.(YM\G@T+13]G M;'`HFQFO\&YTH-<"^#`*EU_YZ/&;$1S*BX=V5@K&?FP^/B3_^X8`:W M;7^FX[(IIB2([U%=%?%=WHL?$\(GRI"G&,QR,1BZ@"Z@"^B"U0ODQ^H/W6UI MS8:657PKKOP6V[A^^*,UVHUNT6)E@X3ZVN>M MO@VEWLJMDU=7!;6!0&U64(=&8YY:=XO:=J2M!7:U";H(NJJ"KEXDXP;L&M!H M).S:25N=PD5B6^0H";P(O`B\CJ^M#I9&)NRJ#KM(69&R.MI6;75[I*XSP+%# MA1"U87OK4:BKZ-8=U*[B?`7&)Q,\"RFN4[XQUEN'6G/8Z!0]UB0)@%HY:NR6 MI,:E_&,LH,"]10:U_%XDERLZI3AW,I?'.9.EW]A;3('"UXP\]B/^]0,6_&!M M[5+TZ'$SB]0Z.IO&Y+(.>XU^48_0(B6N&J*6/2/-,L6>ED2V*HI7SP]*65TN7BA.-43!6&BC$+^)D1EP!*718^5ORP)$5T;RY"1&Q<_ M('Y-\A%YK64/3:1>G&C>FB%N4,O*V,[63*K%%M),"?:=K+Q1F:T#8!:=);4[ M2=K4ZIV&^0.M(?L_/_L_3N)A3?TCL=>:L->:VA=QV!+]^K"X7U]"NG*&M-8^ MA36;%[("L2CO"-?:6*KQ)2WB4)"'W.0AW"3\5*&/E*H4\&)AX5^0^BI%O4J4 M^9R?"Q55&#L*.)!_/G*,Z4QUMFEO<%;>7`6%,TI58@48\<.B9UBGVV@3@:BI MO=.J<`E*W+!K.4.')55@4!\FCH$+A.&Y.@=P>T"X75/((=PFW*XK1R;;(Q`D M$%1%B;N`(*EP286;"O%DI8%74)BGWDHD0*3E@/*6`T:Z\>W!PQ->7[&_&0;G MXS&M$52P1B`/'ZEL&EFX&VG=H*KQ08L)Y2B2HE.Y$":QP/"BU6MHZZD0QQL* MQ%0J4BS-YRK2+$6Z",`/#.`OM&ZC2ZA]^N.!4)M06WU=TJ(%`6O=%$O`JA"P MDEZWZY460@AD:75$_=416@@I:Y8KCV8_1A8=K7248.NTJ$'9M56O7R16,EH] M2KFMK>'3=(Q2;@ET:P*Z+[1AE6O&A+6$M4WEEC.K4'`[&M?POO> MW7Z]_W#]\?K7MQ_>?KR[AT_O_^_K[5=QG3QY6B^RJ%/JZ=9)&7_[>'L#`MZ^ MNWU[YT[9CB MVUN9!75C^8;M^J''[_CWX+7M&M]^^>M?&/MIZ=;WECZR;"NPN/\F]#R.&H2V MPAU?^/CGBVO__M/X7FO=M[7[5E/3+ECH6/)/O\$'K77!3&Y8T+V@\ZONQ2^M M8;/=;>+_5F1EW.YTRA'FG6]Z_=#M,*'4OP;26UMLB5\HK M-\OXT76,,GI0Z_;;@RW"+=ZUATP%U-5MMX=[B>0Z#W?>/T\__A/BWNZ9TR>W_-';E]_M_Q[VWZ^OW[4+1N!_IWK?=5M_I6# M/$*TZZGK!0`_YAO7#S[PZ8A[\Q=\T/]PO;OG&?<_C6_X*(!!_/;/T`J>$[?' M;Y!_^,"#B6O&@SW1(OGD[,Q"!+WP&RN,FZ#!T M@I1!<1;ZG`^5DS;,?H;G4$&1-;3+O=0)<.K.0`L!M%72BXA6+"GU)L0K7.=> MNX^&^YT[UW$.5S-,'3F9[RY-SE92SNW^YZK52_6(103]%%]X;036HZ0>NC]Y M9[M/7P,]X--5)[FG;J_Z_321\XA1A?1%-=Y+M8P=I4?4\[_`6'9"_I&7JF:M M,VRG2;KRRE*%FH/*9\\U0R/XY'WEWJ-E\`6">",K"+_G1(I^+Y5<';D)W[D# M#S!YSD9$!E-M(PI:L388M`XM5.G&<0C[+MR$@L;1U8HWXK/^+)PCL":0P^#< M]-]Y[C3AC9=PJ$Q0:7=6Q2TH3'4M*3@"NLU5:*FB)9&=6(_\VO=Y4&I?:$UM M-8204XKR12\*/^WF*@L$NO-@C>P*\+DUS+*0 MS->7*6U!/9M2Z"E; M,/FDI=OS$.,>,,UF<\W%%M5$[109B;B_U@ZJ-#]E0:_((/HEL?#,4A:A=UN3 M;F4F-FY>9(VJ2XC\GU?LCQ!H__A9KKA^=`/.-.T5^S)7`8MUD%RHWE/.QC"9 M(+%%VLQ5__W%:$F%[2<&3K!GTHB8[IA,6@]G$Z[;P82-I/KF!3(LQ[!#$R@$ M6!N\T[;=)YAU@35-9ZZ#X/@*S+-4L[CJ8*;M\?6]BQSK^1$BH6--@CO\-3M1 M8L>$DS@%RH!NTF<^/"[^](\+9G`;TX8,Z+V?+YKR>Y1"([[+>_%C>C)UBIJ7 M/^4!&^NZ50-;ZY*0=BO M.H01]N^JN.:PT2FXV:J3W*5;COEU3P;9[R8(.A_@CHG/WCHPA<1WC3SV(_[U M`R9-L;9V>7",WPIRJM3DIT&Y8ZT'4AP8G%:XL(O6TPC.-L/9HB-KB&M$WI0? MM43>=E-^F6^:8NZ8 M.6(CEF>YIF7,MUT9KA\H8U\'.\:#$+],;>XS]3S)",>!CD4C/:JS3G!::J1E M@Q*U>;3S(T_*)@DB"2)54B-!)$&D8EHDB"2(5$F-!)$$D8II<;>C<>NC1Y56 MFR@8NQ3_C`I%GT3$E8*KJJ7PG*G.CDAYJUAS%)I8+#F*K]6BT@^)RBZ]=J-Y M',B@].[=]$8,>S?%'8U,EZJVZC#A&"!0?RBOME4KYLT.@2*)^DZ1,H$RBKJ4L*MF\!Y6$>4"XSV$YQ M]5([\.WW&3<"+DZ$#CV'N0Z;V;K#X"T\.-!9C)0BKQQ04OB<,G>4BI2_T/I: M8[U\,27W'-V#K%=&H\PAA9&(9@=G"N`'P.?>D;#@-`":LB_KHCC"4,+0*C"T MK34&!*%U,FF"4(+0@QZ)1/'H+1#::C1S0&B9$6E*_ZZ^7Z^GKA=8_]8#RW6P MC/;,LUR/^2=4S85RPH^K30IJ4QJ+$I'N"@L,4)8+9;F4ND9U!EK)Q0F5#Y5+1)J%R>+BG^OBT-I)D+ELN, MOU.HO=0N_,(-]\&!FTVF&T&H>Y9N,]OU*1G\7(/I%#>G/!BE0N3])E7AK97% M$Z&G-!E"6'4X7B?7MDT"4&4,F@"4`)0`5!T`;;4;?0+0&ADT`2@!*"5J*P2@ MN7(J4L+$\=OC)K4;&NIY+NV!PL=L]?U9O5I:1%GE(V!W"ZWFUB&%6K-#K;F5 M2*%7'-!X@->>`[K3O6"&:_LS'?ZHM9?4:EJ/L;0CUS.Y%PL[Y:853D%%#E^\ M/-F0Z'(AS\C6C6_8W\QW;G&C?FK%NT,L*D&:K)M6J"VFFA#$`IE3AHBEM6JJ>XWSD`9O! M=]>T##;B#A];='X%+:_NKTU::&$6(3XA/YW-7 M90^4#E!&/E69"R#[KG70,C^%^(^_@ZK,]>;V[#LSW7!DIZ^TEKS@W*3U9M77 MFP^:?W'\?(O#VC\E7*@_`!)\0W[4P3@JY4&R9^[#=D6[#%,.W_$OVQ-E$?\02MT[@ M6:,0CVK39S//_6Y-]8#;S^R'-+GP:>WE4`V#M]M8/M?C?X:6!\\)7.;K@>6/ MG^%OCC6%L32&*0V,N?B:*7<"'Z]S0X^9?`SZ,^>9+#/N^%9T7IS/P-9:30`U M=@N-@(&+E7K3Q=\@\$IP:6YXL>CNF)F6;W@N+>"8?V3G5,*O+P%?A7(3H7A^/APZ?ZMT0CX.4YM0)/R]E;G8S> MRME)#?8[!^\%5ATPW0DLPYK!"U%NO%)WGN>=`OI9UN%RLV+M;)J-14A9D+BW M5HD[#,]N&V[QK=?_OH7QG[*]90;:131PSZC*;RW])%E0P]P_Z/K M&*'GH66B[N'Y7_CXYXMK__[3^%YKW;>U>^@"[8*%CB7_]!M\T%H78&P&&)(- MJK[J7OP"<\Y!MXG_R]FXO&(=IJ7MJ*&MK0UM]7N]0S34XS/=,O%(3,?G;\KH MHEZW,UP5/.TMNPF27X/#X;JEY);C3O\.(W$O/6C=K/>+AQ=Z;?Y6MUN=9H&W MN@;GIO_.?]6>!JN]<3UC7.\O1'0.0]-H(K$=A1$N"@2<1I>GOM7NID/L[ M=R[G=NVTUH0L)$IU[6@EV[%=WU4TX0OTE[S]T_CKQ/6".^Y-;_@H*+,#KC2M MMZD3,H4H6^Z""K_2(@LO3>RONLT!4S_H`9"CX/G3^/I1MVR<]T#OX1^_<@/_ M4O8(Z#77<7(GJ:IO6L$^:K4'[4V=5$W;Q$"[=1ZY'T@27V9G:5JASEJ5I:IF M%.P8K=-J;QKTQ=LQXU[PC&PC@/O>`CF?X76_>JZ_K_OL=(`RU:=IZ\1SX\O+DK.H*K6NMDK+ MB\D9>*$1B##*5QX$MIA\P9VW4R#9'GX!NWZT?!%9*%'!_=[JL"XFRX':<1^] MX?Z-.YVY#CPF;E]_M_SYK4O"O9GHW@/W M/_#IB'OUU5)Q!E6'=ARYM\O64J!C".6M[CEPMW]M&.$TM/6`FQA<,:P]7;/6 M&0S[ZP)O>VD)0A;Q-,-F;Y79%)?QD3MAN;.E[J`]7&6N\7OV?OO<%L$T3+"> M3]Y7>,%3;?KY_ZXVL(/R>TRZU9HHO/)RLW[D##S!Y;FFU=:O<6=J"0-?M M-5LEZBH#GLKJ5ZV][EX.)VO!?AT.\W4K3OK\Z$^_NJ[IKY+]?8=N;S!__HYDMP'DAS)[L\7@(L,DU^B[+3Y.K3( M'5I;*+_#7^>KY4O99-U&!Q?,XP3R7ENF)$73KV>Y%=&VL`\K6FO?('R4QS36[LB MP*%>>UY*IM8>J[6[;,F(D&U9"2L_IF_+:!8J0=4:[K3!X)C6L:MJ-&W;3LBD M8K1N+Y%2G7L77[+6C`%DBGN+8C/R>Z8&2GQZG#^7U7-+29Y`Y/Z^O=]6<_$6 M[X#GHH)6+[B;>)RS#W#)Q&=O'9.;*XU>2IQ;SZ*K0AT9HAY"7Q]PP6"A@;9V MF;[!K\HN*Z3_`PS(1K^;CN#I([(W./"()`Q7#<-[[5S[09XLQW2?L.<3%4+3 ME3?(K;LZH0W.K\X>7YI9^+*'N?1+QQU%S$4[>W,Y)K9$48VY6%D[D@AZR8?7 MW8>W.NF6E%$CN=5)L+[JG/419THO;C`\Z8E]1=&6)C_E?.#2RSZ*5M^-IG@Q=MZLH!"M1::NU^K3U@1N.) M==]!(A];(AVJZ:2J'2@M;?FBK5M06E5N05%AGK&^;4OU,,^)=8#8*,9H?QC. M1;<=@[,T-I?.P#G%[6&$V7+>V>BF!^OW60#IGB*6G_E^"K'(YA')LLLP6$DF@+3^U MHPP'"=9586ZJ^_#4S3_]M`T()QN.HVZ/N[V7LB-:+:IPD(!;K?A$=>."2,$HA>E+GMTL9\=@ M]K?RBDB,_$BY_;N?4T/9_759XJ764FNIM0JV]B"3ZEH5/:!M`6J0<=H60-L" MCCV;IFT!A.=U7(6L$\S0E@'%\IL5,0K5,XX.LHQ8CE,X`Z,EKU@#KZAFPGX= MJI`N$BSRY?@KZS]I)*JX\$5;#VCKP>YEXNI>++DS:'35M??C3D? M.AG5-Y6W]I2SDL[3UJO>4E);MJX<"-#DKGZ@21M5U`X1GYBYIEYE18)3H=HU@)8B(W6#XAI!],9[&!2G=7] M,!QN/:A:)^MD&#+BQ?,-V_=#C?LI?Q<:C^:XD[OCP#GG;TK7[ M[$9*=K>6"\?>@$V-/&L%Q"K=PI1B3+@BKK2%L8P#XW<3_1X'2MGGF&H^'WFD49ZH/A`,JHKG63G/"4U-9OZ:5HV:M79*>6=$\N2PR+"7MRP&[F9>`!(E. MCIPHB[PHBQPL$QZV6&@TR9>*B%`\_TZE3VPEM**MS62^\,#"753_Y+H=3!:: M3M5P^8E[A/V$_7507'.X=?/EBN*T3B^![>687_=DD'U]ZR:^:^2Q'_&O6_85 M5HCQ^\9>=C*N5J-?T+;Z-"BA0;U&ORB:[712\\DIKJ4UF@4UI_4T@K/-<+;H MR!KB&I$WY4E+*Z'+QPM4G&B>6N&N$$M*P,Z6S.I%EM(,R78=Y2)6G7:U*#H[*&]5!Y5:Y^&^0,M)OM7 MW/[/@6W4W'42Y]@5A[/25RD]=<>)4H%"BS6?.8W`6SYX;NB8K]C?#(/S\7A_ M@%NNY%DVNLD]?\)&+,<$-.9^#8G,!G[I@Y M6&\1_NJ:EL%&45:NX?J!,O:U(T85-B5"_%*UN<_4\R0C'(55V.X5SR<9D!X5 M6B=,=79$REO%FJ/0Q&+)47RM M%I62A2-[[902VY3>K:[U$\/>47%'(].EJJTZ3#@&"-0?RJOM%4QZ)'2N$<@0 M.A,Z$SJ?2:_`8.\0.M<(9`B="9T/@LXG%-H[8O2\%IVO==(.WJ`LZGH'[F\Q M[Y_[E"M-X?R:YDJ?H"+K/Q\Y&8TRAQ1&(IH=G"F`'P"?>T?"@M,`:,J^K(OB"$,) M0ZO`T+;6&!"$ULFD"4()0@]Z)!+%H[=`:*O1S`&A94:D*?V[^GZ]GKI>8/U; M#RS7P3+:,\]R/>:?4#47R@D_KC8IJ$UI+$I$NBLL,$!9+I3E;JD^/NV-)!F M+E@N,_Y.H?92N_`+-]P'!VXVF6X$H>Y9NLULUZ=D\',-IE/>P[H3O>"&:[MSW3XH]9>4JMI/<;2CES/Y%XL[)2;5C@% M%3E\\?)D0Z++A3PC6S>^87\SW[4M,W\K94\MK7#*Q\I?EH2(KHUD`%XY2-=+ M](3X/G&B?6O&ND$O*T":K9I4JRZDF1+&`)A2A8NFM&FI>H[S MD0=L!M]=TS+8B#M\;-'Y%;2\NK\V:;V[/OS'3#D9V^TEKR@G.3 MUIM57V\^:/[%\?,M#FO_E'"A_@!(\`WY40?C6##+Z(:??@S]JP==G[WZ:DRX M&=K\T_@C#U[+!?\WKA_X=WCC'?\>O+9=X]LO?_T+8S^MW_0IF'#OH^NX,^[I M`33]UC'<*<H%!YM):DV93II&>.)IT*"9 M(#@EQ=1J.XUL-[H%IY':(*&^]GFK;T/%9;&B M0MI:8%>;H(N@JRKHVK`XO5B,IM%(V+6+MCJ%%ZA:Y"@)O`B\"+R.KZU.1BR= ML*LD[")EY4CD6"1ND+I.'\<.%4+4ANVBR2BMKHI)J0DRLCI71C MK+<.M>:PT2D8U.@D`5`K1XW=*C9,&MP)N+?8,2F_%\ETZS=2,.4:2V:G==_= MQ..,//8C_O6#[AD3UM8N18_6.#MR1X>0G;--8W)9ASNE M:I,25PQ1*[S70^MI260K9V/]P9%-)1)(8WZ;#K.9#_4ZJHY$_P(:Y< M:_LBKEQ>C+-??/=@,K123CJ\=@I,&?,6B0:32R0:7'4\LU4T'[_;)\C*@"R- M((L@BR!+;<@J)\WJX)!%L_8:FBJ-]S+&^Z"H(?:Z]:PDTFSPLKWT%Y8)A#=(LYQ/V!<%OLZ"CB0?SYRC.E,=;9;U?W2"V@Q'.OL+\!)HZ!"X3AN3H'<+NZ([,(MPFW ME5?B:>!V[3@RV1Z!((&@*DKHUM/54B'J=]4L84]6Y MOZ39MVN M5UH((9"EU1'U5T=H(:2L6:XX)_TH672TTE&"K=.B!F775KU^D5C):/4HY;:V MAD_3,4JY)="M">B^T(95KAD3UA+6*J]$PMJC8"W9'H$@@:`J2J10_]XJI*@^ M`2(%\*L(X,?"Q2]L-S0<://YT8$"^VSU_53ZNFC0/;\**0B?*PB?6Z$4E-]8 M8CFW'JGD,I5R1I@H7=D!C:F#,!0AJDJQ%$>O2+.GL<)8"<@H`ROD M%G+UF*8U6NIT&OD"\@4UT^QI^`(U=$DI*`2L=5,L`:M"P$IZI_!Z]MU_CVRU__PMA/Z\_XRA^FW`F^\)GKR4>,44&! MY3JOGZ,_SA\"=N=@GL\7/O[YXB;TQ&7W&OS3:FJM^SOWOGW?EE\N?HG@=]X2 MT:ZUCA!2;NN-R!"ZC?1&C@X%G7\]\>$7\"^N8W,2WC#SV(_[U M@^X9$];6+K>OCI[-@#GP2,G/#"/%Y>2&F]2W.#DPO,9-`:NM6&BY.?88D"CY/CI>5_X(W="+@;@ MWP8M30-#?. M1'L$)\>'D]3JG)\G.HAF\#"P#-UF,\\U0R/P"4T(3=35'J&)HFB2]N/BTT<> M>JYO6-PQ.".$*:%3*XN^_*!=#IOM1G^?"`SU5_5;KEJ7G6:W05&/4X7,MX[I M&I[EN+;[\$R8J31F:I>]8;,Q),A4&C*UR^Y@F&<+/"'F\3MK!\3\Y!@$ENJ# MY0#8)4&EVE`Y:`_3^HB`4KVNV@$HW^B>:;F/NF^$MNX17"H-E[WVH-$AN%0: M+KL#+<])5P27Q^^JS MI;N&=J-'GJ&NGH'=N0&NC::IC7:Q)W5!LC+3F^8YCD)(]7K MK%2,O'8LD(Q-N&X'$\)$I3&Q,VS2TK[BB-@&/*1H0BWP4-)#3V9K'SHDD#KC M.OKDKR7NJ>W\K[J\JNYEK]E*6WX^4(B`S*4&V`]6@FMO.6HS$_Q36K8R:=FD MO>.47RE4.F6E_LK*K3>6;]BN'WJ\G%HK.R+CS>W'JP_"N>P$N?%S%H_YQ\7" M0)<1-?XR+]-5YAN*/717?:2^=!>SQ_,`NK+X4BD5'W9O\)TUY3[[R)_8%W>J M._CTQ(,CJV4)0U_KV#PO;A5]\29R+UZ(#\;C([8:SLI[*K6>S6TJS7K*K!52 M`:GZG3-9GXKC5FB@K-!9#XXUM@P=7C0*?9#8]YDO;6N^Z;;UCTD(2LN*_C?8 M)UGTRG5\YHY9,.%,7PJ%K3Z9Z1X'C02@MX"CL'`]N,P)_@PO>HZ?XNM3SCB` MKSNU#''-O+P6,^!JW<#;?1#'9[K/MDAY-^$>A]'"+_'AST((RS'LT.0F.$Z0 M,VMY`VYBL]";N3X7+8R;X<4^`U00>FO-],4K3!30>0@M'YP5&SV+EH5V8&'C M&8=&A=!'<9.C=[Z2C8&W>9$NH0&?N2<&.^X=LGS&P?.'8@OT2/?AWZZ#=X^M M`&\"#P9R>^XT5AEVSD@TG\E#]EB@?^?P5%FH+.UOHMT;>C/^\]CR_(#]&>H> M=(=0$'I"T5]8CX(]0=_\D&;/:)-:J[\R%XSWZ(L'9-[7ZZZL:,2W74*W^#-N M!-8CMY\;&7"U#S721/'AL@9ZM,4=+>,-].:#ZST?'+SWT4:G3&54!O&_NYYM M`COF\R`5Z-N(]"TL5$>#MFWW*:60P,$]Z5*!RTH9V3(CCWY-E&S-OBCMAIP& MU%J;:416%)>]7-8C:O#_7.];NMN>)29>5->0ZAK6.U"B4-6?FI;[H;J&5-?P MQ!+\J*XAV4\9?I'J&IX&8!/#446/5-?P]$=)!5U'=0T56G8D[5$ELGK#26HZ M,M4U)#2IG?8(311%D\U[@ZFN87WR;ZFN82T28*FNX6E#)M4UK`]F4EW#.D`F MU34\;<2DNH:U`$NJ:Z@^5%)=PU,&2JIK6".XI+J&ZL,EU36L-5QN_D1U#4^J M<%UE0$UU#4_!/$IW#537L,:>@>H:UAB0J:YA+0"2ZAK6'".IKF%],)'J&JJ/ MB%37L#9X2'4-3ZU0775Y5537\`3-I0(KH;J&)[29[61X#FE/H;J&VTL2;JYA MF*@*%Y<7VE3"4$N6,-3NHZ?>?PWT@.-S7T<5GZ+7^-??+?_>MI_OY5D] M9WN[`ZVN[5W*4,W97*T[ KVM[D)H:X=ONU;31R^W]'"UIB`EMWK9W>L/.<5N_7%RW6L_4&3;[-6WM3IZI MUQ[4M7=W\DR]8?/(`+9S>W?P3-JPV:ZK.1?U3,UV73MV#\_4[]1U]);@F31- M:^_=>ALF?0^__<6ZZ"&FP-6CO) M!;9\Q[WI:]?SW"=0M[\DU+5__VE\#[+D-L%NJ[4V<-9?LHL4!:RIN<:I